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Osteoarthritis (OA) is a degenerative joint disease that affects millions of people 
worldwide and is the leading cause of disability in the elderly population. To date, no 
cure exists for OA, and the exact cause is not clearly understood. Mechanical loading at 
high magnitudes, however, is a primary risk factor for the disease. To better understand 
the role of mechanical loading in OA, we used an in vivo model that applies cyclic axial 
compression to the knee joints of mice. First, we used the model to study the role of 
abnormal cartilage matrix properties in load-induced OA. Next, we characterized a 
novel hydrogel-based drug delivery system and tested the hydrogel’s therapeutic 
efficacy for intra-articular treatment of load-induced OA. Finally, we applied low-level 
mechanical forces to attenuate OA-like changes after joint injury. 
We first sought to understand the effects of an abnormal cartilage matrix on the 
onset and progression of load-induced OA. The cho/+ mouse has abnormal collagen 
fibrils in its cartilage matrix due to a Col11a1 haploinsufficiency. We hypothesized that 
cho/+ mice would develop more severe load-induced OA pathology compared to 
wildtype (WT) littermates with normal cartilage. Contrary to our hypothesis, cho/+ 
mice had less severe load-induced cartilage damage. Cho/+ mice also had thinner, less 
dense cortical bone and thicker cartilage. Both characteristics may have played a role in 
attenuating load-induced OA pathology in cho/+ mice. 
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The next goal was to characterize an on-demand hydrogel-based drug delivery 
system for intra-articular OA treatment. Synthetic hydrogels were made of cross-linked 
4-arm maleimide functionalized polyethylene glycol, and we analyzed their mechanical 
integrity and on-demand release in vitro. The hydrogels maintained their mechanical 
properties after 10,000 cycles of cyclic compression at 80% strain. In addition, they 
released particles in response to collagenase exposure, highlighting their on-demand 
release characteristics in the OA joint environment. In vivo, hydrogel injections reduced 
load-induced cartilage damage and osteophyte size. Further work is needed to determine 
the most effective drugs to combine with the hydrogel system.  
Finally, we sought to determine whether low-level loads could attenuate post-
traumatic OA. Mice underwent the destabilization of the medial meniscus (DMM) 
surgery to mimic an injury in the knee joint. These DMM joints were then loaded with 
low-level cyclic axial compression. The loading regimen attenuated DMM-induced 
cartilage degradation, osteophyte formation, and subchondral bone sclerosis. Thus, low-
level axial loading may be used to slow post-traumatic OA progression. 
In summary, in vivo cyclic tibial compression allowed us to better understand 
the role of mechanical loading in the pathology, treatment, and prevention of OA. Our 
results show that both cartilage and bone are involved in OA progression, and both 
tissues must be considered when predicting disease severity. Furthermore, synthetic 
hydrogel systems combined with therapeutics may be an effective approach to improve 
intra-articular drug retention time. Finally, low-level axial loading has the potential to 
aid as a preventive intervention for OA, particularly after a joint injury.  
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CHAPTER 1: INTRODUCTION 
 
1.1 Synovial joints 
 A synovial joint (herein referred to as a joint) is a structure where two bones 
meet and articulate to allow motion. Synovial joints consist of a synovial capsule, 
synovial membrane, and articular cartilage. The synovial capsule is a dense, fibrous 
structure that surrounds the entire joint cavity. The synovial membrane is the inner layer 
of the joint capsule, and its primary function is to secrete synovial fluid. This fluid 
contains hyaluronan and lubricin, which interact to serve as a lubricant between the 
bones that make up the joint. Lastly, articular cartilage is a connective tissue that covers 
the ends of articulating bones. Cartilage provides a smooth, lubricated surface with 
minimal friction and aids in transmitting loads.  
A number of synovial joints have additional structures that provide further 
stabilization and support to the joint (Fig. 1.1). For example, ligaments connect bones 
and prevent certain movements that could be harmful to joints. In the knee, the 
anterior/posterior cruciate ligaments (ACL/PCL) prevent excessive anterior/posterior 
motion or twisting, and the medial and lateral collateral ligaments (MCL, LCL) provide 
lateral support to the joint. Another critical part of the knee is the meniscus. The 
meniscus is a thin layer of fibrous tissue that lies between the articular cartilage on the 
tibial plateau and femoral condyles. The meniscus provides additional support to the 
knee and helps to distribute loads from the cartilage to the bone.  
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Figure 1.1. Labeled schematic of knee. The knee joint is the articulation between the femur and 
tibia. Articular cartilage lines the ends of each bone, and menisci provide further support and to 
the joint. Multiple ligaments serve to stabilize the knee. Adapted from umn.edu. 
 
1.1.1 Articular cartilage 
 Articular cartilage is the most important feature of synovial joints. Without 
cartilage present in the joint, bones would not be able to articulate smoothly, and 
movement would be extremely painful. Collagen and proteoglycans are the two main 
constituents of the cartilage extracellular matrix (ECM) (Fig. 1.2). Collagen has two 
functions in the cartilage ECM. Its first function is to provide cartilage with tensile 
strength to withstand any excessive tensile forces in the joint [1]. Its second function is 
to entrap the proteoglycans in the ECM and prevent them from leaking out of the matrix 
[2]. The collagen in cartilage is primarily in the form of collagen II. In addition, collagen 
IX and XI contribute to the formation of collagen fibrils in the cartilage matrix [3,4]. 
Collagen serves as the backbone of the cartilage ECM. 
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 Proteoglycans are hydrophilic components of cartilage that attract and retain 
water in the ECM. The water retained by proteoglycans is responsible for the 
compressive properties of the cartilage ECM [5]. Proteoglycans possess excellent 
hydrophilic properties because of their structure [6]. Their functional structural 
component is the glycosaminoglycan (GAG). Examples of GAGs are chondroitin 
sulfate and keratin sulfate. These GAGs are tethered to a core protein to form a 
paintbrush-like structure that behaves like a sponge to retain water during compression. 
These paintbrush-like structures are attached to long hyaluronic acid chains via linking 
proteins. Together, these components make up the proteoglycan. Aggrecan is the most 
abundant proteoglycan in the cartilage ECM. 
 
Figure 1.2. Cartilage extracellular matrix components. Collagen fibrils are the backbone of the 
cartilage ECM, and the paintbrush-like proteoglycans resist compression by attracting water. 
Adapted from quizlet.com. 
 
 In addition to the ECM, the cells in cartilage, or chondrocytes, form and maintain 
the tissue. Chondrocytes release factors that maintain the cartilage matrix and prevent 
excessive inflammation in the joint. Specifically, they produce and maintain both 
collagen and proteoglycans [7]. Furthermore, in a healthy state, chondrocytes release 
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anti-inflammatory factors, such as interleukin (IL)-10 [8]. Healthy and abundant 
chondrocytes are critical to cartilage function. 
 
1.1.2 Cortical and cancellous bone 
 Bones are composite structures that consist of an exterior cortical shell and inner 
cancellous network. Cortical bone is dense and consists of basic units called osteons. 
Cancellous bone is porous and is composed of individual trabeculae. Osteoblasts and 
osteoclasts are cells found on or near the surface of bone. Osteoblasts form bone, and 
osteoclasts resorb bone. Osteocytes are the cells located within the mineralized bone 
matrix that play a major role in bone cell-to-cell signaling and facilitate the activity of 
osteoblasts and osteoclasts (i.e. remodeling). Bone structure and remodeling are both 
critical factors in the health of synovial joints, because of the direct interaction between 
bone and cartilage [9]. 
In this thesis, we focus on two regions of bone near articulating joints, the 
epiphysis and metaphysis. The epiphysis is the region at the end of a long bone that is 
separated from the rest of the bone by the growth plate. The epiphyseal cortical bone is 
commonly called the subchondral bone plate and lies directly underneath the articular 
cartilage. Epiphyseal cancellous bone consists of a small amount of cancellous bone that 
lies between the subchondral bone plate and growth plate. The metaphysis is the region 
on the opposite side of the growth plate that extends approximately 10% of the bone 
length towards the middle of the bone. The metaphysis contains cancellous bone 
surrounded by a cortical shell.   
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1.2 Osteoarthritis 
 Osteoarthritis (OA) is a progressive, degenerative, and disabling disease that 
affects synovial joints. Approximately 27 million people in the United States suffer from 
OA [10]. As the population ages and obesity rates rise, the prevalence of OA will 
increase, and predictions suggest that 25% of the adult population will have the disease 
by 2030 [11]. OA not only affects the elderly, but also younger, more active individuals 
with prolonged participation in high physical-demand activities. The disease can occur 
in multiple sites, primarily affecting the knees, hips, hands, and spine [12]. 
OA clinically presents as debilitating pain and stiffness and loss of joint function 
[13]. The disease is characterized by three main structural changes in the joint. These 
changes can arise from multiple risk factors that will be discussed in the following 
section. The first structural change is articular cartilage degeneration, indicated by 
narrowing of the joint space. The second change is a thickened, dense subchondral bone 
plate, commonly referred to as subchondral bone sclerosis. The third is the formation of 
bony spurs adjacent to the joint space, known as osteophytes. Together, these three 
structural changes help distinguish a healthy joint from an OA joint on an x-ray. In 
addition to these three hallmarks, changes occur in the menisci, synovium, ligaments, 
and peri-articular muscle as OA progresses (Fig. 1.3). Currently, no cure exists for OA, 
primarily due to the complex pathological mechanisms of the disease. 
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Figure 1.3. Healthy versus OA knee schematic. Cartilage degradation, subchondral bone 
sclerosis, and osteophyte formation are hallmarks for OA. In addition, many changes occur in 
the surrounding tissues. Adapted from [14]. 
 
1.3 Risk factors for osteoarthritis 
Although no cure exists for OA, many risk factors for the disease have been 
identified based on clinical evidence. Some of these factors include obesity [15,16], 
aging [17], excessive mechanical loading during occupational activities [18,19], prior 
joint injuries [20,21], and genetic abnormalities [20]. Although we are aware of these 
risk factors, predicting disease onset remains extremely difficult, thus limiting effective 
preventive measures. Studying the interaction of risk factors will help to understand 
whether individuals with specific genetic backgrounds or physical attributes may be at 
higher risk for developing OA based on their lifestyles. Furthermore, determining the 
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interactions of risk factors may aid in the development of new preventive measures and 
clinical treatment options.  
 
1.3.1 Mechanical loading and OA 
Mechanical loading and joint health have a unique relationship. A large 
spectrum of loading types and magnitudes exists, and each specific load can result in 
different outcomes (Fig. 1.4). As mentioned previously, excessive mechanical loading 
is a primary risk factor for developing OA. Specifically, loading at high magnitudes can 
lead to cartilage degradation by decreasing proteoglycan synthesis [22] and inducing 
chondrocyte apoptosis [23]. Furthermore, high loads can rupture stabilizing ligaments, 
such as the ACL [24]. Other forces applied to the joint can directly damage soft tissue 
in the joint, such as the meniscus or cartilage [25]. Any damage to the joint or tissue 
surrounding the joint can lead to cartilage degradation. 
Despite the consistent agreement that high loads are detrimental to joint health, 
specific types of loading can benefit joint health and potentially aid in the prevention of 
cartilage degradation. For example, low levels of mechanical loading, such as mild to 
moderate exercise or low-level mechanical stimulation, can increase proteoglycan 
synthesis in vitro [26] and maintain thicker cartilage throughout a rodent’s lifespan [27]. 
Treadmill running and low-level loading protocols in rodents have slowed down the 
progression of injury-induced cartilage degradation [28,29]. Clearly, low levels of 
mechanical loading have potential to attenuate cartilage degradation. However, further 
understanding of the specific load levels that result in beneficial effects to the joint is 
necessary to prescribe rehabilitative loading regimens at the clinical level. 
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Figure 1.4. Unique relationship between mechanical loading and cartilage health. Chondrocytes 
exhibit a strain-dependent response. Absence of loading can result in downregulation of matrix 
synthesis. Mild or moderate levels of physical activity lead to beneficial effects, including 
increased matrix synthesis and decreased proinflammatory pathways. Intense activities that may 
lead to injury can cause cell death and increased inflammation. Adapted from [30]. 
 
1.3.2 Abnormal tissue properties and OA 
The role of cartilage and subchondral bone properties in OA pathology has been 
a topic of interest for many years [31,32]. Differences in tissue properties often are due 
to genetics. Epidemiological studies of OA have estimated a heritability of 50% or more 
depending upon the affected joint, suggesting that half of the variation in disease 
susceptibility could be explained by genetic factors [33-36]. The collagen network 
within cartilage can be influenced by genetics. For example, mutations that affect key 
collagen genes, such as Col11a1, lead to abnormally thick collagen fibrils in the 
cartilage ECM [37], accompanied by reduced tissue tensile properties and OA-like 
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features early in life. Alterations in other genes that affect collagen II, collagen IX, or 
proteoglycan structure also lead to abnormal cartilage matrix properties [38].  
Subchondral bone properties can vary among individuals. However, whether 
high or low bone mass increases risk for OA remains unclear. Individuals with 
extremely elevated bone mass are more susceptible to OA [39–41]. However, women 
with decreased bone density due to osteoporosis commonly develop OA. In a preclinical 
model of load-induced OA, higher bone mass protected against cartilage damage [42]. 
Thus, conflicting evidence makes the interaction between subchondral bone properties 
and OA onset/progression an important area of OA research. 
 
1.3.3 Joint injury and post-traumatic OA 
Joint injuries, especially injuries that occur in the knee, account for a significant 
subset of OA cases. Examples of injury include tears to stabilizing ligaments such as 
the ACL, damage to key tissues like the meniscus, or direct impact to subchondral bone 
or articular cartilage. When these types of injuries occur, an inflammatory cascade 
commences, and joint mechanics are often altered because of damage to key stabilizing 
components. Together, excess inflammation and altered joint mechanics resulting from 
joint trauma lead to a form of OA called post-traumatic OA (PTOA). Approximately 
12% of OA cases at the knee are classified as PTOA [43]. Because joint injury is such 
a common risk factor for OA, many models to study OA involve some type of injury. 
These models will be discussed further in section 1.6.1. 
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1.4 Current understanding of OA pathology 
During the evolution of OA, inflammatory factors released by cells residing in 
the synovium, including synovial macrophages and fibroblasts, induce changes in 
chondrocytes within the cartilage matrix. In a healthy state, these chondrocytes normally 
benefit the structural integrity of collagen and aggrecan in the tissue. Under OA 
conditions, however, chondrocytes up-regulate the production of destructive proteases, 
including matrix metalloproteinases (MMPs) and aggrecanases. These proteases 
degrade the cartilage matrix, releasing matrix degradation products. Matrix fragments 
then initiate further inflammatory responses, leading to a vicious cycle of inflammation 
and cartilage destruction. In addition, inflammatory cytokines act on the adjacent 
synovium and bone to stimulate synovial inflammation and de-regulate peri-articular 
bone remodeling. In this section, we briefly review some of the main processes 
associated with OA, including inflammation, cartilage matrix degradation, and bone 
adaptation (Fig. 1.5). 
 
1.4.1 Inflammation 
Inflammatory factors, including tumor necrosis factor (TNF)-alpha and 
interleukins (ILs), play a crucial role in OA pathogenesis. TNF-alpha plays a major 
catabolic role in OA and downregulates production of cartilage extracellular 
components, including aggrecan and collagen type II [44]. In addition to its direct 
effects on cartilage matrix synthesis, TNF-alpha also promotes the production of other 
cytokines, including IL-1 and IL-6. Lastly, TNF-alpha interacts with the receptors 
  11 
TNFR1 and TNFR2 to activate sensory neurons, leading to pain associated with OA 
[45].  
Similar to TNF-alpha, IL-1 directly affects cartilage by decreasing levels of 
matrix components and inhibiting anabolic chondrocyte activity [46]. IL-1 also induces 
production of collagenases and aggrecanases in synovial fibroblasts and chondrocytes, 
leading to further cartilage destruction [47]. IL-6 is another interleukin that is elevated 
in the synovial fluid of individuals with OA. The role of IL-6 in disease onset and 
progression is complex, involving both proinflammatory joint destruction [48] and anti-
inflammatory mediation [49].  
 
Figure 1.5. Osteoarthritis pathology. Schematic of OA pathology with key factors contributing 
to disease progression. Human knee joint x-rays depict healthy and OA conditions. Adapted 
from [50]. (Images courtesy of: Dr. Mathias P. Bostrom at the Hospital for Special Surgery, 
New York). 
 
 
1.4.2 Cartilage matrix degradation 
Structural damage of the cartilage matrix occurs from a variety of proteolytic 
enzymes that break down aggrecan, type II collagen, and other key matrix components. 
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The major aggrecanases in OA include ADAMTS (A Disintegrin and Metalloproteinase 
with ThromboSpondin type I motifs)-4 and -5, and MMP-3. In general, aggrecanases 
cleave the aggrecan protein between the G1 and G2 globular domains. This cleaving 
creates aggrecan fragments that have weakened compressive properties compared to 
intact aggrecan proteins [51].  
The major collagenases associated with OA are MMP-1 and MMP-13, which 
cleave collagen proteins at specific locations, resulting in two or more collagen 
fragments [52,53]. Again, these collagen fragments do not provide the structural support 
or tensile strength that intact collagen fibrils provide to the healthy articular cartilage 
matrix, resulting in compromised load-bearing properties. Importantly, the presence of 
matrix fragments in the synovial joint space initiates further inflammation, perpetuating 
the vicious cycle of inflammation and matrix destruction.  
 
1.4.3 Bone adaptation 
In addition to structural and molecular changes that occur in the cartilage, certain 
enzymes can alter the underlying bone. For example, the RANKL (receptor activator of 
NF-κβ ligand)-to-OPG (osteoprotegerin) ratio, is altered in the OA state. Under healthy 
conditions, the RANKL-to-OPG ratio maintains an appropriate balance between 
osteoblast and osteoclast activity. Under OA conditions, however, osteoblasts in the 
subchondral bone exhibit an altered RANKL-to-OPG ratio [54]. This promotes excess 
bone formation, leading to subchondral bone sclerosis. 
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1.5 Osteoarthritis treatment 
Because of the complexity of OA pathology, developing disease-modifying 
drugs remains extremely difficult. Until we better understand the disease mechanism, 
traditional treatments will be the most effective in alleviating pain associated with OA 
(Fig. 1.6). The first suggested treatment involves lifestyle changes [55]. Improvements 
in diet and more frequent exercise are common non-pharmacologic recommendations 
to relieve pain [56]. Weight loss from diet and cardiovascular exercise can alleviate pain 
by reducing forces experienced by the affected joints. Furthermore, strength training 
targeted at improving quadriceps, hamstring, and calf strength can help absorb forces 
that would otherwise be transmitted through the knee joint [57,58].  However, clinicians 
only recommend mild exercise, because high-intensity exercise involving heavy loads 
may worsen OA-related symptoms. 
 Oral medications are the first pharmacologic treatment option for OA-associated 
pain. Some of the most common oral medications are non-steroidal anti-inflammatory 
drugs (NSAIDs). These drugs target and inhibit cyclo-oxygenase enzyme (COX)-2 
activity associated with inflammation. Acetaminophen is another medication commonly 
used for OA that inhibits the synthesis of prostaglandins and has similar effects to 
NSAIDs. Nutritional supplements may also help to inhibit OA-associated pain. 
Glucosamine-chondroitin is one of the most popular supplements and may even aid in 
production/retention of GAGs in the cartilage ECM [59]. If pain is unbearable, opioids 
can be prescribed by a clinician, but their use can result in physical dependence and 
withdrawal symptoms. Overall, some of the main downfalls of oral administration of 
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drugs is the possibility for gastrointestinal irritation and lack of targeting to the affected 
joint. 
 If oral medications fail to relieve pain, intra-articular (IA) injection is the next 
step. These injections are delivered directly to the joint space and are thus more targeted 
compared to oral delivery. The most common drugs used for IA injections are 
corticosteroids, hyaluronic acid (HA), and platelet-rich plasma (PRP) [60-62]. The main 
limitation of IA injections is the lack of retention time inside the joint, resulting in 
minimal functional improvement in patients. A large area of current research focuses on 
engineering novel drug delivery platforms to improve drug retention time inside the 
joint. Both current drugs used in the clinic and novel drug delivery approaches will be 
discussed in further detail in the following sections. 
 
Figure 1.6. Summary of OA treatments. The majority of interventions typically begin when 
patients present severe OA signs and symptoms. Clearly, earlier, more effective interventions 
are necessary to better prevent and treat the disease. Adapted from [55]. 
 
Surgical intervention is required when both non-pharmacologic and 
pharmacologic treatments become ineffective in relieving pain. Arthroscopic techniques 
remove debris in the joint space or create smooth surfaces on the cartilage surface. 
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Osteotomy removes osteophytes that inhibit physiological joint movement. When 
damage associated with OA becomes too severe, joint replacement, or arthroplasty, is 
the most effective option. Hip and knee replacements are the standard treatments for 
end-stage OA and are generally successful in relieving pain. However, the surgery is 
invasive, requires drastic lifestyle changes, and results in a major financial burden. Thus, 
patients generally want to avoid surgery if possible. 
 
1.5.1 Intra-articular drug therapies in the clinic 
Corticosteroids, hyaluronic acid (HA), and platelet-rich plasma (PRP) are the 
most common drugs used for IA drug delivery in the clinic. Corticosteroids function as 
anti-inflammatory and immunosuppressive agents. Although the mechanism of action 
is not fully understood, corticosteroids suppress local inflammation by down-regulating 
arachidonic acids and prostaglandins [60], leading to vasoconstriction [63]. The clinical 
effects of corticosteroids have been reviewed extensively [64,65]. In general, IA 
injection of corticosteroids effectively reduces pain up to 3 weeks post injection, but the 
effect diminishes after longer periods [66]. Yet, no conclusion can be drawn to confirm 
the improvement in joint function, measured in terms of walking distance, range of 
motion and several scoring systems. 
IA-injected HA has been proposed to alleviate OA symptoms. Physically, HA 
behaves as a viscoelastic lubricant at low shear rates (resting and walking) and an energy  
absorber at high shear rates (exercising) [67]. Exogenous HA also mediates 
inflammation, regulates nerve sensitivity, and enhances synthesis of proteoglycans [68]. 
The outcome from clinical trials of IA injection of HA has been systematically reviewed 
  16 
[69]. When combining the results from multiple clinical trials, the injection of HA did 
not improve joint function at any time point. Like corticosteroids, the benefits of HA 
injection were limited to pain reduction in patients after exercise, but not pain at rest. 
The pain-relieving effects of HA were not significant during the first 5 weeks post-
injection but became significant after 10 weeks. Therefore, the effect of HA has a 
delayed initiation and prolonged duration, compared with corticosteroids. Although HA 
of higher molecular weight (MW) has been suggested to be more effective in alleviating 
OA from in vitro and in vivo models [70], no difference between high and low MW HA 
has been observed in clinical trials [69,70]. 
Another current IA injectable medication for OA that has recently emerged is 
platelet-rich plasma (PRP) [71]. PRP can be separated from a patient's blood via 
centrifugation and injected back into the affected site and potentially increase the rate 
of healing because of its high concentration of growth factors. In the past, PRP was 
primarily used to treat chronic tendon injuries. More recently, PRP is being used to treat 
acute tendon and ligament injuries and chronic knee OA. A recent review discussed how 
PRP reduced pain and improved function significantly better than HA in OA patients 
[72]. Further research is still required to fully understand PRP's effects in treating OA.  
 
1.5.2 Novel biomaterials for intra-articular drug delivery 
Despite the variety of drugs available for IA injection, this mode of delivery 
does not consistently relieve OA symptoms due to limited drug retention times in the 
joint space. Corticosteroids and hyaluronic acid, for example have half lives in 
suspension of 1 to 2 hours and 22-26 hours, respectively [73]. These problems partly 
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arise because of the physical and electrical barriers that the articular cartilage ECM 
provides to the chondrocytes. Specifically, the dense collagen II network, the 
avascularity, and the negatively charged aggrecan molecules may prevent entrance of 
therapeutic agents into the cartilage matrix [74]. In addition, the synovial membrane 
surrounding the intra-articular joint space creates a compartment that can retain larger 
molecules, but many small molecules such as NSAIDs and other therapeutics can 
rapidly leak out of the joint space. 
To overcome these retention challenges, biomaterials-based drug delivery 
platforms have been developed, including microparticles, nanoparticles, and injectable 
hydrogels. Micro- and nano-particle systems involve encapsulating a drug of choice 
inside or tethered to a biomaterial. Particle size ranges from the nanoscale to the 
microscale. In general, drugs combined with particle delivery systems demonstrate 
improved retention time compared to the drug alone [50]. 
Injectable hydrogels offer unique capabilities as a drug delivery system. 
Hydrogels can be made of synthetic or natural materials [75]. Synthetic hydrogels offer 
a few advantages over natural hydrogels, including excellent biocompatibility, inert 
properties, and tunable mechanical properties based on formulation [76,77]. A goal of 
this thesis is to engineer and test a synthetic hydrogel drug delivery system to improve 
retention time inside the joint, and therefore, make IA drug delivery a more effective 
strategy for OA treatment. 
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1.6 Preclinical models of osteoarthritis 
To better understand OA and to test novel treatments for the disease, preclinical 
animal models have been developed to recapitulate OA progression. Animal models can 
be classified under invasive and non-invasive categories (Fig. 1.7). Invasive models 
primarily use chemically-induced cartilage degeneration or surgical injuries, and non-
invasive models involve repetitive joint loading, load-induced impact injury or 
spontaneously occurring OA progression [50,78,79]. 
 
1.6.1 Invasive Preclinical OA Models 
Under the invasive models, chemically-induced cartilage degeneration 
approaches involve intra-articular injection of collagenase [80–82], TGF-β [83], 
monosodium iodoacetate [84–87], or papain [88–90]. These methods have provided 
critical knowledge about key molecular and cellular pathways during disease initiation. 
However, these models do not fully recapitulate human OA progression, limiting their 
use in understanding clinical scenarios [50,78]. 
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Figure 1.7. Preclinical animal models for OA research. Models can be classified as invasive or 
non-invasive. They can also represent traumatic injuries or long-term wear and tear of joints. 
Adapted from [91]. 
 
Post-surgical models of OA better mimic clinical injuries and subsequent OA 
progression. Models, such as anterior cruciate ligament transection (ACLT) [92–95], 
meniscectomy [93,94], and destabilization of the medial meniscus (DMM) [96,97] 
involve the use of surgical methods to disrupt or transect stabilizing ligaments, leading 
to alterations in joint mechanics. With surgical trauma, OA results over time, enabling 
the investigation of the full time course of post-traumatic OA progression. These 
surgical injuries have been applied to a variety of animal models [78], and have 
significantly contributed to the current knowledge of post-traumatic OA progression. 
However, a major limitation of these models is the difficulty in differentiating the 
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surgical inflammatory and healing response from the progression of OA, which 
confounds the understanding of disease etiology. 
 
1.6.2 Non-Invasive Preclinical OA models 
Non-invasive models of OA have been developed to elucidate the mechanism of 
OA progression without the confounding effects of surgical intervention [98]. These 
models include genetic/spontaneous OA development [99,100], non-invasive impact 
injury models [24,25,101,102], and the recently-developed cyclic load-induced OA 
model [103,104].  
Genetic/spontaneous models involve the use of animals, such as the guinea pig 
[100], certain strains of mice (e.g. C57Bl/6 and BALB/c) [105], or mice that have been 
genetically manipulated and develop the disease throughout their lifespan. Such studies 
allow for understanding OA pathology without external intervention and exploring 
genetic pathways for potential therapeutic targets. However, many forms of 
spontaneous OA can take months or even years to develop, limiting their use in 
laboratory settings.  
Non-invasive impact injury models utilize high compressive loads to induce an 
intra-articular fracture of the tibial plateau [25] or rupture of the ACL [24], both leading 
to OA initiation and progression.  Each of these non-invasive models provides key 
advantages in understanding OA pathology, particularly in recapitulating the clinical 
scenario without invasive measures. However, the exact mechanical environment of the 
joint within these models is unknown, and thus the relationship between mechanical 
forces and OA progression is difficult to understand. 
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Figure 1.8. In vivo cyclic tibial compression. a) Representative histological sections from 
loading consisting of 9.0N peak loads for 1200 cycles daily at 4.0Hz frequency for either 1, 2, 
or 6 weeks. Top row shows cartilage (shown in red) thinning and surface damage over time with 
loading, and bottom row shows osteophyte growth and maturation. b) Schematic and 
photograph of the mouse leg inside the loading device. c) Histological scores indicating greater 
severity of OA overtime with 9.0N-loading. Adapted from [104]. 
 
The cyclic load-induced model of OA offers a unique platform to specifically 
elucidate the relationship between mechanical forces and disease initiation (Fig. 1.8). 
Primarily used in mice, the load-induced model applies controlled, cyclic compressive 
loading to the tibia, leading to predictable OA progression in the knee joint [103,104]. 
The next section summarizes the key features of load-induced OA mouse models. 
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1.6.3 Models of load-induced OA 
A common theme in this thesis is the application of cyclic tibial compression. 
Cyclic loading applied to the tibia of mice noninvasively induces OA-like changes over 
time [103,104]. This in vivo loading model allows the user to specify the load 
magnitude, number of cycles, frequency of each cycle, and duration of loading. In 
general, higher loads lasting for longer durations lead to more cartilage degeneration 
and subchondral bone changes. Importantly, unlike other OA animal models, cartilage 
degeneration in this model is most likely not due to joint instability or an injury, but is 
caused by direct mechanical overload of the articular cartilage [106]. The cyclic tibial 
compression model can produce a range of OA severity. Thus, therapeutics can be tested 
for efficacy under moderate and severe OA conditions with the model.  
To date, cyclic tibial compression has been used to study the initiation and 
progression of load-induced OA at high and moderate load magnitudes. High (9.0 
Newtons) load magnitudes induced OA-like changes, including cartilage degradation, 
osteophyte formation, and subchondral bone changes, in young (10-week) and adult 
(26-week) mice. Moderate (4.5 Newtons) loads led to less severe cartilage degradation. 
No evidence of bone changes was evident after 6 weeks of moderate loading in adult 
mice. A goal of our lab is to relate these load magnitudes in mice to physical activities 
in humans (Fig. 1.9). We also seek to determine the effects of mild loads. If we can 
understand the effects of multiple load levels in mice, we may be able to better 
distinguish beneficial versus detrimental loading types in humans. 
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Figure 1.9. Relationship between physical activity levels in humans to cyclic tibial loading 
magnitudes in mice. Our lab previously showed that both 4.5N- and 9.0N-loading induced 
cartilage damage in mice. However, further research is necessary to explore loading magnitudes 
that are beneficial to cartilage health. 
 
1.7 Metrics for determining disease severity  
 Clinically, the main measures for OA severity include a combination of imaging 
and self/clinician assessment to determine morphologic features and symptoms related 
to pain, function, and quality of life. The most common imaging modality to assess OA 
severity is the radiograph. Clinicians score the severity of a radiograph based on the 
joint space width and severity of osteophyte formation. For example, Kellgran and 
Lawrence developed a scoring system that is still used today [107,108]. The scale ranges 
from 0 to 3, with normal joints receiving a score of 0, and severely diseased joints 
indicating a score of 3. In addition to x-ray, magnetic resonance imaging and computed 
tomography scans can further assess 3D structural changes in the bone and soft tissue 
surrounding the joint. 
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Self-reported questionnaires and clinician-administered outcome measures also 
play a key role in identifying pain and function associated with disease. One of the most 
common self-reported questionnaires is the Western Ontario and McMaster Universities 
Osteoarthritis Index (WOMAC) score. The questionnaire consists of 24 questions 
relating to pain, function, and stiffness. The questions are then weighted, and scores are 
measured to determine disease severity. Other common self-reported questionnaires 
include the Knee Injury and Osteoarthritis Outcome Score (KOOS) and the American 
Academy of Orthopaedic Surgeons (AAOS) Outcomes Instruments. Furthermore, 
clinicians assess functional characteristics such as range of motion, muscle strength, and 
instability. 
Clinical measures of OA are effective in determining OA severity based on 
radiograph scores and self-reported pain. However, clinical measures do not offer any 
insights into disease mechanism or tissue-specific changes. On the other hand, 
preclinical models offer a platform to perform end-stage analyses of tissue morphology 
and protein levels. The following two sections will describe the structural and 
cellular/protein-level assays frequently performed in preclinical murine models of OA.  
 
1.7.1 Murine tissue morphology outcome measures 
 In preclinical murine models, outcome measures include cartilage degradation, 
bone morphology, and other joint tissue changes upon experiment completion (Fig. 
1.10). Mice are euthanized, and the knee joints are harvested and fixed. The joints can 
be imaged using microcomputed tomography (microCT) and processed for paraffin 
embedding and histology. MicroCT scans are taken of the knee joints to assess cortical 
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and trabecular bone morphology. Specifically, the thickness and tissue mineral density 
of the subchondral bone plate can be determined. The underlying cancellous bone 
morphology in the epiphysis (distal to the subchondral bone plate and proximal to the 
growth plate) and metaphysis (distal to the growth plate) can also be analyzed for bone 
volume fraction, trabecular thickness and separation, and tissue mineral density. 
The histological analysis seeks to measure the severity of articular cartilage 
damage using semi-quantitative scoring methods. Thin sections are typically stained 
with Safranin O or Toluidine blue and examined for structural and cellular changes in 
the cartilage. In general, normal healthy cartilage is scored low (0) and the score 
increases to represent damaged cartilage. Two frequently used scoring systems are the 
OARSI and Mankin systems [37,109]. The OARSI scoring system is sensitive to 
structural changes in the cartilage, and the Mankin system focuses on cellular and 
proteoglycan-level changes. With the OARSI scoring system [109], normal articular 
cartilage scores a 0, proteoglycan loss is 0.5, small fibrillations on the cartilage surface 
is 1, vertical clefts down to immediately below the superficial layer is 2, and vertical 
clefts/erosion to the calcified cartilage extending <25%, 25-50%, 50-75%, and 75-100% 
of the articular surface are 3, 4, 5 and 6, respectively.  
With the Mankin scoring system, proteoglycan content, indicated by the 
Safranin O staining intensity, is scored 0 to 4, chondrocyte arrangement is scored 0 to 
3, and chondrocyte periphery staining is scored 0 to 2 [37]. Scores for these three 
categories are added together for each tissue section. Both OARSI and Mankin scoring 
are generally performed across the entire joint using evenly spaced tissue sections. 
Scores are then averaged, summed, or the maximum is taken to assess OA severity. 
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Additional histological outcomes include osteophyte severity and changes in the 
synovial lining, meniscus, and ligaments. 
 
 
Figure 1.10. Murine outcome measures for assessment of OA severity. MicroCT scans can be 
used to analyze tissue properties of the a) subchondral bone, b) epiphyseal cancellous bone, c) 
metaphyseal cancellous bone, and d) metaphyseal cortical shell. Histology and IHC can be used 
to assess e) cartilage morphology, f) cell death, d) protein levels, and h) osteophyte formation. 
Adapted from [91]. 
 
1.7.2 Murine cellular outcomes 
In addition to tissue morphology, efforts have increased to understand the 
cellular pathways associated with OA. To this end, immunohistochemistry (IHC) has 
been implemented to further analyze bone, cartilage, synovial and meniscal changes on 
the protein level [102,110]. Briefly, tissue sections are incubated with a primary 
antibody for the protein of choice, and then with a secondary antibody and substrate for 
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visualization. Positive staining in the joint tissues is then quantified and compared to 
contralateral control joints, thus expanding our understanding of OA progression from 
the cellular to the tissue scale. 
 
1.8 Aims 
 This thesis focuses on three key aspects of osteoarthritis: pathology, treatment, 
and prevention. Regarding pathology, we investigated the effect of abnormal cartilage 
material properties resulting from altered genetics on load-induced osteoarthritis 
progression. In terms of treatment, we engineered and tested a novel hydrogel-based 
drug delivery system to improve intra-articular drug retention times and deliver drugs 
on-demand. Lastly, we used low-level mechanical loading to attenuate OA progression 
after joint injury in mice.  
 
1.8.1 Aim 1 
Interactions among risk factors for osteoarthritis (OA) are not well understood. 
We investigated the combined impact of two prevalent risk factors: mechanical loading 
and genetically abnormal cartilage tissue properties. The cho/+ mouse has abnormal 
collagen fibrils in its cartilage matrix due to a point mutation in the Col11a1 gene. We 
used cyclic tibial compression to simulate mechanical loading in the cho/+ (Col11a1 
haploinsufficient) mouse. We hypothesized that the collagen mutation would not alter 
bone properties and that cho/+ mice, which develop early onset OA, would develop 
exacerbated load-induced cartilage damage compared to their littermates. To test our 
hypotheses, we applied cyclic compression to the left tibiae of 6-month-old cho/+ male 
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mice and wild-type (WT) littermates for 1, 2, and 6 weeks at moderate (4.5N) and high 
(9.0N) peak load magnitudes. We then characterized load-induced cartilage and bone 
changes by histology, microcomputed tomography, and immunohistochemistry.  
 
1.8.2 Aim 2 
Short drug retention times in the joint space have limited the success of intra-
articular drug delivery as a treatment for osteoarthritis (OA). Injectable hydrogels 
recently were developed to overcome this retention challenge. Ideally, an intra-articular 
hydrogel delivery system should maintain constant size for long durations under 
hydrolytic conditions, withstand forces that occur in weight-bearing joints, and release 
therapeutics in the presence of inflammatory markers and/or degradative enzymes, such 
as collagenases (e.g. matrix metalloproteinase (MMP)-3 or -13). To this end, we 
engineered an on-demand, biocompatible, injectable hydrogel using crosslinked 4-arm 
maleimide functionalized polyethlyene glycol (PEG-MAL). To crosslink the hydrogel, 
we used nondegradable Dithiothreitol (DTT) or MMP-3 and -13 degradable 
GCRDVPMSMRGGDRCG peptides (VPM). To predict how these hydrogels perform 
as a drug delivery system, we aimed to 1) determine the effect of PEG-MAL weight 
percentages on swelling ratios of hydrogels, 2) understand the effects of cyclic 
compression and hydrolytic degradation on the mechanical properties and particle 
release from hydrogels, and 3) determine the effect of degradable crosslinker on particle 
release from hydrogels in the presence of collagenase. Finally, in an in vivo mouse 
model, we 4) determined if the hydrogels could attenuate OA progression after a single 
bout of high-magnitude cyclic tibial compression. 
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1.8.3 Aim 3 
Mechanical loading and joint health have a unique relationship in OA onset and 
progression. Intense physical activity or high levels of loading lead to cartilage 
degradation by decreasing proteoglycan synthesis, inducing chondrocyte apoptosis, and 
rupturing stabilizing ligaments. On the other hand, mild exercise resulting in low-level 
loads benefits cartilage by preventing injury-induced cartilage degradation, maintaining 
thicker cartilage, and increasing proteoglycan synthesis in vitro. However, exercise 
leads to systemic effects, such as muscle growth and weight loss, that are also beneficial 
to joint health. Therefore, whether low levels of mechanical loading can directly aid 
cartilage health remains unclear. We sought to understand the beneficial effects of low-
level mechanical loading using in vivo cyclic tibial compression. We used low-level 
cyclic compression in combination with a surgically-induced model of post-traumatic 
OA, the destabilization of the medial meniscus (DMM), to determine whether daily 
cyclic compression would directly benefit knee joints. We hypothesized that low-level 
cyclic compression would attenuate post-traumatic OA pathology induced by DMM. 
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CHAPTER 2: COLLAGEN XI MUTATION LOWERS SUSCEPTIBILITY TO 
LOAD-INDUCED CARTILAGE DAMAGE IN MICE 
 
2.1 Introduction 
 
Osteoarthritis (OA) is a whole joint disease characterized by pain and stiffness 
due to articular cartilage degradation, subchondral bone changes, and osteophyte 
formation. OA is the leading cause of disability in the elderly and affects approximately 
27 million people in the United States alone [1–5]. The disease primarily affects 
articulating joints subjected to loading and motion such as the knees, fingers, and hips. 
OA has many risk factors, including aging, obesity, previous joint injury, joint 
malalignment, high levels of mechanical loading, and genetic abnormalities that affect 
cartilage integrity [6]. Determining the interactions of these factors in influencing joint 
damage is critical to better understanding the disease and developing effective treatment 
options. In this study, we focused on the combined impact of mechanical loading and a 
genetically abnormal cartilage matrix in OA pathogenesis. 
Mechanical loading and joint health have a unique relationship. Low levels of 
mechanical loading, such as mild exercise, can benefit cartilage by preventing injury-
induced cartilage degradation [7,8], maintaining thicker cartilage [9], and increasing 
proteoglycan synthesis [10]. However, higher levels of loading can lead to cartilage 
degradation by decreasing proteoglycan synthesis [11], inducing chondrocyte apoptosis 
[12], and rupturing critical stabilizing ligaments [13]. To further elucidate the role of 
mechanical loading in OA, we and others developed a noninvasive preclinical model 
that applies controlled cyclic compression to mouse knee joints [14,15]. We previously 
demonstrated that this model recapitulates OA pathology in healthy mouse knees [14]. 
  37 
Epidemiological studies of OA have estimated a heritability of 50% or more 
depending upon the affected joint, suggesting that half of the variation in disease 
susceptibility could be explained by genetic factors [16–19]. Collagen XI is essential 
for collagen fibril formation in articular cartilage [20,21]. Collagen fibrils, containing 
primarily type II collagen with the alpha 1 collagen XI [1(XI)] chain incorporated, 
form a network in the cartilage extracellular matrix (ECM) that contributes to tensile 
strength and retention of proteoglycans in cartilage tissue. In this study, we focused on 
a mutation in the gene encoding 1(XI) that results in chondrodysplasia in humans and 
the development of secondary OA. Mice with the same point mutation in one allele of 
the Col11a1 gene (cho/+), display abnormally thick collagen fibrils in their cartilage 
ECM [22], accompanied by reduced tissue tensile properties and OA-like features 
starting at 3 months of age [22]. The expression levels of both discoidin domain receptor 
(DDR)-2 and  matrix metalloproteinase (MMP)-13 are elevated in the articular cartilage 
of cho/+ mice [23] and contribute to degradation of the pericellular matrix [24]. 
Although mice homozygous for the cho mutation display severe skeletal abnormalities 
resulting in perinatal lethality [20], cho/+ mice do not display overt skeletal or extra-
skeletal developmental defects besides the aforementioned age-related changes in the 
cartilage matrix [25]. Thus, cho/+ mice provide a model to study the contribution of a 
genetically abnormal cartilage matrix to load-induced OA in a well-controlled manner. 
The influence of a genetically abnormal cartilage matrix on the severity of load-
induced cartilage damage is unknown. Because cartilage damage was enhanced in mice 
overexpressing DDR-2 subjected to a surgically-induced posttraumatic model of OA 
[26], we predicted that cho/+ cartilage, with elevated levels of DDR-2, would 
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experience exacerbated load-induced damage. Furthermore, the mechanical properties 
of the cartilage matrix are impaired in the cho/+ mouse, so we expected the cartilage to 
deform more under load, thereby increasing the strains on the chondrocytes, leading to 
cell death and cartilage degradation. However, the skeletal phenotype has not been 
carefully examined in adult cho/+ mice. Our previous RNAseq analyses on total RNA 
isolated from mouse bone showed that Col11a1 is among the most highly expressed 
genes in both cancellous and cortical bone [27]. Altered subchondral bone properties in 
cho/+ mice could also influence the cartilage response to loading, and thus we could 
not accurately predict the overall response to load in the knee joints of the cho/+ mouse. 
Therefore, we aimed to 1) determine whether the collagen XI mutation affects 
the intrinsic cortical and cancellous bone phenotype of cho/+ mice, and 2) examine the 
interaction between mechanical loading and genetically abnormal cartilage matrix 
properties in the onset and progression of OA. We subjected cho/+ mice and wild-type 
(WT) littermates to cyclic tibial compression in vivo and used radiographic, 
histological, and immunohistochemical techniques to assess the phenotypic bone and 
cartilage changes in the knee joint. We hypothesized that cartilage abnormalities due to 
the collagen XI mutation would exacerbate cartilage damage and subchondral bone 
adaptation associated with load-induced OA. However, we found that the development 
and progression of OA cartilage pathology was less severe in the mutant mice compared 
to their WT littermates. Our findings indicate that the altered bone and cartilage 
phenotypes may have contributed to these unexpected results and highlight the complex 
nature of the interactions between bone and cartilage properties in the evolution of load-
induced OA. 
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2.2 Materials and Methods 
 
2.2.1 Mouse Genotyping 
Mouse genotyping was performed as described previously [20]. Heterozygous 
cho/+ mice and WT littermates were housed together (2 to 4 mice per cage). Lighting 
was maintained at a 12-hours-on-12-hours-off schedule. Mice were given food and 
water ad libitum. Male 6-month-old cho/+ mice and WT littermates were used for the 
phenotype characterization and loading experiments. We previously confirmed the 
presence of cartilage damage in response to moderate and high loads in male 6-month-
old C57BL/6 mice [14] and the loss of superficial proteoglycan staining in non-loaded 
male cho/+ mice by 6 months of age, indicative of early OA-like changes [28]. 
 
2.2.2 Mechanical Loading 
We applied cyclic compression to the left tibiae of cho/+ mice [20,22,29] and 
WT littermates at moderate (4.5N) and high (9.0N) peak load magnitudes for durations 
of 1, 2, and 6 weeks (n=6/group/genotype). Right limbs served as contralateral controls. 
With mice under general anesthesia (2% isoflurane, 1.0L/min, Webster), loading was 
applied to the left tibiae 5 days/week for 1200 cycles at a frequency of 4 Hz. [30] Upon 
completion of loading, mice were euthanized.  Knee joints were harvested and fixed in 
4% paraformaldehyde overnight at 4°C. All experimental techniques were approved by 
the Cornell IACUC. 
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2.2.3 Cartilage and Bone Morphology Analyses 
Microcomputed tomography (microCT) scans were used to assess phenotypic 
bone morphology and changes in response to loading. After fixation, tissues were 
transferred to 70% ethanol for short-term storage. Intact knee joints were scanned using 
microCT, with an isotropic voxel resolution of 10 µm (μCT35, Scanco, Bruttisellen, 
Switzerland; 55kVp, 145μA, 600ms integration time). The effects of beam hardening 
were reduced with a 0.5 mm aluminum filter. After scanning, knee joints were 
decalcified in formic acid and processed for paraffin embedding. Paraffin blocks were 
sectioned at a thickness of 6 µm from posterior to anterior using a rotary microtome 
(Leica RM2255, Wetzlar, Germany). 
To assess cartilage morphology, sections were stained with Safranin O/Fast 
Green at 90-µm intervals throughout the joint. Histological scoring was performed on 
these sections by two blinded researchers to examine cartilage damage in the medial 
and lateral tibial plateaus. Scores from all sections of each limb were averaged. In 
control limbs, a modified Mankin scoring system was used to characterize the articular 
cartilage phenotype of cho/+ and WT mice [22]. Structural cartilage damage after 
loading was evaluated in all limbs using the OARSI scoring system [31]. Cartilage 
thickness was measured in both the medial and lateral plateaus on three representative 
sections in the joint (posterior, middle, and anterior) as described previously [14,32]. 
To assess osteophyte formation in response to loading, we examined Safranin 
O/Fast Green-stained histological sections for ectopic bone formation surrounding the 
joint. Osteophyte maturity was evaluated as described previously [33]. Briefly, we 
identified the section from each joint that contained the largest portion of the medial 
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tibial osteophyte. Using the representative slide, we scored osteophyte maturity: 0 for 
no osteophyte, 1 for a primarily cartilaginous osteophyte, 2 for a mixture of cartilage 
and bone, or 3 for primarily bony structure. We also measured the medial-lateral width 
of the osteophyte, defined as the distance between the medial end of the epiphysis and 
the end of the ectopic bone. Widths are reported as absolute values. 
To assess peri-articular bone morphology, we examined cortical and cancellous 
bone in the epiphysis and metaphysis of the proximal tibia using microCT. We analyzed 
the subchondral cortical bone plate (SBP) and metaphyseal cortical shell for thickness 
and tissue mineral density (TMD). For the SBP, the volume of interest (VOI) 
encompassed all cortical bone beginning at the proximal end of the tibia extending 
distally until the epiphyseal cancellous bone was evident. The VOI for the metaphyseal 
cortical shell began distal to the growth plate and extended 10% of the tibial length, 
excluding cancellous bone. We analyzed isolated cancellous bone in the epiphysis and 
metaphysis for bone volume fraction (BV/TV), trabecular thickness (Tb.Th), trabecular 
separation (Tb.Sp), and TMD. For the epiphysis, the VOI encompassed cancellous bone 
proximal to the growth plate and distal to the subchondral bone plate, excluding cortical 
bone. The VOI for metaphyseal cancellous bone encompassed the same region analyzed 
for the cortical shell, excluding the cortex. 
 
2.2.4 Immunohistochemistry and TUNEL assay 
We performed immunohistochemistry (IHC) to assess load-induced changes in 
cartilage proteins in cho/+ and WT mice. We evaluated markers of OA disease using 
specific antibodies against MMP-13 (Abcam, AB39012, Cambridge, MA) and DDR-2  
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(Abcam, AB5520, Cambridge, MA). We also assessed chondrocyte apoptosis using a 
TUNEL kit to detect DNA strand breaks (Sigma, 11684795910 Roche, Darmstadt, 
Germany). We analyzed the medial posterior tibial plateau at early time points under 
high loads, because the majority of load-induced damage occurs in this region [14], and 
a single session of 9N cyclic compression leads to progressive cell-mediated changes 
and cartilage degradation at 1 and 2 weeks [32]. 
We stained one representative section from the posterior region of control and 
loaded limbs from animals loaded for 1 or 2 weeks at 9N. For MMP-13 and DDR-2 
IHC, sections were deparaffinized, rehydrated, and incubated with 2.5% hyaluronidase 
at 37°C for antigen retrieval, and quenched for endogenous peroxidase activity. Sections 
for MMP-13 IHC were then incubated with 1% bovine serum albumin and 0.5% Triton 
X-100 for 1h. Sections for DDR-2 IHC were incubated with Dako protein block for 
5min at room temperature. Then, the samples were incubated overnight at 4°C with 
specific antibodies against MMP-13 or DDR-2, followed by incubation with anti-rabbit 
horseradish peroxidase-conjugated secondary antibodies. Color development was 
performed using the peroxidase substrate DAB. Samples were dehydrated, 
coverslipped, and the percentage of positive immunostaining in the articular cartilage 
of the medial tibial plateau was calculated using ImageJ software (NIH) as described 
previously [34,35]. 
For the TUNEL assay, sections were deparaffinized, rehydrated, and incubated 
with proteinase K at 37°C. The samples were then incubated with the TUNEL reaction 
mixture for 1h at 37°C. Finally, sections were coverslipped with antifade mounting 
media containing DAPI. TUNEL positive cells were measured in the articular cartilage 
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of the medial tibial plateau, as described previously [34,35], and normalized to the total 
number of chondrocytes (DAPI+ signal) to account for potential changes in cellularity. 
 
2.2.5 Statistical analyses 
Bone parameters and Mankin scores of control limbs were compared between 
WT and cho/+ mice using a Student’s t-test. To minimize potential systemic effects of 
loading and aging, we analyzed control limbs only from the 1-week time point for our 
baseline bone phenotype comparisons. Baseline IHC parameters in control limbs were 
also compared between WT and cho/+ mice using a t-test. 
To understand the effects of loading, we used a four-way ANOVA with load 
(loaded vs. control limb), magnitude (high vs. moderate), duration (1 vs. 2 vs. 6 weeks), 
and genotype (WT vs. cho/+) as variables, with animal as a random effect. We applied 
the ANOVA to assess OARSI histological scores, cartilage thickness, and all bone 
morphological parameters. To analyze the IHC and TUNEL results and osteophyte 
formation at high loads, we used a three-way ANOVA with load, genotype, and duration 
as variables, with animal as a random effect. Post-hoc testing was performed with 
Tukey's tests for interaction effects and t-tests for individual effects. 
 
2.3 Results 
 
2.3.1 Bone and Cartilage Phenotypes 
Cortical bone thickness and TMD were different between genotypes. The 
metaphyseal cortical shell was thinner (p=0.029) and had lower TMD (p=0.002) in 
cho/+ mice compared to WT littermates (Fig. 2.1A). Similarly, the medial subchondral 
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bone plate was thinner (p=0.041) with a trend towards lower TMD (p=0.051) in cho/+ 
mice (Fig. 2.1B). Cancellous bone morphology in the proximal tibia was similar 
between WT and cho/+ mice. Specifically, cancellous BV/TV, Tb.Th, Tb.Sp, and TMD 
were not different in the epiphyseal and metaphyseal regions of either genotype (Fig. S-
2.7).  In addition, tibial length was not different between cho/+ and WT mice 
(17.70±0.32 vs. 17.75±0.34mm). 
Consistent with previous reports [22], loss of proteoglycan in the articular 
cartilage in cho/+ mice occurred spontaneously at 6 months of age, resulting in higher 
Mankin scores (p=0.011, Fig. S-2.8). Proteoglycan loss was localized to the superficial 
layer of the articular cartilage, as evident from the representative Safranin O/Fast Green 
images of control limbs (Fig. S-2.8). Cho/+ mice also had ~10% thicker cartilage than 
WT on the medial side of the joint in the posterior (78.49 vs. 71.28μm, p=0.028, Fig. 
2.2C), middle (93.15 vs. 87.16μm, p=0.036), and anterior (93.07 vs. 84.97μm, p=0.071) 
regions. Cartilage in cho/+ mice was also thicker on the lateral side in the posterior 
region (75.94 vs. 68.63μm, p=0.012). In the medial tibial plateau, calcified cartilage 
thickness was not different between genotypes (data not shown), indicating that the 
thickened articular cartilage in cho/+ mice was due to thicker hyaline cartilage. 
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Figure 2.1. Cortical bone phenotypes were different between cho/+ mice and WT littermates. 
Cortical bone in the (A) metaphyseal shell and (B) medial subchondral bone plate in cho/+ mice 
was thinner and less dense compared to WT littermates. Lines behind the dots show the mean ± 
SD of 24 mice (n=12/group). TMD = Tissue Mineral Density. *p<0.05 vs. WT by t-test. 
 
2.3.2 Load-Induced Articular Cartilage Morphological Changes 
Mechanical loading induced articular cartilage degradation in the tibial plateaus 
of both WT and cho/+ mice (Fig. 2.2A). Moderate loading (4.5N) caused little damage 
after 1 and 2 weeks, but fibrillation of the articular surface was present after 6 weeks. 
Load-induced damage under moderate loads was similar in both genotypes. With high 
loads (9.0N), cartilage fibrillation occurred by 1 week. Erosion of the articular surface 
occurred after 2 weeks. At the 6-week time point, the articular cartilage was completely 
eroded to the tidemark, and in some cases, erosion occurred through the entire calcified 
cartilage layer, most often on the medial tibial plateau of WT mice. Under high loads, 
the medial tibial plateau of loaded limbs in cho/+ mice had significantly less cartilage 
damage than in WT (OARSI score 1.22 vs. 1.67, p=0.016, Fig. 2.2B). 
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Figure 2.2. Cho/+ mice were less susceptible to load-induced cartilage degradation. (A) 
Moderate loading led to fibrillation after 6 weeks. High loads led to fibrillation after 1 week and 
progressed to erosion after 2 and 6 weeks. Damage is indicated by arrow heads. (B) Under high 
load magnitudes, cho/+ mice experienced less severe cartilage damage compared to WT mice, 
but moderate loads caused similar damage between genotypes. (C) High loads caused thinning 
in the posterior region of the tibial plateau. Cho/+ mice had approximately 10% thicker cartilage 
than WT mice. Scale Bars = 50 μm. Bars show the mean ± SD of 72 mice (n=6/group). Solid 
and dashed lines indicate post-hoc comparisons of the effect of genotype and genotype*load, 
  47 
respectively. p<0.05 by ANOVA indicated on vertical axis for effects of aGenotype, bLoad, 
cDuration, dMagnitude, eGenotype*Load, fGenotype*Duration, gGenotype*Magnitude, 
hLoad*Duration, iLoad*Magnitude, jDuration*Magnitude, kGenotype*Load*Duration, 
lGenotype*Load*Magnitude, mGenotype*Duration*Magnitude, nLoad*Duration*Magnitude, 
oGenotype*Load*Duration*Magnitude. 
 
The high load caused localized cartilage thinning in the posterior region of the 
tibial plateau (Fig. 2.2C). Cartilage thinning was also evident in cartilage in the middle 
region of the joint on the medial side with loading. The majority of thinning occurred in 
the hyaline cartilage (Fig. 2.2A). Load-induced cartilage thinning was similar in both 
genotypes. In contrast, moderate loading caused little to no thinning. 
 
2.3.3 Osteophyte formation 
Osteophyte formation was evident only in limbs loaded at high load magnitudes 
(Fig. 2.3A). After 1 week of high loads, small cartilaginous pre-osteophytes were 
present on the medial tibial plateau of all loaded joints. After 2 weeks, medial 
osteophytes grew significantly in size, but remained primarily cartilaginous with little 
to no mineralization. After 6 weeks of loading, osteophytes had undergone ossification 
and were predominantly bone. In the knees of a few animals, these bony osteophytes 
extended along the entire medial side of the joint. Osteophyte size and maturity was 
similar between genotypes (Fig. 2.3B,C), with a slight trend towards smaller 
osteophytes in cho/+ mice (p=0.185, Fig. 2.3B). 
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Figure 2.3. Osteophyte formation was similar between genotypes. (A) Osteophytes formed on 
the medial tibial plateau of loaded limbs. (B,C) After 1 week, osteophytes were small and 
primarily cartilagenous. After 6 weeks, osteophytes were larger and more mineralized. Scale 
Bars = 500 μm Bars show the mean ± SD of 36 mice (n=6/group). Same letters over the bars 
indicate similar mean values, and groupings with different letters indcate that the difference is 
significant by post-hoc comparisons of the effect of load*duration. p<0.05 by ANOVA 
indicated on vertical axis for effects of aGenotype, bLoad, cDuration, fGenotype*Duration, 
gGenotype*Load, hLoad*Duration, kGenotype*Load*Duration. 
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2.3.4 Load-Induced Peri-Articular Bone Morphological Changes 
High loads had no effect on medial subchondral cortical bone plate thickness 
(Fig. 2.4A), but decreased TMD (Fig. 2.4B). Moderate loads did not change SBP 
thickness (Fig. S-2.9A) or TMD (Fig. S-2.9B). Load-induced changes in the SBP were 
similar between the genotypes. 
High loads maintained thickness in the metaphyseal cortical shell (Fig. 2.4C), 
whereas moderate loads had no effect on metaphyseal cortical thickness (Fig. S-2.9C). 
TMD was not affected by either load level (Fig. 2.4D, Fig. S-2.9D). The cortical shell 
changed similarly in response to loading in both genotypes. When pooled by genotype, 
cho/+ mice had thinner (p=0.002) and less dense (p<0.0001) cortical bone in the 
metaphyseal region. 
Loading led to epiphyseal cancellous bone loss in both cho/+ and WT mice (Fig. 
2.5A). Bone loss in the epiphysis was primarily trabecular thinning (p=0.038) with a 
trend towards greater separation (p=0.054, Fig. 2.5B) as a result of both high and 
moderate loads (Fig. S-10A,B). Load-induced epiphyseal cancellous bone changes were 
similar in both genotypes. When pooled by genotype, cho/+ mice had a trend towards 
thinner trabeculae compared to WT (0.053 vs. 0.054mm, p=0.095). 
Unlike the epiphysis, metaphyseal cancellous BV/TV was unaffected by loading 
in either genotype (Fig. 2.5C). However, loading increased Tb.Th and TMD (Fig. 2.5D). 
Tb.Sp did not change with loading in the metaphysis. These changes were not different 
between high and moderate loads (Fig. S-10C,D). Load-induced metaphyseal 
cancellous bone changes were similar between genotypes. When pooled by genotype, 
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metaphyseal trabeculae were thinner in cho/+ than WT mice (0.051 vs. 0.054mm, 
p=0.014), similar to the epiphysis. 
Bone loss occurred over time in all four regions of bone we analyzed. 
Specifically, cortical bone thickness in the subchondral bone plate decreased over time 
in control and loaded limbs, and metaphyseal cortical shell thickness decreased in 
control limbs. In addition, epiphyseal and metaphyseal cancellous BV/TV decreased 
over time in both control and loaded limbs. 
 
Figure 2.4. Cortical bone in the subchondral bone plate and metaphyseal cortical shell 
responded differently to high loads. (A,B) The subchondral cortical bone plate thinned and 
became less dense with loading. (C,D) The metaphyseal cortical shell maintained thickness and 
its density remained the same with loading. Bars show the mean ± SD of 36 mice (n=6/group). 
Same letters over the bars indicate similar mean values, and groupings with different letters 
indcate that the difference is significant by post-hoc comparisons of the effect of (A) 
load*duration, (B) genotype*load*duration*magnitude, and (C) load*duration*magnitude. 
p<0.05 by ANOVA indicated on vertical axis for effects of aGenotype, bLoad, cDuration, 
dMagnitude, eGenotype*Load, fGenotype*Duration, gGenotype*Magnitude, hLoad*Duration, 
iLoad*Magnitude, jDuration*Magnitude, kGenotype*Load*Duration, 
lGenotype*Load*Magnitude, mGenotype*Duration*Magnitude, nLoad*Duration*Magnitude, 
oGenotype*Load*Duration*Magnitude. 
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Figure 2.5. Cancellous bone in the epiphysis and metaphysis responded differently to high 
loads. (A) Epiphyseal cancellous bone decreased in bone volume fraction with high load 
magnitudes. (B) Epiphyseal trabecular separation increased with duration. (C) Cancellous bone 
in the metaphysis decreased with duration, but (D) trabecular thickness increased with loading. 
Bars show the mean ± SD of 36 mice (n=6/group). Same letters over the bars, or pooled bars, 
indicate similar mean values, and groupings with different letters indcate that the difference is 
significant by post-hoc comparisons of the effect of (A) load*duration, (B,C) duration, and (D) 
load*duration*magnitude. p<0.05 by ANOVA indicated on vertical axis for effects of 
aGenotype, bLoad, cDuration, dMagnitude, eGenotype*Load, fGenotype*Duration, 
gGenotype*Magnitude, hLoad*Duration, iLoad*Magnitude, jDuration*Magnitude, 
kGenotype*Load*Duration, lGenotype*Load*Magnitude, mGenotype*Duration*Magnitude, 
nLoad*Duration*Magnitude, oGenotype*Load*Duration*Magnitude. 
 
2.3.5 Immunohistochemical and TUNEL analyses 
Control cho/+ limbs had high MMP-13 levels (p=0.031) and a trend towards 
increased DDR-2 immunostaining (p=0.111) compared to WT littermates, consistent 
with previous reports [28]. Loading induced a trend towards decreased MMP-13 (1.3 
vs. 1.9%) and DDR-2 (1.3 vs. 2.9%) immunostaining in cho/+ mice, whereas MMP-13 
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and DDR-2 levels were not altered with loading in WT littermates (Fig. 2.6). In addition, 
loading decreased cellularity in both genotypes (data not shown), and high loads also 
increased chondrocyte apoptosis in both genotypes (p=0.009), with a greater percentage 
of TUNEL+ cells in cho/+ mice compared to WT littermates after 2 weeks of loading 
(1.8 vs. 0.8μm2/cell #, Fig. 2.6). 
 
 
Figure 2.6. MMP-13 and DDR-2 levels were higher in control limbs of cho/+ mice compared 
to WT littermates. Loading induced a trend towards decreased MMP-13 and DDR-2  
immunostaining in cho/+ mice, whereas it did not alter MMP-13 and DDR-2 levels in WT 
littermates. Apoptosis increased in loaded limbs, with slightly higher levels of apoptosis in 
cho/+ mice after 2 weeks of loading. Scale Bars = 50 μm. Lines behind the dots show the mean 
± SD of 16-24 mice (n=4-8/group). 
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2.4 Discussion 
 
We sought to determine whether the mutant alpha XI collagen chain 
incorporated into the cartilage collagen fibrillar network and resultant changes in 
articular cartilage composition in cho/+ mice altered the responses in the cartilage and 
bone in knee joints subjected to cyclic tibial compression compared to WT littermates. 
We confirmed the presence of differences in cartilage morphology and the development 
of the spontaneous onset of OA-like features between 6-month-old cho/+ mice and WT 
littermates as previously reported [28]. Unexpectedly, we found that prior to loading, 
the cortical bone in the subchondral bone plate and metaphysis was thinner and less 
dense in cho/+ mice compared to their WT littermates, whereas the collagen XI 
mutation was not associated with any change in cancellous bone structure. 
We originally hypothesized that the collagen XI mutation would not affect bone 
phenotype based on collagen XI's key role in fibril formation in cartilage [21,28,36]. 
Our results, however, suggest that collagen XI plays a role in the formation and/or 
maintenance of cortical bone. Indeed, previous studies support our results that fibrillar 
collagen components play a role in bone morphogenesis and structure [20,37]. Mice 
homozygous for the Col11a1 mutation (cho/cho) do not survive after birth because of 
improper skeletal formation, including a shortened spine and shortened bones in the 
appendicular and thoracic skeleton [20]. Col11a1-deficient mice also have altered bone 
microarchitecture during embryonic development [38]. In addition, mice with a 
deficiency in collagen IX, another key component of collagen fibrils in the cartilage 
ECM, have abnormal skeletal properties [37]. Lastly, Col11a2 mutations lead to mild 
dwarfism in Labrador retrievers [39]. Consistent with these previous findings, cho/+ 
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mice had thinner and less dense cortical bone compared to WT littermates. These results 
emphasize the involvement of collagen XI in the development and potentially the 
composition and properties of bone in the mature skeleton. 
Contrary to our hypothesis, cho/+ mice were less susceptible to load-induced 
cartilage damage compared to WT littermates, despite the spontaneous proteoglycan 
loss and increased DDR-2 and MMP-13 levels associated with the collagen XI mutation. 
One explanation for the less severe cartilage damage may be related to the differences 
in cartilage thickness between genotypes. Cho/+ mice had ~10% thicker cartilage in the 
medial tibial plateau compared to WT littermates. Cartilage swelling correlates with 
proteoglycan loss in early-stage experimental OA [40]; thus, the cartilage in 6-month-
old cho/+ mice may experience swelling concurrently with the associated spontaneous 
proteoglycan loss typical of the early OA-like phenotype of cho/+ mice at this age. 
Whereas load-induced cartilage thinning was not different between genotypes, the 
overall thicker cartilage in cho/+ mice may have reduced the load-induced structural 
cartilage stresses. Our observation is consistent with previous reports, also based on in 
vivo loading experiments, that showed thicker cartilage decreased the peak contact 
pressures and shear forces in the articular cartilage [41]. Furthermore, mice susceptible 
to spontaneous cartilage lesions (Str/ort) were protected from load-induced mechanical 
trauma compared to control mice (CBA) because of thicker articular cartilage [41]. In 
both studies, the decreased susceptibility to load-induced cartilage damage may be due, 
partly, to dissipation of mechanical stresses by the thicker articular cartilage. 
The thinner, less dense cortical bone in the metaphyseal shell and medial 
subchondral bone plate in cho/+ mice may also have played a role in attenuating load-
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induced cartilage damage. Subchondral cortical bone stiffness is important in initiating 
OA [42–44]. Clinically, individuals with extremely elevated bone density are more 
likely to develop OA in the hip and knee [45,46], and bone density and OA incidence 
may be inversely related [47]. Thus, the thinner, less dense cortical bone in cho/+ mice 
could have contributed to the reduced severity of load-induced cartilage damage. Of  
interest, these results differ from previous findings showing enhanced cartilage damage 
in transgenic mice conditionally overexpressing DDR-2 in the articular cartilage 
subjected to the surgical destabilization of the medial meniscus (DMM) OA model [26]. 
However, the bone properties of these transgenic mice prior to DMM surgery were not 
assessed and most likely differed from those of cho/+ mice, which could account for 
our different results. 
Our findings confirm the mechanistic connection of DDR-2 and MMP-13 in 
cartilage degradation in cho/+ mice. DDR-2 is a cell surface receptor that drives MMP-
13 expression and activity and is elevated in OA disease in both human articular 
cartilage and murine models, including the cho/+ mouse [23,24,28,48]. We found that 
elevated DDR-2 and MMP-13 levels correlated with spontaneous proteoglycan loss in 
cho/+ mice but were not associated with the OA-like changes induced by loading in 
either genotype. In loaded limbs, we observed trends towards decreased MMP-13 and 
DDR-2 levels in cho/+ mice, whereas loading did not alter MMP-13 or DDR-2 levels 
in WT littermates. Independent of the differences in DDR-2 and MMP-13 levels 
between genotypes, loading decreased cellularity and increased cell death similarly in 
cho/+ and WT cartilage, with only minor differences in apoptosis at 2 weeks post-
loading, when cho/+ mice showed a trend towards increased numbers of TUNEL+ cells 
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compared to WT. Taken together, differences in susceptibility to load-induced cartilage 
damage may be due to tissue-level characteristics rather than the cellular responses we 
examined. Specifically, the thicker cartilage and the thinner, less dense cortical bone in 
cho/+ mice were likely the driving factors in lowering the susceptibility of cho/+ mice 
to load-induced cartilage degradation, in agreement with previous findings [41]. 
We clearly observed two distinct etiologies of OA and an unexpected interaction 
in the development of cartilage damage in our study. Cho/+ mice developed 
spontaneous OA from genetically weaker matrix properties that resulted in DDR-2-
driven collagenase activity and gradual proteoglycan loss throughout their lifespan [28]. 
On the other hand, cyclic tibial compression at high-load levels led to rapid structural 
changes in the cartilage matrix with little evidence of proteoglycan loss [14]. The lack 
of correlation between loading and DDR2/MMP13 levels was unexpected but was likely 
an example of the different mechanisms involved in load-induced versus genetic OA. 
We can only speculate that other receptors and cartilage-degrading enzymes (i.e., 
collagenases and aggrecanases) not analyzed in the context of this study contributed to 
load-induced cartilage degradation. Ultimately, the contribution of the genetic 
abnormalities of the cartilage in the cho/+ mouse was not additive to load-induced 
cartilage damage, suggesting that these two risk factors do not act synergistically or 
additively [49]. 
Our study had several limitations, potential alternative strategies, and strengths. 
With our microCT analysis of subchondral bone, we analyzed the full volume of the 
subchondral cortical bone plate but could not isolate specific regions within the 
subchondral bone. To examine location-specific changes, we measured localized 
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subchondral bone thickness from histology slides in the anterior, middle, and posterior 
regions. The histology measurements matched our microCT findings. In particular, 
loading did not affect subchondral bone plate thickness in any of these three regions, 
and thickness decreased over time. Similarly, cortical and cancellous bone in the 
epiphysis and metaphysis decreased with time in this study. The changes in bone 
architecture over time can be attributed to aging, as rapid bone changes can occur in 
mice around 6 months of age [50]. 
The mechanical loading regimen is not representative of all forms of joint 
loading. Cyclic tibial compression allows for precise control of the loading regimen, 
produces consistent cartilage damage, and does not depend on mouse activity levels or 
willingness to run on a treadmill or wheel. However, alternative techniques for applying 
elevated loads could be considered. For example, excessive treadmill running leads to 
OA in C57Bl/6 mice [51] and could have produced a different response in cho/+ mice 
compared to cyclic tibial compression, but treadmill running also has a multitude of 
systemic effects [52]. Cyclic tibial compression allowed us to focus solely on the 
specific characteristics of mechanical loading, including duration and magnitude, and 
their effects on the progression of load-induced OA. 
Alternative forms of genetic OA also should be considered. Mice that are 
deficient in type IX collagen (Col9a1-/-) also develop abnormal collagen fibrils in the 
cartilage matrix leading to OA [53] and show trabecular bone deterioration [54]. Mice 
with mutations in other matrix-related genes, such as lubricin, have decreased cellularity 
in the superficial layer of their articular cartilage [55]. Lastly, investigating the effects 
of cyclic tibial compression in older cho/+ mice at more advanced stages of OA [28] 
  58 
may provide insights into the interaction between genetics and loading during the 
progression of OA. 
To our knowledge, this study is the first to examine the cortical and cancellous 
bone properties in the cho/+ mouse strain. We demonstrated that mice with mutant 
collagen XI exhibit changes in cortical bone, with limited changes in cancellous bone. 
Our study provides evidence that thinner, less dense cortical bone and thicker cartilage 
may be associated with decreased severity of load-induced OA. Genetically abnormal 
cartilage matrix properties due to the collagen XI mutation were not additive to load-
induced cartilage damage. The modes of damage involved in spontaneous OA in cho/+ 
mice and load-induced OA differed from each other at both the tissue and cellular levels. 
Our findings provide further insights into the complex nature of the interactions between 
bone and cartilage properties in the evolution of load-induced OA and demonstrate the 
utility of using mice with intrinsic alterations in cartilage and bone properties and 
defined loading conditions to elucidate the role of mechanobiological factors in OA 
development and progression. 
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Figure S-2.7. Cancellous bone phenotypes were similar between cho/+ mice and WT 
littermates. (A) Epiphyseal and (B) metaphyseal cancellous bone in control limbs of both 
genotypes was similar.  BV/TV = Bone Volume Fraction, Tb.Th = Trabecular Thickness, Tb.Sp 
= Trabecular Separation, TMD = Tissue Mineral Density. Lines behind the dots show the mean 
± SD of 24 mice (n=12/group). *p<0.05 vs. WT by t-test. 
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Figure S-2.8. Spontaneous proteoglycan loss occurred in cartilage of cho/+ mice at 6 months 
of age. (A) Cho/+ mice had higher Modified Mankin Score in control limbs compared to WT 
mice. (B) Arrow indicates proteoglycan loss in the superficial layer of articular cartilage in 
cho/+ mice. Scale Bars = 50 μm. Lines behind the dots show the mean ± SD of 36 mice 
(n=18/group). *p<0.05 vs. WT by t-test. 
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Figure S-2.9. Moderate loading did not affect subchondral bone or metaphyseal cortical shell 
properties. (A,B) Moderate loading had no effect on cortical bone thickness or tissue mineral 
density in the medial subchondral bone plate. (C,D) Thickness and tissue mineral density in the 
metaphyseal cortical shell decreased with duration, similarly in both gentoypes. Bars show the 
mean ± SD of 36 mice (n=6/group). p<0.05 by ANOVA indicated on vertical axis for effects of 
aGenotype, bLoad, cDuration, dMagnitude, eGenotype*Load, fGenotype*Duration, 
gGenotype*Magnitude, hLoad*Duration, iLoad*Magnitude, jDuration*Magnitude, 
kGenotype*Load*Duration, lGenotype*Load*Magnitude, mGenotype*Duration*Magnitude, 
nLoad*Duration*Magnitude, oGenotype*Load*Duration*Magnitude. 
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Figure S-2.10. Moderate loading had little effect on cancellous bone in the epiphysis and 
metaphysis, but bone did change with duration. (A) Epiphyseal cancellous bone volume fraction 
decreased and (B) trabecular separation increased with duration. Similarly, (C) metaphyseal 
cancellous bone volume fraction decreased with duration, and (D) trabecular thickness was 
unaffected by moderate loads. Bars show the mean ± SD of 36 mice (n=6/group). p<0.05 by 
ANOVA indicated on vertical axis for effects of aGenotype, bLoad, cDuration, dMagnitude, 
eGenotype*Load, fGenotype*Duration, gGenotype*Magnitude, hLoad*Duration, 
iLoad*Magnitude, jDuration*Magnitude, kGenotype*Load*Duration, 
lGenotype*Load*Magnitude, mGenotype*Duration*Magnitude, nLoad*Duration*Magnitude, 
oGenotype*Load*Duration*Magnitude. 
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CHAPTER 3: MECHANICALLY STABLE, INJECTABLE HYDROGELS FOR 
ATTENUATION OF LOAD-INDUCED OSTEOARTHRITIS 
 
3.1 Introduction 
Osteoarthritis (OA) is a degenerative joint disease that affects 27 million 
individuals in the United States and is the leading cause of disability in the elderly 
population [1]. Three primary characteristics of OA are cartilage degradation, 
osteophyte formation, and synovial inflammation. During the development of OA, 
enzymes such as aggrecanases (e.g. matrix metalloproteinase (MMP)-3) and 
collagenases (e.g. MMP-13), degrade the cartilage matrix and are elevated in the joint 
space [2–4]. Post-traumatic osteoarthritis (PTOA) is a subset of OA associated with 
instability due to mechanical trauma [5]. Providing interventions following mechanical 
trauma may be beneficial to attenuate PTOA. 
Intra-articular (IA) injections for OA treatment are advantageous because of the 
low drug dosage and reduced risk of side effects, but fast drug clearance from the joint 
space limits their functional outcome  [6,7]. Recent strategies to improve IA drug 
retention include biomaterials-based drug delivery systems, such as microparticles, 
nanoparticles, and hydrogels [8]. Micro- and nanoparticles can be engineered to target 
drug delivery locally to the joint tissues, resulting in longer retention of drugs [9–11]. 
Injectable hydrogels provide a unique platform with tunable mechanical properties and 
degradation profiles  [12,13]. However, biomaterials in the joint space are subject to 
daily mechanical loading that leads to undesirable drug release into circulation [14]. 
Here, we sought to engineer a hydrogel that could withstand the environment in weight-
bearing joints and therefore improve IA drug retention. 
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Ideally, an IA hydrogel delivery system should withstand routine forces in 
weight-bearing joints (up to 40% strain in cartilage) [15], maintain constant volume for 
long durations under hydrolytic conditions, and release therapeutics in the presence of 
degradative proteases, such as aggrecanases and collagenases (e.g. MMP-3 and -13). 
However, the ability of injectable hydrogels to withstand cyclic mechanical loading in 
weight-bearing joints remains unknown. Optimizing mechanical integrity and 
controlling the rate of hydrogel degradation with a collagenase-specific crosslinking 
system would improve retention time and enable on-demand therapeutic release under 
OA conditions. 
We engineered an on-demand, biocompatible, injectable hydrogel using 
crosslinked 4-arm maleimide functionalized polyethylene glycol (PEG-MAL). We used 
either non-degradable or MMP-3- and -13-specific dithiolated crosslinkers to control 
degradation rates under OA-like conditions. We first characterized the mechanical 
properties, swelling, and degradation characteristics of these hydrogels in vitro. 
Specifically, we 1) examined the effects of cyclic compression on the mechanical 
properties and particle release from hydrogels, 2) characterized the effect of PEG-MAL 
weight percentage on swelling ratios of hydrogels, and 3) determined the effect of 
degradable crosslinker on particle release from hydrogels in the presence of collagenase. 
Then, using an in vivo mouse model, we 4) determined whether injectable, MMP-
degradable hydrogels combined with a commonly used corticosteroid, dexamethasone 
(DEX), could attenuate OA progression after a single bout of high-magnitude 
mechanical loading [16]. We hypothesized that the PEG-MAL hydrogel drug-delivery 
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system would withstand routine forces in weight-bearing joints, maintain constant 
volume, release therapeutics in response to collagenase, and attenuate load-induced OA. 
 
3.2 Methods 
3.2.1 PEG-MAL Hydrogel Synthesis 
PEG-MAL hydrogels were synthesized, as described previously [17–20]. 
For our in vitro dynamic cyclic compression and swelling experiments, 50 μL 
synthetic hydrogels with 2.5, 5, 10, and 20% (w/v) macromer concentration were 
fabricated using PEG-MAL (Laysan Bio, Inc., >90% purity) and thiolated crosslinkers. 
We fabricated hydrogels by crosslinking PEG-MAL to non-degradable Dithiothreitol 
(DTT) using a 1:1.5 macromer-to-crosslinker molar ratio. All components were diluted 
in 1% HEPES buffer with a pH 7.4; the HEPES buffer was composed of PBS (+/+)and 
HEPES chemical agent. Each hydrogel contained fluorescent FITC particles (5 μm, 
Duke Scientific Corporation) suspended in the crosslinker solution at a 2000/μL 
concentration. After 25 μL of macromer solution was placed in the middle of each well 
on a nontreated 24-well plate, 25 μL of particle-containing crosslinker solution was 
injected into the initial droplet and mixed. Hydrogel droplets were prepared and cured 
at 37°C inside a cell culture incubator for complete crosslinking. PBS was then added 
to each well to cover the hydrogels (n=6/group).  
 For our in vitro collagenase experiments, 10 μL hydrogels with 10% (w/v) 
macromer concentration were fabricated by crosslinking PEG-MAL to non-degradable 
Dithiothreitol (DTT) and MMP-degradable GCRDVPMSMRGGDRCG peptides 
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(VPM) (AAPPTec, LLC, >90% purity). PEG-MAL was combined with DTT and/or 
VPM at a 1:1.5 ratio with 0, 50, and 100% VPM  (n=4/group). 
 For our in vivo experiments, we used 2 μL hydrogels with 10% (w/v) macromer 
concentration and 50% VPM (n=5/group) [18]. 
 
3.2.2 Dynamic Cyclic Compression 
Immediately after fabrication, hydrogels were placed in PBS. Hydrogels underwent 
unconfined cyclic compression at 37°C with a custom-built, displacement-controlled 
bioreactor, as described previously  [21,22] (Fig. 3.1A). We applied cyclic compression 
at strain levels of 0, 20, 40, and 80% at a 1 Hz frequency for 10,000 cycles. Particle 
release was measured in the supernatant from each well following loading of the 
hydrogel. The supernatant was analyzed by flow cytometry (BD Accuri C6 flow 
cytometer, BD Biosciences). The resulting particle counts were then gated to output the 
number of particles in the FITC fluorescent range (Accuri software). In addition, we 
measured storage and loss modulus of each hydrogel, also described below. 
 
3.2.3 Mechanical properties 
Mechanical properties of the hydrogels were measured in shear (Discovery Hybrid 
Rheometer, TA Instruments, New Castle, DE). We used a parallel plate geometry of 8 
mm diameter. The oscillatory degree of rotation (5 degrees), frequency (0.1 Hz), and 
temperature (37°C) were constant throughout all tests. All samples underwent one cycle 
of preconditioning. We recorded shear storage (G’) and loss (G”) moduli as a function 
of time and calculated average moduli over four cycles for each hydrogel.  
 
  72 
3.2.4 Swelling ratio 
Immediately after fabrication, we measured the initial hydrogel weight. We then 
incubated the hydrogels in 1 mL PBS (-/-) at 37°C. For the next 15 days, we removed 
the PBS, weighed the swollen hydrogels, and replaced the PBS. We calculated the 
swelling ratio according to the follow equation: 
𝑆𝑤𝑒𝑙𝑙𝑖𝑛𝑔 𝑟𝑎𝑡𝑖𝑜 =  
𝑆𝑤𝑜𝑙𝑙𝑒𝑛 𝑤𝑒𝑖𝑔ℎ𝑡
𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡
∗ 100 
 
3.2.5 Collagenase exposure 
Hydrogels were subjected to collagenase at 0 U/μL, 0.1 U/μL, or 10 U/μL. After 3 hours 
of collagenase exposure, particle release was measured in the supernatant from each 
well. The supernatant was analyzed by flow cytometry (BD Accuri C6 flow cytometer, 
BD Biosciences). The resulting particle counts were then gated to output the number of 
particles in the FITC fluorescent range (Accuri software). Gels were then resuspended 
in PBS for 21 hours. We then reintroduced the hydrogels to collagenase for another 3 
hours, and the supernatant was collected and analyzed again. This process was repeated 
daily for 4 days. 
 
3.2.6 In vivo mechanical loading 
To test the therapeutic potential of the hydrogel system, we first induced OA in mice 
using cyclic tibial compression [16]. We applied a single session of cyclic compression 
to the tibia of 26-week-old C57Bl/6 male mice (n=5/group; Jackson Laboratory).  With 
the mice under general anesthesia (2% isoflurane, 1.0 L/min, Webster), loading was 
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applied to the left or right tibia at a 9.0 N-peak load magnitude for 1200 cycles at a 4 
Hz frequency. Contralateral limbs served as controls. All experimental techniques were 
approved by the Cornell IACUC.  
 
3.2.7 Intra-articular injections 
Approximately 48 hours after the single loading session, both mouse knee joints 
received intra-articular injections. With mice under general anesthesia (2% isoflurane, 
1.0 L/min), a 2 mm skin incision was made with a #15 blade to expose the patellar 
tendon. Then, 2 µl of formulation (described in the following section) was injected into 
the joint space with a Hamilton syringe. The injection location was immediately medial 
to the patellar tendon. Skin incisions were closed with 6-0 prolene suture (8706H, 
Ethicon). Buprenorphine (0.1 mg/kg, Reckitt) was administered for two days following 
surgery. Two weeks after injection, mice were euthanized, and knee joints were 
harvested and fixed in 4% paraformaldehyde overnight at 4°C.  
 
3.2.8 Treatment groups 
To determine the therapeutic efficacy of the hydrogel system, mice were divided into 
five groups (Fig 3.3A): 1) saline; 2) bolus DEX; 3) DEX-loaded nanoparticles; 4) 
hydrogel with DEX-loaded nanoparticles; 5) hydrogel alone. For bolus injections, DEX 
(5 mg/mL, Sigma D1881) was dissolved in PBS [23,24]. For the DEX-loaded 
nanoparticles (described below), the final concentration of DEX in the nanoparticles 
was approximately 4.8 mg/mL. The hydrogel group with DEX-loaded nanoparticles 
contained approximately 10% nanoparticles.  
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3.2.9 PLGA-DEX nanoparticle fabrication 
Nanoparticles were synthesized based on established protocols with modifications [25]. 
PLGA (30 mg) and DEX (10 mg) were co-dissolved in 1 mL acetone. The solution was 
vortexed and sonicated for 7 min to create a water-in-oil emulsion. This emulsion was 
added to 6 mL 2% PVA solution in PBS and sonicated for 7 min. The resulting solution 
was stirred at 900 rpm for 4 hr, followed by stirring at 900 rpm for 1 hr in a vacuum 
desiccator. The nanoparticles were centrifuged at 20,000g, resuspended in PBS, and 
sonicated for 30 sec. The wash step was repeated three times. 
 
3.2.10 Cartilage degradation 
Knee joints were decalcified in EDTA (10%) for 2 weeks and embedded in paraffin. 
Paraffin blocks were sectioned at a thickness of 6 µm from posterior to anterior using a 
rotary microtome (Leica RM2255, Wetzlar, Germany). Cartilage morphology in the 
tibial plateau was assessed using Safranin O/Fast Green-stained sections at 90 μm 
intervals throughout the joint. The OARSI scoring system was used to assess structural 
cartilage damage [26]. Scores were measured in the medial tibial plateau and averaged 
across all sections of each limb.  
 
3.2.11 Osteophyte formation 
We examined Safranin-O/Fast Green-stained sections for osteophyte formation on the 
medial aspect of the tibia. We analyzed medial osteophytes from three representative 
sections in the joint (posterior, middle, and anterior). We measured the medial-lateral 
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width of the osteophyte, defined as the distance between the medial end of the epiphysis 
and the end of the osteophyte [27]. Overall osteophyte size is reported as mean width of 
the three sections. 
 
3.2.12 Synovial Inflammation 
We analyzed synovial thickness and pathology using three representative Safranin-
O/Fast Green stained sections (posterior, middle, and anterior). Alterations in thickness 
and cellularity at the synovial insertion of medial tibia were rated with a previously-
established synovitis scoring system [28]. Briefly, the synovitis score (maximum score 
of 6) was the sum of the synovial lining thickness on a scale of 0 to 3 (0: thickness 1-2 
cells, 1: thickness 2-4 cells, 2: thickness 4-9 cells, 3: thickness  10 cells ) and cellular 
density in the synovial stroma on a scale of 0 to 3 (0: normal cellularity, 1: slightly 
increased cellularity, 2: moderately increased cellularity, 3: greatly increased 
cellularity). The synovitis score is reported as a whole joint average from 3 evenly 
spaced slides per limb. 
 
3.2.13 Statistical Analyses  
To analyze the effects of cyclic compression on cartilage mechanical properties and 
particle release, we used a 2-way ANOVA, with PEG-MAL weight percentage and 
loading condition as variables. To analyze the effects of collagenase exposure on the 
hydrogels, we used a 3-way ANOVA, with crosslinker, collagenase concentration, and 
day as variables. For in vivo joint morphology, a linear mixed-effects model was used 
to assess the effects of loading, the effects of hydrogel vs. no hydrogel nested by loading, 
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and the effects of DEX vs. no DEX nested by loading and the presence of hydrogel. 
Alpha levels for significance were set to p=0.05.   
 
3.3 Results 
3.3.1 Hydrogels maintained mechanical properties after dynamic cyclic compression 
Hydrogels of all PEG-MAL weight percentages withstood mechanical loading. 
Hydrogels maintained overall structure even after cyclic compression at 80% strain 
levels (Fig. 3.1B). Shear storage and loss moduli did not change after cyclic 
compression (p=0.996) (Fig. 3.1D,E). Furthermore, hydrogels with higher PEG-MAL 
weight percentage had greater shear storage and loss moduli (Fig. 3.1D,E). Particle 
release was below 20% in all groups besides 2.5% PEG-MAL group in response to 
mechanical loading of up to 40% strain (Fig. 3.1C). However, approximately half of the 
encapsulated particles were released after cyclic compression with 80% strain.  
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Figure 3.1. Hydrogels maintained mechanical integrity after in vitro dynamic cyclic 
compression. A) Schematic of custom made bioreactor. Adapted from DiDomenico et al. 2017 
[22]. B) Hydrogels of all PEG-MAL weight percentages overall structure even after cyclic 
compression at 80% strain levels. C) Particle release was under 20% (indicated by dotted line) 
in all hydrogel groups besides the 2.5% PEG-MAL group with cyclic compression up to 40% 
strain. Approximately half of the particles were released with cyclic compression at 80% strain, 
but the 10% PEG-MAL group released approximately 20% fewer particles compared to the 
other groups. D/E) Hydrogels maintained viscoelastic properties with mechanical loading. 
Shear storage and loss moduli increased with increased PEG-MAL weight percentages. 
 
3.3.2 Swelling ratio increased with PEG-MAL weight percentage 
Initially, all gels were similar weight. After 1 day in excess PBS, hydrogel weight 
increased. Higher PEG-MAL weight percentages resulted in larger swelling ratios (Fig. 
3.2A). Hydrogel weight remained constant thereafter for 16 days.  
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3.3.3 On-demand particle release occurred following collagenase exposure 
Particle release in response to collagenase exposure depended on hydrogel formulation, 
collagenase concentration, and days of exposure (Fig. 3.2B). Hydrogels made with 
100% VPM demonstrated greater particle release at all doses of collagenase (p<0.0001). 
Higher concentrations of collagenase led to greater degradation and significantly more 
release from the gels (p=0.002). Particle release was maximum after the first collagenase 
exposure (p<0.0001) and remained relatively constant at a lower level after additional 
exposures. 
 
Figure 3.2. A) The majority of swelling occurred within the first 24 hours after hydrogel 
fabrication. Higher PEG-MAL weight percentages resulted in larger swelling ratios. B) 
Hydrogels fabricated with 0% VPM crosslinker did not degrade with collagenase 
exposure. Hydrogels made with 100% VPM degraded at each collagenase 
concentration. Particle release was dependent on the presence of degradable crosslinker, 
collagenase concentration, and day of exposure.  
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3.3.4 Hydrogel-containing formulations attenuated in vivo load-induced cartilage 
degradation 
Cartilage degradation occurred in all groups two weeks after a single bout of cyclic 
compression at 9.0 N (Fig. 3.3). In general, loading induced cartilage erosion extending 
to the tidemark in the posteromedial aspect of the tibial plateau. Specifically, loading 
followed by injection with non-hydrogel formulations increased OARSI scores 
compared to control limbs (p=0.0037). However, less cartilage damage occurred in 
loaded limbs injected with hydrogel-containing formulations versus non-hydrogel 
formulations (p=0.0316). Treatment with DEX, regardless of formulation, did not affect 
cartilage degradation compared to groups treated without DEX. 
 
3.3.5 Hydrogel-containing formulations attenuated load-induced osteophyte formation 
Osteophytes formed on the medial tibial plateau of loaded limbs in all groups (Fig. 3.3). 
However, osteophyte size was significantly smaller in the hydrogel-containing injection 
groups than the non-hydrogel groups (p=0.0095). Treatment with DEX, regardless of 
formulation, did not affect osteophyte size compared to groups treated without DEX. 
 
3.3.6 Hydrogels had no effect on load-induced synovial inflammation  
Synovium thickness and synovium cellularity increased in all groups following loading, 
with no effect of hydrogel (Fig. 3.3). Treatment with DEX, regardless of formulation, 
did not affect synovitis scores compared to groups treated without DEX. 
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Figure 3.3. IA injections of PEG-MAL hydrogels attenuated load-induced OA. A) Schematic 
of 5 injection formulations: saline, bolus DEX (5 mg/mL in PBS), DEX-loaded nanoparticles 
(4.8 mg/mL), hydrogel with DEX-loaded nanoparticles, and hydrogel alone. Hydrogel groups 
were 10% w/v PEG-MAL with 1:1 DTT:VPM ratio [18]. The hydrogel group with DEX NPs 
was approximately 10% NPs. B) Hydrogel-containing IA injections had beneficial effects on 
both cartilage degradation and osteophyte formation, but not synovial thickening induced by a 
single bout of loading. Red groups = non-hydrogel injections; blue groups = hydrogel-
containing injections. Ψ = p<0.05 for loading; and * = p<0.05 for hydrogel vs. no hydrogel 
nested by loading. Cartilage scale bars = 100μm. Osteophyte scale bars = 200 μm. 
 
3.4 Discussion 
We sought to characterize and test the therapeutic efficacy of an on-demand 
PEG-MAL hydrogel for IA drug delivery. Our in vitro results showed that increased 
PEG-MAL weight percentage led to greater mechanical properties and higher swelling 
ratios. Hydrogels maintained their mechanical properties after 10,000 cycles of cyclic 
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compression at strain levels ranging from 0 to 80%. Furthermore, hydrogels 
demonstrated on-demand particle release in response to daily collagenase exposure. In 
vivo, hydrogels reduced the severity of cartilage damage and osteophyte formation after 
a single session of high-level cyclic compression. DEX did not have any protective 
effects on joint tissues, regardless of formulation. Our results support that the PEG-
MAL hydrogel system has potential to improve IA injections for OA treatment. 
First, we ensured our hydrogels could withstand mechanical loading. All 
hydrogel groups maintained their viscoelastic properties after dynamic cyclic 
compression. Both storage and loss moduli increased with higher PEG-MAL weight 
percentages, due to greater crosslinking density and the inter-chain entanglements of the 
components [29–31]. Joint loading can result in cartilage strains up to 40% during 
normal activity and 80% during injurious activity [15]. All hydrogel groups besides the 
2.5% PEG-MAL group demonstrated minimal particle release (<20%) with up to 40% 
strain. Therefore, hydrogels would release minimal therapeutics during typical daily 
activities. Importantly, 10% PEG-MAL hydrogels released approximately 20% fewer 
particles compared to other groups after cyclic compression at 80% strain.  
Next, we sought to find a balance between hydrogel swelling and mechanical 
properties.  We wanted to ensure minimal swelling because of the limited space in the 
joint cavity. The majority of swelling occurred within the first 24 hours after 
crosslinking before reaching equilibrium, consistent with previous reports [32]. 
Previously, higher PEG-MAL weight percentage resulted in lower swelling ratios [33]. 
However, higher PEG-MAL weight percentage also increased the number of 
hydrophilic groups [34]. Therefore, the increased swelling ratio with higher PEG-MAL 
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weight percentage observed in our system may be due to increased numbers of 
hydrophilic groups. Furthermore, the addition of DTT increased the molecular weight 
between crosslinks [35]. Thus, the high percentage of DTT in these hydrogels also may 
have increased the swelling ratio with higher PEG-MAL weight percentages. 
Combining the mechanical and swelling results, the 10% PEG-MAL hydrogel was the 
optimal balance between mechanical integrity and limited swelling. 
  We used MMP-degradable hydrogels to improve drug release in the OA 
environment. MMP-responsive hydrogels have been used for other in vivo applications, 
including bone regeneration [36], myocardial infarction [37], and inflammatory arthritis 
[38]. We chose crosslinker peptides that degrade in the presence of MMP-3 and -13, 
because these MMPs are elevated in the joint space during early and late stages of OA 
[3,4]. Therefore, the most rapid degradation and drug release would occur in an OA 
joint environment where MMP levels are elevated. Hydrogels demonstrated minimal 
particle release upon in vitro collagenase exposure with non-degradable crosslinkers, 
whereas higher percentages of particle release occurred with MMP-degradable 
crosslinkers. Furthermore, the amount of particle release decreased with each 
collagenase exposure, consistent with previous reports [38]. Thus, PEG-MAL hydrogels 
demonstrated prolonged, on-demand drug release in vitro.  
 PEG-MAL hydrogels had protective effects on the joint after a single session of 
in vivo high-level cyclic compression. We first compared the therapeutic efficacy of 
hydrogel-containing vs. non-hydrogel-containing formulations in the load-induced OA 
joint environment. Hydrogel treatment with or without DEX-loaded nanoparticles 
attenuated load-induced cartilage damage and osteophyte formation but did not affect 
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synovitis. On the contrary, injections of bolus DEX or DEX-loaded nanoparticles did 
not have any beneficial effects on any load-induced tissue changes. Therefore, PEG-
MAL hydrogels protected the joints independent of the presence of drug. Natural 
hydrogels made from hyaluronic acid (HA) have shown similar protective effects in 
joints without additional therapeutics [39,40]. Thus, our synthetic PEG-MAL hydrogel 
may possess similar lubricating or cushioning effects as HA hydrogels [12] and future 
studies will focus on direct comparison to HA. The combination of the hydrogel’s 
protective effects in the joint space and its inert, biocompatible properties provides an 
excellent platform for an IA drug delivery system. 
The lack of response to DEX may be attributed to the severity of load-induced 
OA and the mechanism of corticosteroids. Previous approaches using IA injections of 
corticosteroids with or without hydrogels attenuated surgically-induced OA [23,41] and 
inflammatory arthritis [38,42]. Here, DEX had no beneficial effects on load-induced 
OA, regardless of formulation (i.e. hydrogel, NPs, or bolus). A single bout of cyclic 
tibial compression at 9.0 N induced cartilage erosion extending to the tidemark after 2 
weeks [16]. This severity of cartilage erosion is an indicator of more advanced or severe 
stages of OA [26]. Although corticosteroids are OARSI-recommended treatment 
options for knee OA [43], corticosteroids are most effective in treating milder, but not 
severe, forms of OA [44–46]. In addition, the primary biochemical action of 
corticosteroids is the local suppression of inflammation [47]. Although cyclic loading 
increased synovitis, whether inflammation is a driving factor of load-induced OA 
remains unclear. Thus, the anti-inflammatory effects of corticosteroids may not be 
sufficient to attenuate load-induced OA progression. 
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 Future work will focus on improving the hydrogel system and understanding its 
efficacy in larger preclinical models of OA. First, although our hydrogels maintained 
mechanical properties after cyclic compression, a high percentage of particle release 
occurred at the 80% strain level. Depending on where the hydrogel resides in the joint 
and the degree of physical activity, physiological strains in cartilage could result in 80% 
strain levels [15] and cause particle release. However, based on preliminary retrieval 
studies, the hydrogel resides near the fat pad, but further work is necessary to determine 
whether the hydrogel needs to withstand forces induced by tibiofemoral contact. 
Second, although our collagenase studies demonstrated daily on-demand release, a high 
percentage of particles were released on Day 0. Future work can focus on achieving a 
constant 5-10% particle release for each collagenase exposure, leading to approximately 
3 weeks of therapeutics in the joint. The release profile can be controlled with peptides 
of varying levels of MMP-sensitivity [36]. Here, we used a fast-degrading peptide, but 
slow-degrading peptides may attenuate therapeutic particle release with collagenase 
exposure. Third, we used a mouse model of load-induced OA because of its non-
invasive means and reproducibility. Future work will focus on larger animal models of 
OA. Larger joint spaces will allow for greater volumes of injectable hydrogel and more 
closely mimic the human joint environment. Fourth, we can use alternative drugs to 
better inhibit OA-like changes. For example, combinatorial approaches involving 
hydrogels with growth factors [48,49] and glucosamine/chondroitin [39] attenuated OA 
progression in preclinical animal models. The PEG-MAL hydrogel system may be more 
effective in combination with other therapeutics compared to DEX.  
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 In summary, we developed an on-demand hydrogel-based drug delivery system 
that maintained its mechanical properties in response to high levels of cyclic 
compression. The hydrogel system attenuated load-induced OA, and future work will 
investigate its efficacy with other therapeutics and loading protocols. Ultimately, this 
synthetic PEG-MAL hydrogel system is a promising drug delivery strategy for the 
treatment of OA.  
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CHAPTER 4: LOW-LEVEL CYCLIC TIBIAL COMPRESSION ATTENUATES 
OSTEOARTHRITIS PROGRESSION AFTER JOINT INJURY IN MICE 
 
4.1 Introduction 
Osteoarthritis (OA) is degenerative joint disease that affects millions of 
individuals and is the leading cause of disability in the elderly population [1–4]. The 
three hallmarks of the end-stage disease are cartilage degradation, osteophyte formation, 
and subchondral bone sclerosis. During the OA process, chondrocyte apoptosis occurs 
[5], and collagenases and aggrecanases degrade the cartilage matrix, resulting in cleaved 
aggrecan and collagen [6,7]. Post-traumatic osteoarthritis (PTOA) is a subset of OA 
associated with joint injury and instability due to mechanical trauma [8]. Individuals 
who experience a joint injury, such as anterior cruciate ligament (ACL) rupture or 
meniscal tear, are at risk for developing PTOA due to altered joint kinematics and any 
trauma directly to the cartilage or adjacent bone [9,10]. Providing interventions 
following joint injury may be beneficial to attenuate PTOA. 
Mechanical loading, exercise, and joint health have a unique relationship in OA 
onset and progression. Excessive mechanical loading is a primary risk factor for OA 
[11]. Loading at high levels can decrease aggrecan synthesis and induce chondrocyte 
apoptosis [12,13]. Furthermore, high loads can rupture stabilizing ligaments or damage 
joint tissue, such as the meniscus or cartilage [14]. Conversely, mild exercise is a 
recommended intervention for early-stage OA [15]. Mild exercise involving low-level 
loading can increase aggrecan synthesis in vitro and maintain thicker cartilage in vivo 
[16,17]. In rodents, treadmill running  slowed the progression of injury-induced 
cartilage degradation [18]. Although low-level mechanical loading has potential to 
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attenuate OA, most experiments investigating the effects of beneficial loading have been 
either in vitro or have involved exercise. In vitro studies using cartilage explants and/or 
chondrocyte culture do not recapitulate the response of the entire joint [12,19]. In 
addition, exercise leads to systemic effects, including peri-articular muscular 
strengthening, improvements in proprioception, and weight reduction [20,21]. These 
multiple effects obscure the contribution of factors that specifically benefit the joint 
[21]. Here, we sought to isolate the beneficial effects of low-level loading using in vivo 
cyclic tibial compression. 
To date, in vivo cyclic tibial compression has been an effective approach to study 
the initiation and progression of load-induced OA. Cyclic compression at moderate 
(4.5N) and high (9.0N) load magnitudes induced OA-like joint pathology, including 
cartilage degradation, osteophyte formation, and subchondral bone changes, in young 
(10-week) and adult (26-week) mice [22-25]. This same approach has the potential to 
benefit cartilage health at lower load levels. Thus, we sought to determine whether daily 
cyclic compression at low load magnitudes (1.0N and 2.0N) would attenuate PTOA. To 
accomplish this objective, we used  low-level cyclic compression in combination with 
a surgically-induced model of PTOA, the destabilization of the medial meniscus 
(DMM) [26]. We assessed tissue-level changes in the cartilage, peri-articular bone, and 
menisci. In addition, we analyzed for chondrocyte apoptosis, aggrecan cleavage, and 
surface collagen loss. We hypothesized that cyclic compression at low load magnitudes 
would attenuate DMM-induced PTOA. 
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4.2 Methods 
4.2.1 Animals 
We used fifty-one 10-week-old male C57BL/6J mice (The Jackson Laboratory, 
Bar Harbor, ME, USA). Mice were housed in groups of 3 to 5 per cage. Lighting was 
maintained at a 12-hours-on-12-hours-off schedule. Mice were given food and water ad 
libitum. All experimental techniques were approved by the Cornell IACUC. Briefly, 
animals underwent DMM surgery [26]. Starting five days after surgery, cyclic tibial 
compression was applied to the operated limbs for either 2 or 6 weeks. Upon completion 
of loading, mice were euthanized, and knee joints harvested for histological and 
architectural analyses. 
 
4.2.2 Surgical destabilization of the medial meniscus 
We performed DMM surgery on the right knee joints of all mice [26]. A 3mm 
skin incision was made with a #15 blade to expose the patellar tendon. Then a soft tissue 
incision was made immediately medial to the patellar tendon from the distal patella to 
the proximal tibial plateau. While a second researcher gently pulled the patellar tendon 
laterally with a Tyrell Hook (without dislocating the patella), the fat pad was shifted 
laterally with a #11 scalpel blade until the medial meniscotibial ligament (MMTL) was 
in view. Then, we positioned the scalpel blade inferior to the MMTL with the sharp 
edge facing laterally. Finally, we rotated the blade clockwise until the MMTL was 
ruptured. To verify each surgery, we translated the medial meniscus medially using the 
blunt edge of the scalpel blade. We closed the soft tissue and skin incisions with 6-0 and 
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7-0 prolene suture, respectively (8706H, 8708H, Ethicon). Buprenorphine (0.1 mg/kg) 
was administered during recovery, immediately after surgery and once daily for the 
following 4 days. 
 
4.2.3 Mechanical loading 
After the 5-day recovery period from DMM, mice were divided into seven 
groups (n=7-8/group) (Fig. 4.1). One group was euthanized immediately after the 
recovery period to investigate short-term damage caused by DMM (DMM-only: +0-
weeks). Two groups were used for +2-week time points (after the 5-day recovery 
period). For one +2-week group, cyclic compression was applied to DMM-treated tibiae 
at peak loads of 1.0N for 2 weeks (DMM+1.0N: +2-weeks). The second +2-week group 
received daily 5-minute doses of anesthesia without cyclic tibial compression (DMM-
only: +2-weeks). The remaining four groups were used for +6-week time points (after 
the 5-day recovery period). For three of the +6-week groups, cyclic compression was 
applied to the DMM-treated right tibiae at 1.0N, 2.0N, or 4.5N peak loads for 6 weeks 
(DMM+1.0N, DMM+2.0N, DMM+4.5N: +6-weeks). The final +6-week group received 
daily anesthesia without cyclic tibial compression (DMM-only: +6-weeks). For all 
loaded groups, cyclic compression was performed with mice under general anesthesia 
(2% isoflurane, 1.0L/min, Webster) and consisted of 1200 cycles/day at 4 Hz for 5 
days/week. All load waveforms were triangular with load/unload ramps for 0.075 
seconds each and dwell times of 0.100 seconds. Contralateral limbs served as controls. 
Mice were euthanized, and knee joints were harvested and fixed in 4% 
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paraformaldehyde. After fixation, tissues were transferred to 70% ethanol for short-term 
storage. 
 
Figure 4.1. Experimental design. 10wk C57Bl/6 male mice underwent DMM surgery on their 
right limbs. Five days later (+0-weeks), DMM-treated limbs were either subjected to no loading 
(DMM-only),1.0N-loading (DMM+1.0N), 2.0N-loading (DMM+2.0N), or 4.5N-loading 
(DMM+4.5N) for 2 or 6 weeks. Contralateral limbs served as controls at each time point. n=7-
8 mice per group. 
 
4.2.4 Cartilage morphological changes 
Knee joints were decalcified in EDTA, processed, and paraffin-embedded. 
Paraffin blocks were sectioned at a 6-µm-thickness from posterior to anterior using a 
rotary microtome (Leica RM2255, Wetzlar, Germany). To assess cartilage morphology, 
sections were stained with Safranin-O/Fast Green at 90-µm intervals. Histological 
scoring was performed to examine structural cartilage damage in the medial tibial 
plateau, using the OARSI scoring system [27]. Average and maximum scores of each 
limb were calculated. 
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4.2.5 Osteophyte formation 
We examined Safranin-O/Fast Green-stained histological sections for 
osteophyte formation surrounding the joint. We analyzed osteophytes in the medial 
tibial plateau from three representative sections in the joint (anterior, middle, posterior). 
Osteophyte maturity was evaluated as described previously: 0 for no osteophyte, 1 for 
a primarily cartilaginous osteophyte, 2 for a mixture of cartilage and bone, or 3 for 
primarily bony structure [28]. We also measured the medial-lateral width of the 
osteophyte, defined as the distance between the medial end of the epiphysis and the end 
of the osteophyte. Widths are reported as absolute values [24].  
 
4.2.6 Peri-articular bone morphological changes 
Bone architecture changes at the +6-week time point were determined by 
microcomputed tomography (microCT). Prior to decalcification, intact knee joints were 
scanned by microCT, with an isotropic voxel resolution of 10 µm (μCT35, Scanco, 
Bruttisellen, Switzerland; 55kVp, 145μA, 600ms integration time). We examined bone 
in the epiphysis and metaphysis of the proximal tibia. In the epiphysis, we analyzed the 
subchondral bone plate (SBP) and epiphyseal cancellous bone. For the SBP, the volume 
of interest (VOI) encompassed all cortical bone below the cartilage surface at the 
proximal end of the tibia extending distally until epiphyseal cancellous bone was 
evident. The VOI for epiphyseal cancellous bone encompassed cancellous bone distal 
to the SBP and proximal to the growth plate, excluding cortical bone. In the metaphysis, 
we analyzed cancellous bone. The VOI for metaphyseal cancellous bone began distal to 
the growth plate and extended 10% tibial length, excluding the cortex. Outcome 
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parameters for the SBP included thickness and tissue mineral density (TMD). 
Cancellous bone parameters included bone volume fraction (BV/TV), trabecular 
thickness (Tb.Th), trabecular separation (Tb.Sp), and cancellous TMD (TMD).  
 
4.2.7 Chondrocyte apoptosis  
We assessed chondrocyte apoptosis after DMM surgery and 1.0N-loading using 
a TUNEL kit to detect DNA strand breaks (Sigma, 11684795910 Roche, Darmstadt, 
Germany). We stained representative sections from the middle region of each limb at 
all time points. Sections were deparaffinized, rehydrated, and incubated with proteinase 
K at 37°C. Then, samples were incubated with the TUNEL reaction mixture for 1h at 
37°C. Finally, sections were coverslipped with antifade mounting media containing 
DAPI. DAPI+ cells were measured in the articular cartilage of the medial tibial plateau 
[29,30]. The DAPI+ signal was normalized to cartilage area. Similarly, TUNEL+ cells 
were measured and normalized to the total number of chondrocytes (DAPI+ signal) to 
account for potential changes in cellularity. 
 
4.2.8 Cleaved Aggrecan 
Cleaved aggrecan levels after DMM and 1.0N-loading were assessed using 
immunohistochemistry (IHC). We stained representative sections from the middle 
region of control and DMM-treated limbs from animals in the DMM-only and 
DMM+1.0N groups at the +2-week and +6-week time points [31]. Sections were 
deparaffinized and rehydrated. Antigen retrieval was performed with a mild temperature 
retrieval solution at 60°C for 30 minutes (UNI-TRIEVE, Innovex, Richmond, 
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California). Endogenous peroxidase activity was quenched for 15 minutes at room 
temperature (RT) (PEROX-BLOCK, Innovex). Background staining was minimized 
using Background Buster for 30 minutes at RT (STAT Animal IHC Kit, Innovex). 
Detection of cleaved aggrecan was performed using an anti-NITEGE primary antibody 
(ThermoFisher PA-1-1746) diluted 1:100 in immunodiluent (Immuno Diluent and 
Block, Innovex) for 2 hours at RT. Secondary linking antibody and horseradish 
peroxidase-enzyme (STAT Animal IHC Kit, Innovex) were used for 10 minutes each at 
RT. Fresh DAB solution was applied and incubated for 5 minutes at RT, and staining 
intensity was enhanced for 3 minutes at RT (Quick DAB Enhancer, Innovex). Sections 
were washed with water and mounted (Advantage Mounting Medium, Innovex). 
Percentage of positive immunostaining in the articular cartilage of the medial tibial 
plateau was calculated using ImageJ software (NIH) [29,30]. Positive signal was 
normalized to cartilage area. 
 
4.2.9 Surface collagen content 
 We assessed surface collagen content using picrosirius red staining. We stained 
representative sections from the middle region of each limb at all time points. Sections 
were deparaffinized, rehydrated, and incubated with 0.1% Direct Red 80 (Sigma-
Aldrich, 365548) in saturated picric acid for 60 minutes at RT, followed by dehydration 
and coverslipping. Using custom software (MATLAB, MathWorks), the number of 
positively stained pixels in the cartilage surface was counted. Positive staining was 
normalized to the total number of pixels in the cartilage surface. 
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4.2.10 Meniscal ossicle morphology  
MicroCT scans were used to characterize the anterior meniscal ossicle after 
DMM and loading. The VOI included all positive signal in the medial joint space, 
excluding the fabella. We assessed meniscus volume and density [32]. 
 
4.2.11 Statistical analyses 
For histological evaluations, we compared limbs across groups using a one-way 
ANOVA with animal as a random effect. We applied the ANOVA to analyze OARSI 
scores, osteophytes, cellularity, apoptosis, cleaved aggrecan, and surface collagen 
content. Contralateral limbs from the DMM-only group were used as our control group 
for histological evaluations. For microCT comparisons, we used a two-way ANOVA 
with limb and group as variables, and animal as a random effect. The two-way ANOVA 
was used to analyze the subchondral bone plate, cancellous bone, and meniscal ossicles. 
 
4.3 Results 
4.3.1 Low-level cyclic compression attenuated DMM-induced cartilage degradation 
After the 5-day recovery period post-DMM surgery (+0-weeks), cartilage 
damage was minimal (Fig. 4.2A,B,C). Mild localized proteoglycan loss occurred in 
some limbs, but neither average nor maximum OARSI scores were different from 
control limbs at +0-weeks. Two weeks after the 5-day recovery (+2-weeks), 
proteoglycan loss and mild erosion were present in DMM-only limbs, and average 
OARSI scores were greater compared to + control limbs at +0-weeks. In the 
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DMM+1.0N group at +2-weeks, moderate proteoglycan was visible in the cartilage, but 
average OARSI scores were not different from control limbs at +0-weeks. At the +6-
week time point, severe cartilage erosion occurred in DMM-only limbs. In the 
DMM+1.0N group at +6-weeks, the cartilage surface was generally intact, and structural 
changes were limited to focal proteoglycan loss. At +6-weeks, average and max OARSI 
scores in the DMM+1.0N group were significantly lower than scores from the DMM-
only limbs.  
Cyclic compression at 2.0N had similar effects to 1.0N-loading at +6-weeks 
(Fig. 4.2A,D,E). The cartilage surface from 2.0N-loaded limbs was generally intact, but 
proteoglycan loss was evident. At +6-weeks, average OARSI scores were significantly 
lower in the DMM+2.0N group compared to the DMM-only group, but maximum 
OARSI scores were not different between the two groups. Loading at 4.5N led to 
moderate cartilage erosion and proteoglycan loss. At +6-weeks, neither average nor 
maximum OARSI scores were significantly different between the DMM-only and 
DMM+4.5N groups. 
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Figure 4.2. Low-level cyclic compression attenuated post-traumatic cartilage degradation. (A) 
Representative Safranin O/Fast Green histological images show that DMM surgery led to focal 
erosion extending to the tidemark in the medial tibial plateau in the DMM-only group. Loading 
at 1.0N attenuated DMM-induced cartilage erosion, evident from the intact cartilage surface. 
Loading at 2.0N had similar effects to 1.0N-loading, with an intact cartilage surface after 6 
weeks. Moderate loading at 4.5N resulted in mild erosion and proteoglycan loss that was not 
different from DMM-only. (B) Average and (C) max OARSI scores for cartilage damage were 
significantly different between the DMM-only vs. DMM+1.0N groups at +6-weeks. (D) 2.0N-
loading also led to lower average OARSI scores than DMM-only, (E) but not lower max OARSI 
scores. Scale bars = 100 μm. Arrows indicate proteoglycan loss; arrow heads indicate erosion. 
Groups with the same letters over the bars are not significantly different; groups with different 
letters indicate that the means are significantly different by post-hoc comparisons. 
 
4.3.2 Low-level cyclic compression attenuated DMM-induced osteophyte formation 
Low-level tibial compression attenuated osteophyte growth (Fig. 4.3). DMM 
surgery led to osteophytes that extended the length of the medial aspect of the tibial 
plateau. On the anterior portion of the tibial plateau, medial osteophyte size increased 
after the 5-day recovery period in the DMM-only group (+0-weeks) compared to 
controls (Fig. 4.3A-B). Anteromedial osteophyte size continued to increase in the 
DMM-only group after 2 and 6 weeks. However, anteromedial size was not different 
between the +0-week DMM-only group and DMM+1.0N groups at +2-weeks or +6-
weeks. Anteromedial osteophyte maturity was not different between DMM-only and 
DMM+1.0N groups.  
On the posterior portion of the tibial plateau, medial osteophytes formed in the 
DMM-only groups at all time points, but growth was inhibited with 1.0N-loading at the 
+2-week and +6-week time points in nearly all animals (Fig. 4.3C,D). In addition, 
osteophyte maturity at +6-weeks was lower in the DMM+1.0N group compared to the 
DMM-only group. 
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Figure 4.3. Low-level cyclic compression attenuated post-traumatic osteophyte formation. (A) 
Representative Safranin O/Fast Green histological images indicate that DMM surgery led to 
osteophyte formation on the anteromedial aspect of the tibial plateau as quickly as 5 days post-
surgery. (B) Anteromedial osteophyte size increased in the DMM-only groups after 2 and 6 
weeks but was not different between the DMM+1.0N groups and +0-week DMM-only group 
(C) Low-level cyclic compression completely suppressed posteromedial osteophyte formation 
in nearly all animals. (D) Posteromedial osteophyte size in the DMM+1.0N group was lower 
compared to DMM-only groups. Scale bars = 100 μm. Groups with the same letters over the 
bars are not significantly different; groups with different letters indicate that the means are 
significantly different by post-hoc comparisons. 
 
4.3.3 Loading attenuated DMM-induced subchondral bone sclerosis but not cancellous 
bone loss 
Cyclic compression at all load levels attenuated subchondral bone sclerosis after 
DMM surgery (Fig. 4.4). At +6-weeks, DMM led to a significant increase in tissue 
mineral density (TMD) in the medial subchondral bone plate compared to control limbs 
in the DMM-only group (Fig. 4.4A). DMM surgery followed by 1.0N-, 2.0N-, or 4.5N-
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loading, however, did not result in increased TMD in DMM-treated limbs compared to 
control limbs. Subchondral bone plate thickness was greater in the DMM-only group 
than the DMM+4.5N group (Fig. 4.4B). 
 
Figure 4.4. Low-level cyclic compression attenuated post-traumatic subchondral bone 
sclerosis. (A) At the +6-week time point, subchondral bone plate TMD increased in the medial 
tibial plateau in DMM-only limbs compared to contralateral control limbs. TMD was not 
different between control and treated limbs in the 1.0N-, 2.0N-, or 4.5N-loaded groups. (B) Mice 
in the DMM-only group had thicker medial subchondral cortical bone compared to mice in the 
moderate load group (DMM+4.5N). Groups with the same letters over the bars or pooled bars 
are not significantly different; groups with different letters indicate that the means are 
significantly different by post-hoc comparisons. Asterisk on y-axis title indicates significance 
by post-hoc comparisons for control vs. DMM-treated limbs. 
 
At +6-weeks, cancellous bone volume fraction (BV/TV) in the epiphysis 
decreased in DMM-treated limbs compared to control limbs in all groups, regardless of 
whether the limbs underwent loading (Fig. 4.S-7A). The decreased BV/TV was due to 
increased trabecular separation (Tb.Sp) following DMM (Fig. 4.S-7B). Trabecular 
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thickness (Tb.Th) was not different between any of the groups (Fig. 4.S-7C). The DMM-
only group had higher TMD compared to the three loaded groups (Fig. 4.S-7D).
 Similarly, bone loss occurred in the metaphysis at +6-weeks after DMM surgery, 
regardless of whether the limbs underwent loading (Fig. 4.S-8A). Tb.Sp was greater in 
all DMM-treated limbs compared to control limbs (Fig. 4.S-8B). DMM surgery did not 
induce any changes in metaphyseal Tb.Th (Fig. 4.S-8C). Lastly, TMD was lower in all 
DMM-treated limbs compared to control limbs, regardless of whether the limbs 
underwent loading (Fig. 4.S-8D). 
 
4.3.4 Low-level loading had subtle beneficial effects on chondrocyte loss and apoptosis  
Chondrocyte numbers decreased following DMM surgery, indicated by a loss 
of DAPI+ signal (Fig. 4.5A,B). At +0-weeks, cellularity was not different between 
DMM-only and control limbs. At +2-weeks, small localized areas of the cartilage had 
decreased cellularity in the DMM-only and DMM+1.0N groups. At +6-weeks, the 
DMM-only group had the least number of remaining cells with large portions of the 
tibial plateau lacking cellularity. DAPI+ stained cells in the +6-week DMM-only group 
were significantly lower compared to the +0-week DMM-only group. DAPI+ stained 
cells in the +6-week DMM+1.0N group were not significantly different from the +0-
week DMM-only group but were lower than the +0-week controls.  
 Subtle differences in chondrocyte apoptosis were evident between groups (Fig. 
4.5A,C). Minimal apoptosis occurred in the +0-week DMM-only group. TUNEL+ 
staining increased slightly at +2-weeks in the DMM-only group but was not significantly 
different from +0-week levels. At +6-weeks, the DMM-only group had higher levels of 
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apoptosis compared to the +0-week control group, whereas the DMM+1.0N group was 
not different from the +0-week control group. However, apoptosis levels at +6-weeks 
were not significantly different between the DMM-only and DMM+1.0N groups. 
 
Figure 4.5. Low-level cyclic compression had subtle beneficial effects on cellularity and 
apoptosis. (A) Representative DAPI (blue) overlaid with TUNEL (green) images show 
chondrocyte loss and apoptosis with DMM surgery, with the greatest degree of cell loss in the 
+6-week DMM-only group. (B) Cellularity decreased in the +6-week DMM-only group 
compared to the +0-week DMM-only group, whereas cellularity in the +6-week DMM+1.0N 
group was not different from the +0-week DMM-only group. However, cell loss was not 
different between the and DMM-only and DMM+1.0N groups at the +2-week and +6-week time 
points. (C) Chondrocyte apoptosis increased with DMM surgery. Only the +6-week DMM-only 
group was different from the +0-week control group. Scale bars = 100 μm. Arrow heads indicate 
apoptosis. Yellow curves indicate tibial cartilage surface. Groups with the same letters over the 
bars are not significantly different; groups with different letters indicate that the means are 
significantly different by post-hoc comparisons. 
 
4.3.5 Low-level loading had subtle beneficial effects on cleaved aggrecan levels  
Cleaved aggrecan levels in the DMM-only and DMM+1.0N were not 
significantly different from control limbs (Fig. 4.6). However, DMM-only limbs had a 
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mean increase of 116% in cleaved aggrecan levels compared to control limbs, whereas 
DMM+1.0N limbs had an increase of 53% compared to control limbs. In addition, 
cleaved aggrecan levels decreased by 59% from +2-weeks to +6-weeks.  
 
Figure 4.6. Low-level cyclic compression had subtle beneficial effects on cleaved aggrecan 
levels. (A) Representative IHC images show cleaved aggrecan levels in control, DMM-only, 
and DMM+1.0N at the +2-week and +6-week time point, with the highest levels of positive 
immunostaining in the DMM-only group. (B) Cleaved aggrecan levels were 116% higher in 
DMM-only limbs compared to control limbs, and only 53% higher in DMM+1.0N limbs 
compared to controls. However, these changes were not significant due to small sample size. 
Scale bars = 100 μm. Arrow heads indicate positive signal. 
 
4.3.6 Loading had no effect on surface collagen content 
 Surface collagen content decreased with time in both DMM-only and 
DMM+1.0N groups (Fig. 4.S-9). At +6-weeks, limbs from the DMM-only and 
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DMM+1.0N groups had lower surface staining compared to the +0-week DMM-only 
group. However, picrosirius red staining between the DMM-only and DMM+1.0N 
groups was not different. 
 
4.3.7 Loading had no effect on DMM-induced meniscal ossicle expansion 
At +6-weeks, DMM surgery increased anteromedial meniscal ossicle volume 
compared to control limbs in all groups, regardless of whether the limbs underwent 
loading (Fig. 4.S-10A,B). Meniscus volume in DMM-treated limbs was approximately 
1.5x the volume of control limbs. In addition, meniscal ossicles decreased in density 
after DMM surgery (Fig. 4.S-10C).  
 
4.4 Discussion 
We examined whether non-invasive axial compression at low load magnitudes 
could attenuate PTOA progression following DMM. We hypothesized that low-level 
cyclic tibial compression would slow DMM-induced OA-like changes. After 6 weeks, 
limbs that underwent DMM surgery without additional loading had cartilage erosion 
extending to the tidemark, osteophytes present on medial aspect of the tibial plateau, 
and sclerotic subchondral bone, consistent with previous studies [26]. In addition, 
DMM-only limbs had decreased cellularity, a trend towards increased cleaved aggrecan 
levels, loss of surface collagen, meniscal growth, and cancellous bone loss. Low-level 
cyclic compression initiated 5 days after DMM surgery attenuated many of these DMM-
induced factors, including the three hallmarks of OA: cartilage erosion, osteophyte 
formation, and subchondral bone sclerosis. Furthermore, low-level loading had subtle 
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beneficial effects on cellularity, and a trend towards decreased aggrecan cleavage 
compared to DMM-only limbs. However, loading did not attenuate DMM-induced 
cancellous bone loss, meniscal growth, or surface collagen loss. Overall, our results 
support our hypothesis that low-level axial cyclic compression can slow the progression 
of multiple OA-like features induced by DMM. 
 The effect of low-level cyclic tibial compression in the knee was the opposite of 
tibial compression at higher load magnitudes. Previously, cyclic tibial compression 
focused on the induction of OA-like damage following high levels of mechanical 
loading [22,23]. Loading at 9.0N caused cartilage erosion, osteophyte formation, and 
subchondral bone changes in both 10- and 26-week-old mice. In addition, moderate 
loading at 4.5N caused mild cartilage surface degradation in 26-week-old mice, but 
minimal bone changes. Here, moderate loads did not exacerbate DMM-induced 
cartilage damage in 10-week-old mice, although we expected DMM-induced cartilage 
damage to worsen with 4.5N-loading based on previous studies using 26-week-old mice 
[22,24]. Both the younger mouse age and the addition of DMM may have altered the 
cartilage response to 4.5N-loading. In contrast to prior tibial loading studies, we applied 
low-level cyclic compression at 1.0N or 2.0N. The low loads attenuated many of the 
damaging effects of DMM surgery. Therefore, low-level (1.0N) and high-level (9.0N) 
loading resulted in opposite responses in terms of cartilage, osteophytes, and 
subchondral bone. These results demonstrate the importance of load magnitude in 
determining the knee joint response to tibial loading. In addition, the constant 
load/unload and dwell times between waveforms caused lower strain rates for lower 
magnitudes. Because strain rate is an important parameter in the cartilage response to 
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compressive forces [12], the lower strain rate during the lower-magnitude loading also 
may have benefited the cartilage. 
The beneficial effects of cyclic axial compression were comparable to other 
noninvasive preclinical loading regimens. To our knowledge, the only other studies to 
focus directly on the beneficial effects of in vivo cyclic loading in isolation involved 
transverse loading of the knee at 1.0N for 2 weeks after surgical induction of OA in 
mice [33,34]. Low-level transverse knee loading attenuated post-traumatic cartilage 
damage and bone mineral density changes. Furthermore, transverse knee loading 
accelerated bone healing after a surgical wound of the tibia [35]. Therefore, low-level 
loading of the knee joint in both the transverse and axial directions can attenuate 
cartilage and bone changes after injury. However, no study involving transverse knee 
loading has reported effects on osteophyte formation. In addition, transverse knee 
loading rarely occurs during exercise, whereas axial joint loading occurs in most lower 
extremity exercises (i.e. walking, running, etc.). Thus, our findings support the direct 
beneficial effects of axial loading on articular cartilage during exercise.  
Controlled, low-level loading was equally as effective, if not more effective, 
compared to preclinical exercise regimens used to benefit joint tissues. Activities 
involving mild to moderate mechanical loading of joints benefited articular cartilage in 
multiple preclinical studies [17,18,36,37]. Mice with lifelong access to running wheels 
maintained thicker cartilage compared to mice without running wheels [17]. In addition, 
low- (15min/day) and moderate-intensity (30min/day) treadmill exercise at 12-18m/min 
attenuated cartilage degeneration in rats after ACL transection or DMM surgery [18,36]. 
Lastly, treadmill exercise reduced pain associated with chemically-induced OA in rats 
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[37]. Although these preclinical exercise studies showed beneficial effects in articular 
cartilage, none of these studies showed protective effects at the osteophyte level. In fact, 
gentle treadmill walking had no effect on osteophyte formation after DMM surgery [36], 
whereas low-level cyclic compression significantly attenuated DMM-induced 
posteromedial osteophyte formation in our study. The posterior region most likely 
showed the most significant changes, because the contact point during tibial loading 
occurs in the posterior region of the tibial plateau [38]. Nonetheless, although exercise 
is beneficial to articular cartilage, low-level cyclic compression resulted in additional 
benefits in the joint, possibly due to the controlled nature of the loading protocol. 
 The cartilage response to mechanical loading at the cellular and protein levels 
depends on load-induced strain levels [39]. Low-level cyclic compression likely 
resulted in a beneficial response in large part due to tissue strain. Static tibial 
compression at 1.0N-loads resulted in cartilage strain levels of approximately 15%, 
estimated by linear elastic computational models [40]. During the stance phase of 
human gait, deformation ranged between 7 and 23% of resting cartilage thickness [41]. 
Hence, we achieved normal physiologic strains in murine cartilage using cyclic tibial 
compression. In turn, these dynamic physiologic strains may have induced anabolic, 
anti-catabolic, or anti-inflammatory effects [39], resulting in attenuation of PTOA. 
Therefore, we should have observed beneficial effects from loading at the cellular and 
protein levels. Based on our TUNEL data, low-level loading had subtle protective 
effects on cellularity and apoptosis. In addition, although significance was not observed 
due to small sample size, cleaved aggrecan levels increased by approximately twice as 
much in DMM-only limbs compared to DMM+1.0N limbs. However, the surface 
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collagen content was not retained with 1.0N-loading, but more intact cartilage tissue 
remained in the DMM+1.0N groups compared to the DMM-only groups. Therefore, the 
strain induced by low-level loading resulted in subtle protective effects at the cellular 
and protein levels that most likely contributed to the beneficial effects at the tissue level. 
 The translation of these findings from mice to humans is an important question. 
Further understanding of the mouse loading conditions is required. Although cartilage 
strain levels during static tibial compression have been approximated using 
computational models [40], stresses and strains resulting from dynamic cyclic 
compression should be quantified. Clinically, novel imaging modalities can determine 
cartilage strain after physical activities [41–43], and computational models can be used 
to predict load-induced cartilage stresses and strains [44,45]. Using these techniques, 
the load magnitude required to achieve healthy physiologic strain levels can be 
determined. With the appropriate load magnitudes, controlled loading regimens could 
improve pre- and post-operative treatment of joint injuries. For example, knee 
immobilization is generally required for 4 weeks following ACL reconstruction surgery 
[46]. Weight-bearing activity during these first 4 weeks is restricted to touch-down 
weight bearing [47]. Although immobilization is critical to preventing unwanted 
stresses on the graft during rehabilitation, low-magnitude cyclic forces that minimize 
stresses on the graft but produce healthy tissue strains may maintain healthy cartilage. 
However, the success of loading following DMM in mice may reflect the limited joint 
instability associated with the model [38]. Loading following ligament injuries 
associated with increased instability, such as ACL rupture, could lead to detrimental 
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effects. Thus, understanding the degree of instability associated with the injury is critical 
before applying compressive loading to the joint.  
 In conclusion, controlled low-level cyclic loading was beneficial to joint health 
and attenuated PTOA following DMM. Although protection was not observed in all 
regions of the knee joint, cartilage erosion, osteophyte formation, and subchondral bone 
sclerosis were attenuated. Low-level cyclic compression was equally as effective, if not 
more effective, in attenuating OA-like changes compared to similar non-invasive 
approaches. The beneficial effects were likely due to tissue strain achieved by the low 
load magnitudes. Future work needs to focus on determining the molecular events that 
result from daily beneficial loading and translating these loads to clinical use. 
Ultimately, rehabilitation protocols following joint injury may benefit from controlled, 
low-level cyclic compression to maintain healthy cartilage and attenuate the 
development of PTOA. 
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Figure 4.S-7. Low-level loading had no effect on epiphyseal cancellous bone mass. (A) At +6-
weeks, DMM-treated limbs had significantly lower cancellous bone volume fraction in the 
epiphysis compared to control limbs, regardless of whether the limbs underwent loading. (B) 
Cancellous bone loss was primarily due to greater trabecular separation in the epiphysis. (C) 
Trabecular thickness was not affected by DMM or loading. (D) The DMM-only group had 
higher TMD in the epiphysis compared to the three loaded groups. Graphs on the left show raw 
data for each limb; graphs on the right show deltas between control and DMM-treated limbs. 
Groups with the same letters over the bars or pooled bars are not significantly different; groups 
with different letters indicate that the means are significantly different by post-hoc comparisons. 
Asterisk on y-axis title indicates significance by post-hoc comparisons for control vs. DMM-
treated limbs. 
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Figure 4.S-8. Low-level loading had no effect on metaphyseal cancellous bone mass. (A) At 
+6-weeks, DMM-treated limbs had significantly lower cancellous bone volume fraction in the 
metaphysis compared to control limbs, regardless of whether the limbs underwent loading. (B) 
Cancellous bone loss was primarily due to greater trabecular separation in the metaphysis. (C) 
Trabecular thickness was not affected by DMM or loading. (D) DMM-treated limbs had 
significantly lower TMD in the metaphysis compared to control limbs, regardless of whether 
the limbs underwent loading. Graphs on the left show raw data for each limb; graphs on the 
right show deltas between control and DMM-treated limbs. Groups with the same letters over 
the bars or pooled bars are not significantly different; groups with different letters indicate that 
the means are significantly different by post-hoc comparisons. Asterisk on y-axis title indicates 
significance by post-hoc comparisons for control vs. DMM-treated limbs. 
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Figure 4.S-9. DMM surgery led to reduced surface collagen content. (A) Representative 
picrosirius red images show surface collagen content, indicated by the red staining at the 
cartilage surface. (B) Picrosirius red staining at the cartilage surface decreased after 6 weeks in 
both the DMM-only and DMM+1.0N groups compared to the +0-week DMM-only group. Scale 
bars = 100 μm.  
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Figure 4.S-10. DMM surgery led to increased anteromedial meniscal ossicle volume. (A) 
Representative microCT 3-D reconstructions show significant changes between control and 
DMM-treated meniscal ossicle sizes for all groups. (B) Menisci in DMM-treated limbs were 
approximately 1.5 times larger than in control limbs, regardless of whether the limbs underwent 
loading. (C) Meniscal ossicle density decreased after DMM surgery in all groups. Scale bars = 
250 μm. Asterisk on y-axis title indicates significance by post-hoc comparisons for control vs. 
DMM-treated limbs. 
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CHAPTER 5: CONCLUSIONS AND DISCUSSION 
5.1 Summary 
 This thesis focused on three key aspects of osteoarthritis: pathology, treatment, 
and prevention. These OA questions were addressed by three aims: 1) determine the 
effects of altered cartilage matrix properties on the severity of load-induced OA, 2) 
design and test the efficacy of a hydrogel-based intra-articular on-demand drug delivery 
system, and 3) determine whether low-level cyclic tibial compression can attenuate 
surgically-induced OA. Together, these three aims advanced our knowledge and 
understanding of load-induced OA and created a path for promising OA therapeutic 
strategies. This final chapter will summarize the findings from each research project, 
discuss key strengths and limitations of the studies, and conclude with future directions. 
 
5.1.1 Aim 1: Load-induced osteoarthritis in mice with altered cartilage tissue  
 Our first aim was to investigate the influence of genetically abnormal cartilage 
matrix properties on load-induced OA onset and progression. Mechanical loading and 
abnormal tissue properties resulting from genetics are two prevalent risk factors for OA 
[1,2]. Understanding interactions between risk factors is critical to predict, prevent, and 
treat OA. We used the cho/+ mouse that has abnormal collagen fibrils and reduced 
tensile properties in its cartilage due to a point mutation in the Coll11a1 gene [3,4]. We 
first characterized the musculoskeletal phenotype. 6-month-old cho/+ mice had OA-
like proteoglycan loss and increased MMP-13 levels in their cartilage, as expected from 
previous studies [3]. However, the mutant mice also had thicker cartilage and thinner, 
less dense subchondral bone compared to wildtype (WT) littermates.  
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Contrary to our hypothesis, cho/+ mice developed less severe load-induced 
cartilage damage after cyclic tibial compression at high load magnitudes. The 
combination of two characteristics of the cho/+ mouse could explain this finding. First, 
when mice with different genetic backgrounds were compared, mice with thicker 
cartilage developed less-severe load-induced cartilage damage, because thicker 
cartilage resulted in decreased contact pressures [5]. Second, high bone mass has been 
linked to increased OA risk clinically [6,7]. Cho/+ mice had both thicker cartilage and 
thinner, less dense cortical bone compared to WT littermates, which may explain the 
development of less severe load-induced OA. Overall, this study showed that the 
collagen XI mutation in cho/+ mice did not exacerbate load-induced OA progression, 
suggesting that loading and the altered cartilage tissue properties induced by the genetic 
abnormality in collagen may be independent risk factors for OA. 
 
5.1.2 Aim 2: Hydrogels for on-demand drug delivery 
 Our second aim was to characterize and test the therapeutic efficacy of an 
injectable hydrogel-based intra-articular drug delivery system. Intra-articular injection 
is a common treatment to alleviate pain associated with severe OA of the knee prior to 
surgical intervention. Although these injections can be effective long-term for a subset 
of patients, the efficacy in most individuals is generally inconsistent due to the lack of 
drug retention time in the joint space [8,9]. Thus, we sought to improve retention time 
using a hydrogel-based drug delivery system. The hydrogel backbone featured 
maleimide-functionalized polyethylene glycol (PEG-MAL) and collagenase-specific 
crosslinkers to induce on-demand therapeutic release under OA conditions [10]. 
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 We first determined the effects of cyclic compression on hydrogel mechanical 
properties and measured therapeutic release with collagenase exposure. After subjecting 
our hydrogels to 10,000 cycles of dynamic cyclic compression up to 80% strain, the 
mechanical properties were not different from non-loaded gels. In response to daily 
collagenase exposure, particle release occurred in hydrogels fabricated with 
collagenase-specific crosslinkers. Our in vitro results suggest that these PEG-MAL 
hydrogels can withstand routine forces in the knee joint that occur during physical 
activity and can release drugs on-demand in response to OA-associated 
inflammation/degradation.  
We also tested the therapeutic efficacy of our hydrogel system in combination 
with a common corticosteroid, dexamethasone (DEX). Our in vivo results indicated that 
DEX, either in bolus form or encapsulated in nanoparticles, did not attenuate load-
induced OA pathological changes. However, hydrogel injections with or without DEX 
attenuated load-induced cartilage degradation and osteophyte formation. Therefore, the 
lubricating effects of the hydrogel were beneficial to joint health. Overall, our combined 
in vitro and in vivo results suggest that this hydrogel system is a promising therapeutic 
strategy to treat OA. 
 
5.1.3 Aim 3: Low-level loading to attenuate osteoarthritis in vivo 
 Our third aim was to attenuate OA progression using low-level cyclic 
compression. Exercise is recommended to alleviate pain associated with mild to 
moderate OA. Effects of exercise include weight loss and muscle strengthening 
surrounding the joint [11,12]. Together, these effects reduce loading experienced by 
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weight-bearing joints. However, exercise has an additional beneficial effect that is 
commonly overlooked. Mild to moderate exercise induced low-level loads in the joint 
that directly benefited cartilage health by stimulating chondrocytes to upregulate 
cartilage matrix synthesis and decrease proinflammatory pathways [13]. The specific 
characteristics of these beneficial loads, however, are not well understood. Preclinical 
models to isolate the effects of beneficial loading associated with exercise do not exist. 
Therefore, we investigated the effects of low-level loading using cyclic tibial 
compression. 
 
Figure 5.1. Improved understanding of relationship between cyclic tibial compression and 
physiological activities. To date, cyclic tibial compression was not used to investigate low load 
magnitudes that mimic mild exercise in humans and result in beneficial cartilage responses. We 
determined that cyclic compression at 1.0N or 2.0N resulted in cartilage protection after injury. 
 
 Low-level cyclic compression slowed the progression of surgically-induced OA. 
Specifically, cyclic loading at 1.0N and 2.0N attenuated cartilage degradation, 
osteophyte formation, and subchondral bone changes associated with DMM-induced 
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OA. These results indicate that controlled loading at the correct magnitude can be 
beneficial to joint health (Fig. 5.1). We can now directly compare the specific tissue-
level and molecular responses of beneficial versus detrimental mechanical loading in 
vivo. Overall, this study showed that low-level mechanical loading can be used as a 
rehabilitative approach after joint injury. 
 
5.1.4 Discussion 
 Although this thesis consisted of three distinct projects, tissue strain in the 
cartilage matrix was a key factor in each aim. The degree of cartilage deformation 
during mechanical loading plays a major role in determining a beneficial versus 
detrimental response [13]. Physiologic dynamic activities lead to cartilage tissue strains 
of 15-35% and result in matrix synthesis and reduction of inflammation. However, 
hyperphysiologic or injurious activities produce cartilage strains greater than 50% and 
cause matrix catabolism, increased activity of proinflammatory pathways, and 
chondrocyte apoptosis [13]. Therefore, we believe that the relationship between load 
magnitude, tissue strain, and cartilage response contributed to the results throughout this 
thesis. 
 Based on our findings from Aim 1 and previous studies [14–17], tibial loading 
at high load magnitudes (9.0N) results in OA-like joint pathology, including cartilage 
damage, osteophyte formation, and subchondral bone changes. These tissue-level 
changes suggest that cartilage strains reach hyperphysiologic levels during cyclic 
compression at high load magnitudes. Although further work is necessary to understand 
the exact degree of cartilage deformation at these high load levels, we can speculate that 
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tissue strains had an influence in the responses to high-level cyclic compression in Aims 
1 and 2. 
 In Aim 1, cho/+ mice developed less severe load-induced cartilage damage 
compared to their WT littermates, despite abnormal cartilage matrix properties in cho/+ 
mice. We believe that cartilage thickness and its influence on tissue strain may have 
been a key factor in these results. Thicker cartilage resulted in increased contact area 
and lower contact pressure in finite element models of similar tibial loading models [5]. 
In our study, cartilage was 10% thicker in cho/+ mice compared to WT littermates. 
Taken together, the thicker cartilage in cho/+ mice may have resulted in increased 
contact area in the cartilage. The increased contact area led to decreased pressure and 
tissue strain. To this end, the area of cartilage contact, the thickness of the tissue, and 
the tissue properties contribute to tissue strains in response to high-level tibial 
compression. 
 In Aim 2, intra-articular injection of hydrogels attenuated cartilage damage and 
osteophyte formation after a single bout of high-level loading. Although the exact 
reasons behind this result are not clear, the hydrogel clearly had a beneficial effect on 
joint health. Again, we can speculate that the hydrogel influenced cartilage tissue strain. 
Like Aim 1, the hydrogel in the joint space may have led to increased contact area 
between the cartilage surfaces during cage activities post-loading. In addition, the 
hydrogel may have effectively “thickened” the joint space after injection. The increased 
contact area and thickened joint space would have resulted in more highly distributed 
loads, leading to decreased tissue strain. 
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 In Aim 3, low-level cyclic compression induced a beneficial response in the knee 
joint. These results suggest that we achieved healthy physiologic levels of strain in the 
cartilage during cyclic compression. Based on tissue-level results, low-level loading 
decreased DMM-induced matrix catabolism. Furthermore, low-level loading had a 
subtle beneficial effect on chondrocyte apoptosis. Finite element models from our lab 
estimated that tibial loading at 1.0N produced approximately 15% cartilage strain [18]. 
These combined experimental and computational data are consistent with previous 
literature that indicates cartilage strains of 15-35% results in healthy responses [13]. 
Overall, the beneficial and detrimental effects of mechanical loading in this thesis were 
most likely the result of modulating cartilage tissue strain.  
 
5.2 Strengths 
 The research described in this thesis contributed significantly to the 
understanding of OA pathology, treatment, and prevention. A key theme throughout the 
thesis was addressing the questions with an integrative approach. We combined 
biomedical engineering, mechanical engineering, biomaterials, biology, and physiology 
to solve key problems associated with OA. In Aim 1 (Chapter 2), we combined 
genetically-induced abnormal material properties with an altered mechanical 
environment to study the interaction of risk factors in OA onset and progression. In Aim 
2 (Chapter 3), we used biomaterials characterization techniques, in vitro and in vivo 
dynamic cyclic compression, and collagenase-driven degradation inspired by disease 
pathology to develop a novel approach for IA drug delivery. In Aim 3 (Chapter 4), we 
used surgical techniques to induce OA and novel loading regimens to successfully slow 
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down post-traumatic OA. Overall, the interdisciplinary nature and integrative 
approaches of this work are major strengths. 
 Another consistent strength of this thesis was the focus on load-induced OA 
using in vivo cyclic tibial compression. Prior studies showed that repetitive loading 
[14,19] or a single bout of loading [15] both induce OA-like pathology in mice. Based 
on these findings, we used repetitive and single bouts of load in this thesis to study 
disease progression and test novel treatments. This model of OA offers several 
advantages over traditional OA models. Cyclic tibial compression at high load levels 
offers a noninvasive, nontraumatic approach to induce OA [20]. This allows researchers 
to investigate the direct relationship between controlled mechanical loading and 
cartilage damage [21]. Furthermore, the OA model closely mimics the well-known 
clinical “wear and tear” form of OA.  
 The use of cyclic tibial compression allowed a spectrum of load-induced 
responses to be studied. In addition to the damaging effects of high loads, we explored 
the positive effects of loading. Aim 3 (Chapter 4) is the first use of in vivo cyclic tibial 
compression to benefit cartilage health. To date, most experiments investigating the 
beneficial effects of loading either have been in vitro [22–24] or examined exercise, 
such as treadmill running or mouse running wheels  [25,26]. In vitro experiments using 
cartilage explants and chondrocyte culture cannot recapitulate the response of the 
multiple tissues that comprise the joint. Furthermore, exercise induces systemic effects, 
including muscle gain and weight loss. Isolating the independent contribution of low to 
moderate loading is difficult with studies involving exercise. In this thesis, we 
demonstrated that controlled low-level loads applied by in vivo cyclic tibial compression 
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attenuated OA-like changes after an injury. The translation of this loading regimen to 
the human level could result in improvements in physical therapy techniques after 
traumatic joint injury, or maintenance of cartilage health throughout a lifetime. 
  
5.3 Limitations 
 This thesis combined in vitro and in vivo techniques to analyze specific aspects 
of OA. The entirety of the in vivo work was performed using preclinical murine models 
of OA. Although the mouse is an extremely common in vivo model to study human 
diseases, distinct differences between mouse and human knee joint morphology must 
be considered. First, mouse cartilage is thinner than human cartilage. Therefore, the 
distinct zones in human cartilage (i.e. superficial, middle, and deep) are not as 
distinguishable in mouse cartilage. In humans, each of these zones plays a distinct role 
in responding to specific types of loads [27]. Thus, the mechanics of the overall cartilage 
structure in the mouse may be different from humans. Second, the chondrocyte density 
is approximately 24-times higher in mice compared to humans [28]. The increased 
number of chondrocytes makes mouse cartilage more responsive to changes in 
environment, contributing to the rapid development of OA in mice. Finally, animal size 
and body weight differ between mice and humans. Because humans are more than three 
orders of magnitude heavier than mice, determining the appropriate mechanical 
properties of a drug delivery system, such as the hydrogel system described in Aim 2, 
is difficult in a mouse model of OA.  
Although these limitations of the mouse are important to consider, mouse 
cartilage also shares several key characteristics with human tissue. Specifically, the 
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composition of the cartilage matrix, including the collagen II fibrils and proteoglycans, 
is similar between the two species. Furthermore, OA disease pathology is similar 
between mice and humans, and a tremendous amount of OA knowledge has come from 
mouse studies [29]. Therefore, despite the limitations, the mouse is an excellent 
preclinical model to study OA. 
OA is a complex disease with many etiologies. For example, the disease can be 
divided into six different phenotypes: aging-, cartilage-, subchondral bone-, traumatic 
injury-, inflammation-, and metabolic-driven OA [30]. Recapitulating the full range of 
these phenotypes in a single research project is nearly impossible, but understanding 
which phenotypes are relevant to a specific research question is important to consider. 
Although the load-induced OA model in Aims 1 and 2 does not fit into a single 
phenotype based on Mobasheri et al.’s definitions [30], the model has attributes of the 
aging phenotype and demonstrates both cartilage- and subchondral bone-driven 
changes. The DMM model in Aim 3 is an example of the traumatic injury-driven 
phenotype. Thus, although we were not able to investigate all OA etiologies in this 
thesis, we are aware of what these mouse models represent in a clinical scenario. 
 
5.4 Future Work 
 This work examined two novel treatments for OA. The first was a hydrogel-
based on-demand delivery system for sustained intra-articular drug retention. The 
second involved the application of low-level loading to attenuate cartilage degradation 
after a traumatic injury. Both projects demonstrated promising results, but further 
research is necessary to understand their potential impact in treating OA in the clinic. 
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Specifically, we need to determine whether in vivo drug retention time of our PEG-
MAL hydrogels is improved compared to bolus drug injections under both healthy and 
OA conditions. In addition, we need to continue preclinical testing of the low-level 
loading approach to understand the underlying mechanism and develop potential 
clinical applications of the loading regimen. 
 
5.4.1 Determining intra-articular drug retention time with in vivo imaging 
 Improving the clinical outcome of intra-articular injection requires increasing 
intra-articular retention time of drugs. To further characterize our hydrogel-based drug 
delivery system, a future goal is to quantify drug retention with the hydrogel compared 
to a bolus drug alone. To accomplish this goal, we have been working with a fluorescent 
in vivo imaging system (IVIS). With the system, we are able to visualize fluorescently 
labeled markers inside a knee joint [31]. To date, we have focused on quantifying 
fluorescent signal intensity in the knee joints of mice. However, due to the small size of 
the intra-articular joint space in mice, we are only able to inject 2 μL of drug or hydrogel 
into the knee. No matter the intensity of the fluorescent label used, a 2-μl volume is 
extremely difficult to visualize with IVIS. Therefore, I propose that future work needs 
to be shifted to a larger animal model to quantify drug retention with the hydrogel 
system. Larger animal models allow higher volumes to be injected and have shown 
success in tracking intra-articular drug retention previously [32]. 
 The proposed project would involve injecting five different preparations into the 
knee joints of rats. Previous studies involving intra-articular injections in rat knee joints 
have used up to 100 μL [33]. The proposed study would be designed similarly to the in 
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vivo study in Chapter 3 with slight modifications. The injection groups would be 1) 
hydrogel + drug-loaded nanoparticles, 2) hydrogel + drug, 3) drug-loaded nanoparticles, 
4) drug, and 5) saline. The drug would be labeled with a fluorescent dye, such as 
DyLight 650 (ThermoFisher). The fluorescent intensity in the knee joint would be 
visualized and quantified with daily IVIS images. We would expect that the drug-loaded 
nanoparticles inside the hydrogel would lead to the longest drug retention, and the bolus 
drug would leave the joint rapidly. This proposed experiment is critical in determining 
whether the hydrogel system extends the retention time of drugs inside the joint space. 
 Upon completion of the drug retention studies, further work needs to focus on 
the translation of this therapeutic approach to animal models that more closely mimic 
the human joint environment. The hydrogel system showed promise in attenuating load-
induced OA pathology in mice. To move the hydrogel system closer to clinical use, 
similar studies with other therapeutics should be performed in the rat/rabbit, and 
ultimately the pig because of its similarities to humans [34]. If the PEG-MAL hydrogel 
system attenuates OA more effectively compared to bolus drug in these larger animal 
models, the hydrogel system can be moved to clinical trials. 
 
5.4.2 Translating beneficial loads to clinical scenarios 
 In Aim 3, low-level cyclic tibial compression attenuated OA progression. Future 
preclinical studies need to focus on further developing the approach for clinical 
scenarios. One example is combining the loading approach with immobilization after a 
joint injury and determining cartilage health long-term after injury. Current clinical 
protocols immobilize the joint after surgical repair. Confined mouse cages restrict 
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movement and have decreased OA severity in mice after joint injury [35]. We believe 
that controlled loading combined with immobilization of the affected joint may aid in 
long-term protection of cartilage. A proposed experiment would be similar to the project 
described in Aim 3. The major modification would be the addition of hindlimb 
unloading after DMM [36], rather than normal cage activity. Three groups would be 
compared: 1) DMM + loading, 2) DMM + hindlimb suspension, and 3) DMM + loading 
+ hindlimb suspension. Comparing the severity of DMM-induced cartilage damage 
would determine whether controlled loading adds to the beneficial effects of 
immobilization after an injury.  
 In addition to preclinical studies, a future direction is translation of controlled, 
low-level axial loading from mice to humans. The strain levels in the cartilage resulting 
from 1.0N tibial compression are approximately equal to ~15% [18]. Because cartilage 
tissue strain is generally translatable across species [34], future work needs to determine 
load magnitudes that result in ~15% strain in human cartilage. New technologies, such 
as magnetic resonance imaging and biplanar fluoroscopy, will allow us to determine 
loads that result in beneficial cartilage strains [37]. Then, fixtures capable of applying 
controlled, cyclic compression at these load magnitudes to human tibiae need to be 
designed. These loading fixtures would contribute to physical therapy post-injury or 
rehabilitation centers for the elderly population to maintain cartilage health. Ultimately, 
the approach has potential to help both younger individuals fully recover from injury 
and older individuals who are unable to actively move their joints. 
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5.5 Conclusion 
 In this thesis, we not only learned about OA progression, but we also showed 
promising results for novel treatment options and preventive measures. Overall, the 
findings from this research will hopefully play a role in treating clinical OA in the future. 
To conclude, I want to end with a quote from my three-minute thesis title that we should 
continue telling ourselves to overcome this painful disease: “OA, no way!” 
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Histological (OARSI) Score (Scorer #1): OARSI scoring of articular cartilage 
damage measured by Safranin O/Fast Green stain for wildtype (WT) and cho/+ (HET) 
mice. Each column corresponds to a slide separated at a 90 μm interval, with start and 
end slides indicated. Average (Avg) and maximum (Max) scores reported for articular 
cartilage in the medial (M) and lateral (L) tibial plateaus. 
 
ID Genotype Duration Magnitude Limb Plateau Start End 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Avg Max 
5546 WT 1 week 4.5N control M 2 11 0.5 0 0 0 0 0 0 0 0 0.5     0.10 0.5 
     L 3 10 1 0.5 0 0 0.5 0 0 0.5       0.31 1 
    loaded M 1 11 1 1 0 1 0.5 0.5 0.5 0 0.5 0.5 0.5    0.55 1 
     L 1 11 1 1 2 1 0.5 1 0.5 0.5 0.5 0.5 0.5    0.82 2 
5547 WT 1 week 4.5N control M 7 15 0 0.5 0 0 0 0 0 0 0.5      0.11 0.5 
     L 4 11 0.5 0 0.5 1 1 0.5 0.5 0       0.50 1 
    loaded M 2 12 0.5 0.5 0.5 0 0 0.5 1 0.5 0.5 0.5 0.5    0.45 1 
     L 2 10 3 0.5 0.5 1 1 0.5 1 0.5 0.5 0.5     0.90 3 
5556 WT 1 week 4.5N control M 2 12 0.5 0.5 0.5 0 0 1 0.5 0 0 0.5 1    0.41 1 
     L 1 10 0.5 0.5 1 0 0.5 1 0.5 0.5 0.5 0.5     0.55 1 
    loaded M 2 12 0.5 0.5 0 0 0 0.5 0.5 0 0.5 0 0.5    0.27 0.5 
     L 3 13 1 2 2 2 2 1 1 0.5 0.5 0.5 0.5    1.18 2 
5567 WT 1 week 4.5N control M 3 13 0.5 0 0 0 0 0 0 0.5 0 0 0    0.09 0.5 
     L 3 13 0.5 0.5 0.5 0.5 0.5 0.5 1 0.5 0 0.5 0.5    0.50 1 
    loaded M 2 11 1 0.5 0 0 0.5 0.5 1 2 0.5 0.5     0.65 2 
     L 2 11 2 1 1 0.5 2 2 2 0.5 0.5 0.5     1.20 2 
5554 WT 1 week 4.5N control M 2 12 0 0 0 0 0 0 1 1 1 0 0.5    0.32 1 
     L 1 9 1 0.5 0.5 1 0 0.5 1 0.5 0.5      0.61 1 
    loaded M 1 12 0.5 0.5 0 0 0.5 0.5 0.5 2 0.5 0.5 0.5 0.5   0.54 2 
     L 2 12 0.5 1 2 1 2 1 0 1 0.5 0.5     0.95 2 
5557 WT 1 week 4.5N control M 2 11 0 0.5 0 0 0 0.5 0 0 0 0     0.10 0.5 
     L 6 16 1 0.5 0 0.5 0.5 0 0.5 0 0 0.5 0.5    0.36 1 
    loaded M 1 5 0.5 0.5 0.5 0.5 0.5 0.5 0.5        0.50 0.5 
     L 3 11 0.5 1 1 1 2 0 1 0.5 0.5 0.5     0.80 2 
5545 HET 1 week 4.5N control M 3 12 0 0 0 0 0 0 0 0 0 0.5     0.05 0.5 
     L 2 10 0.5 0.5 0 0.5 0 0 0 0.5 0.5      0.28 0.5 
    loaded M 6 15 2 0.5 0.5 0 0 1 0.5 0.5 0.5 0.5     0.60 2 
     L 4 12 2 0.5 1 0.5 0.5 1 1 0.5 1 0.5     0.85 2 
5561 HET 1 week 4.5N control M 4 11 0 0 0 0 0 0 0 0.5       0.06 0.5 
     L 3 11 1 0 1 1 0 1 0.5 0 0.5      0.56 1 
    loaded M 8 14 0.5 0.5 0 0.5 0.5 0.5 0.5 0.5       0.44 0.5 
     L 5 11 1 1 1 2 1 2 0.5        1.21 2 
5559 HET 1 week 4.5N control M 4 12 0.5 0.5 0.5 0.5 0.5 0 0.5 0 0.5      0.39 0.5 
     L 2 8 0.5 0.5 0.5 0.5 0.5 1 0        0.50 1 
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    loaded M 5 12 0.5 0 0.5 0.5 0.5 1 0.5 0.5 0.5      0.50 1 
     L 3 9 2 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5      0.67 2 
5558 HET 1 week 4.5N control M 2 10 0.5 0.5 0 0 0 0 0 0 0.5      0.17 0.5 
     L 5 11 0.5 0.5 0 0 0 0.5 0 0 0      0.17 0.5 
    loaded M 10 15 0.5 0.5 0 0 0.5 1         0.42 1 
     L 4 8 1 2 0.5 0.5 2 0.5         1.08 2 
5562 HET 1 week 4.5N control M 10 16 0.5 0.5 0 0.5 0 0 0        0.21 0.5 
     L 3 8 0 0.5 0.5 0.5 0 0.5         0.33 0.5 
    loaded M 7 15 0.5 1 0 0.5 0 0.5 1 2 0.5      0.67 2 
     L 3 9 1 2 2 2 1 1 0 0.5 0.5      1.11 2 
5565 HET 1 week 4.5N control M 7 13 0 0.5 0 0.5 0 0 0.5        0.21 0.5 
     L 4 9 0 0 0 0 0 0         0.00 0 
    loaded M 1 11 0 0.5 1 0 0.5 0.5 0.5 0 0.5 0.5 0 0.5 0.5  0.38 1 
     L 2 13 0.5 0 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5   0.46 0.5 
5539 WT 2 week 4.5N control M 9 15 0 0 0 0 0 0.5 0        0.07 0.5 
     L 5 12 0 0 2 0.5 0.5 0.5 0 0       0.44 2 
    loaded M 6 14 0.5 0.5 0 0.5 1 2 0.5 0 0.5      0.61 2 
     L 4 10 2 1 0.5 0.5 1 1 1 0.5       0.94 2 
5537 WT 2 week 4.5N control M 4 13 0 0 0 0 0 0 1 0 0 0     0.10 1 
     L 2 11 0 1 1 0 1 1 2 0.5 0 0.5     0.70 2 
    loaded M 1 12 1 0.5 0.5 0.5 0.5 0.5 0.5 1 1 0.5 0.5 0.5   0.63 1 
     L 3 13 0.5 0.5 1 2 1 1 2 2 1 0.5 0.5    1.09 2 
5538 WT 2 week 4.5N control M 11 15 0 0 1 1 0.5          0.50 1 
     L 2 7 1 0 0 1 1 0         0.50 1 
    loaded M 1 9 2 1 0 0.5 2 1 0.5 0 0.5 0.5     0.80 2 
     L 4 12 2 2 2 2 2 2 1 2 0.5 0.5     1.60 2 
5541 WT 2 week 4.5N control M 6 14 0 0 0 0.5 1 1 0 0 0      0.28 1 
     L 2 9 1 1 1 0.5 2 2 0 0.5       1.00 2 
    loaded M 1 11 0.5 0.5 0 1 1 1 0.5 0 0.5 0.5 0.5    0.55 1 
     L 3 12 2 2 2 1 1 1 2 1 2 0.5 0.5 0.5   1.29 2 
5518 WT 2 week 4.5N control M 3 16 0.5 0 0 0 0 0 0 0 0 0 0 0 0 0.5 0.07 0.5 
     L 3 14 1 0.5 0.5 0.5 0.5 0 0.5 0.5 0 0 0 0   0.33 1 
    loaded M 6 15 0.5 0.5 0 0 0 0.5 0.5 0 0.5 0.5 0.5    0.32 0.5 
     L 3 10 2 0 0.5 0.5 1 0 1 0.5 0.5 0.5     0.65 2 
5522 WT 2 week 4.5N control M 4 14 0 0 0 0 0 0 0 0 0 0 0.5    0.05 0.5 
     L 2 10 0 1 0.5 0.5 0.5 1 0.5 0 0.5      0.50 1 
    loaded M 3 14 0.5 0.5 0.5 0 0 1 0.5 0.5 0.5 0 0.5 0.5   0.42 1 
     L 1 7 2 1 0.5 0.5 2 2         1.33 2 
5472 HET 2 week 4.5N control M 2 10 0 0 0 0 0 0 0 0 0.5      0.06 0.5 
     L 1 8 1 0.5 0.5 0 0.5 2 0 0       0.56 2 
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    loaded M 1 7 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5     0.50 0.5 
     L 5 12 1 1 1 0.5 2 2 0.5 0.5 0.5 0.5     0.95 2 
5474 HET 2 week 4.5N control M 1 6 0 0 0 0.5 0.5 0.5         0.25 0.5 
     L 9 14 1 1 0 0.5 2 1         0.92 2 
    loaded M 1 11 0.5 0.5 1 0 0.5 0.5 0.5 0 0.5 0.5 0.5    0.45 1 
     L 2 10 0.5 2 2 2 0.5 2 2 2 0.5 0.5     1.40 2 
5475 HET 2 week 4.5N control M 2 12 0.5 0 0 0 0 0 0 0 0 0 0.5    0.09 0.5 
     L 2 9 1 0.5 0 0 0.5 2 2 0       0.75 2 
    loaded M 8 14 1 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5      0.56 1 
     L 2 7 0.5 1 1 2 2 2 0.5        1.29 2 
5490 HET 2 week 4.5N control M 8 15 0 0 0 0 1 0.5 0.5 0.5       0.31 1 
     L 1 5 0 0 0.5 0.5 1          0.40 1 
    loaded M 3 12 0.5 1 0.5 2 1 0.5 0.5 0.5 0.5 0.5     0.75 2 
     L 1 6 0.5 2 2 0.5 0.5 0.5 0.5        0.93 2 
5491 HET 2 week 4.5N control M 1 9 0 0 0 0 0.5 0 0 0 0.5      0.11 0.5 
     L 2 10 0 0 0 1 0.5 0 1 0.5 0      0.33 1 
    loaded M 2 8 0.5 0 0.5 0.5 0.5 1 0.5 0.5 0.5      0.50 1 
     L 7 13 0.5 0.5 0.5 2 2 2 2 2 0.5 0.5     1.25 2 
5493 HET 2 week 4.5N control M 11 15 0 0 0 1 0          0.20 1 
     L 2 5 0 0 1 1           0.50 1 
    loaded M 3 7 0.5 0.5 0.5 0.5 1 1 0.5 5       1.19 5 
     L 11 16 2 0.5 2 0 1 2         1.25 2 
5535 WT 6 week 4.5N control M 11 17 0 0 0 1 0.5 0 0.5        0.29 1 
     L 4 11 0 2 1 1 1 2 2 1       1.25 2 
    loaded M 8 14 1 0.5 1 1 1 2 0.5        1.00 2 
     L 15 18 2 0.5 1 0.5           1.00 2 
5524 WT 6 week 4.5N control M 4 12 0 0 0 0 0 0 0 0 0.5      0.06 0.5 
     L 5 13 0 1 0.5 0.5 1 0.5 0.5 0 0.5      0.50 1 
    loaded M 14 19 0.5 0.5 0 0 2 2 0.5        0.79 2 
     L 10 16 2 2 1 1 2 1 2 2       1.63 2 
5529 WT 6 week 4.5N control M 4 12 0 0 0 0 0 0 0.5 0 0      0.06 0.5 
     L 9 14 0.5 0.5 0.5 0.5 0.5 0         0.42 0.5 
    loaded M 14 20 0.5 2 0.5            1.00 2 
     L 16 20 2 0.5 1 0.5           1.00 2 
5532 WT 6 week 4.5N control M 10 18 0 0 0 0 0 0 0.5 0 0.5      0.11 0.5 
     L 12 18 0.5 0.5 0.5 0 0.5 0 1        0.43 1 
    loaded M 6 13 0 1 0 1 0.5 0 0 0.5 0.5 0.5     0.40 1 
     L 6 14 2 2 2 1 0.5 1 2 2 0.5      1.44 2 
5534 WT 6 week 4.5N control M 4 16 0 0 0 0 0 0 0 1 0 0 0 0 0  0.08 1 
     L 4 16 0 0 0 1 1 1 1 1 1 0.5 0.5 0 0.5  0.58 1 
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    loaded M 1 9 0 0.5 1 1 0 2 1 0.5 0.5 0.5 0.5    0.68 2 
     L 5 14 4 0 0 1 0 0.5 1 2 0.5 0.5     0.95 4 
5528 WT 6 week 4.5N control M 3 14 0.5 0.5 0 0 0 0 0 1 0.5 0 0 0   0.21 1 
     L 7 16 2 1 1 0 0 0 0.5 0 0 0.5     0.50 2 
    loaded M 14 20 0.5 0 0.5 0 1 2 2 0.5       0.81 2 
     L 8 14 2 3 2 2 1 2 2 0.5 0.5      1.67 3 
5531 HET 6 week 4.5N control M 8 17 0 0 0 0 0 0 0 0 0 0.5     0.05 0.5 
     L 8 15 0 0.5 0 0 0 0.5 1 0       0.25 1 
    loaded M 7 18 1 0.5 1 0 0.5 2 0.5 0.5 0.5 0.5 0.5 0.5   0.67 2 
     L 8 15 3 1 1 2 2 0.5 0.5 0.5 0.5 0 0.5    1.05 3 
5526 HET 6 week 4.5N control M 3 12 0.5 0.5 0.5 0.5 0.5 1 0 0 0 0     0.35 1 
     L 5 13 2 2 0.5 0.5 0.5 1 0.5 1 0      0.89 2 
    loaded M 7 16 0.5 1 0 0 0.5 0.5 0.5 2 0.5 0.5 0.5    0.59 2 
     L 5 13 4 2 0.5 1 1 2 2 1 0.5 0.5     1.45 4 
5527 HET 6 week 4.5N control M 2 10 0.5 0 0.5 0.5 1 0.5 0 0.5 0.5      0.44 1 
     L 3 11 0.5 1 1 0.5 0.5 1 0.5 0 0.5      0.61 1 
    loaded M 9 18 0.5 0.5 0.5 0.5 0.5 2 1 0.5 0.5 0.5 0.5 0.5   0.67 2 
     L 8 15 3 2 2 1 0.5 1 0.5 1 0.5 0.5     1.20 3 
5536 HET 6 week 4.5N control M 7 16 0.5 0.5 0.5 0.5 0 0 0 0 0 0     0.20 0.5 
     L 4 14 0.5 0 1 0 0.5 0 1 0 1 0 0.5    0.41 1 
    loaded M 5 12 2 1 0.5 1 2 2 0 1 1 0.5     1.10 2 
     L 5 12 4 1 2 2 0 2 0.5 2 0.5      1.56 4 
5544 HET 6 week 4.5N control M 8 17 0.5 1 0.5 0 0 0 0 0 0 0     0.20 1 
     L 8 17 0.5 0.5 1 0.5 0.5 1 1 1 0 0.5     0.65 1 
    loaded M 5 15 0.5 0.5 0 0 0 0.5 0.5 0.5 0.5 0.5 0.5    0.36 0.5 
     L 4 13 2 1 1 1 1 2 1 2 2 0.5 0.5    1.27 2 
5560 HET 6 week 4.5N control M 8 17 0.5 0.5 0.5 0 0 0 0.5 0 0 0.5     0.25 0.5 
     L 6 14 0 0 0 0 0 0.5 1 0 0      0.17 1 
    loaded M 3 11 0.5 0.5 0.5 0 0.5 1 0.5 0.5 0.5 0.5     0.50 1 
     L 8 13 2 2 0.5 0 0.5 0.5         0.92 2 
5578 WT 1 week 9.0N control M 4 13 0 0.5 0 0 0 0 1 0 0 0     0.15 1 
     L 4 11 2 1 0.5 0.5 1 0.5 0 0       0.69 2 
    loaded M 7 15 4 0.5 0 0.5 0 1 0.5 0.5 0.5      0.83 4 
     L 12 15 3 2 1 1           1.75 3 
5576 WT 1 week 9.0N control M 1 10 0 0 0.5 0 1 1 0 0 0 0.5     0.30 1 
     L 1 10 1 1 1 1 0.5 0.5 1 1 0 0     0.70 1 
    loaded M 9 14 3 3 3 0 2 1         2.00 3 
     L 8 14 3 2 1 1 0.5 1 2        1.50 3 
5579 WT 1 week 9.0N control M 7 15 0 0 0 0 0 0.5 0 0 0.5      0.11 0.5 
     L 4 12 0 0 1 1 1 1 1 0 0      0.56 1 
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    loaded M 6 13 2 1 1 0 1 0 2 0.5       0.94 2 
     L 3 9 2 1 2 2 2 2 0.5 0.5       1.50 2 
5571 WT 1 week 9.0N control M 4 12 0.5 0 0 0 0 0 0 0 0.5      0.11 0.5 
     L 2 9 0 1 1 0.5 0.5 1 1 0       0.63 1 
    loaded M 7 15 3 3 0.5 1 1 0.5 0.5 1 0.5      1.22 3 
     L 7 15 2 1 2 2 0.5 0.5 1 2 2      1.44 2 
5572 WT 1 week 9.0N control M 8 14 0 0 0 0 0 0 0        0.00 0 
     L 8 14 0 0.5 0.5 0 0.5 1 0        0.36 1 
    loaded M 12 15 3 2 0 0           1.25 3 
     L 13 15 3 1 1            1.67 3 
5570 WT 1 week 9.0N control M 7 16 0.5 0 0 0 0 0 0 0 0 0.5     0.10 0.5 
     L 4 12 0 0 1 0.5 1 0.5 0 1 0      0.44 1 
    loaded M 7 16 0.5 0 1 0 0 0 0.5 0 0 0.5     0.25 1 
     L 4 12 2 3 0.5 0 1 1 0.5 1 0      1.00 3 
5564 HET 1 week 9.0N control M 8 16 0 0 0 0 0 0 0 0 0      0.00 0 
     L 5 13 0 0 0 0 0 0 0.5 0.5 0      0.11 0.5 
    loaded M 8 16 0 0 0.5 2 0.5 0.5 1 0.5 0.5 0.5     0.60 2 
     L 5 13 4 0.5 0.5 0.5 1 1         1.25 4 
5577 HET 1 week 9.0N control M 13 16 0 0 0 0           0.00 0 
     L 10 15 0.5 0 1 1 1 0         0.58 1 
    loaded M 13 16 2 0.5 0 2 0          0.90 2 
     L 10 15 2 4 2 1 0.5 1         1.75 4 
5574 HET 1 week 9.0N control M 7 13 0 0 0 0 0 0 0        0.00 0 
     L 4 9 1 0.5 1 2 1 0.5         1.00 2 
    loaded M 7 13 3 2 2 1 0.5 1 0        1.36 3 
     L 4 9 2 2 2 2 2 1         1.83 2 
5580 HET 1 week 9.0N control M 10 16 0 0 0 0.5 0 0.5 0        0.14 0.5 
     L 6 12 0 0 1 0 1 2 0        0.57 2 
    loaded M 10 16 0 0 0 0.5 0.5 0.5 1 0       0.31 1 
     L 6 12 2 1 1 1 0 0 1 2       1.00 2 
5573 HET 1 week 9.0N control M 2 8 0 0 0 0 0 0 0.5        0.07 0.5 
     L 4 10 0 1 0 0.5 1 1 0        0.50 1 
    loaded M 9 14 1 1 0.5 0.5 0.5 0.5         0.67 1 
     L 4 12 2 3 2 2 1 1 2 2 2      1.89 3 
5569 HET 1 week 9.0N control M 3 10 0.5 0 0 0 0 0 0.5 0.5       0.19 0.5 
     L 2 7 0.5 0.5 0 1 2 0.5         0.75 2 
    loaded M 15 20 0.5 3 2 0 0.5 1         1.17 3 
     L 11 18 1 2 0.5 1 1 2 0.5 0.5       1.06 2 
5519 WT 2 week 9.0N control M 2 8 0 0 0 0 1 0 0.5        0.21 1 
     L 3 8 0.5 0.5 0 0 0 0.5         0.25 0.5 
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    loaded M 14 21 2 2 2 0 1 2 0.5 2       1.44 2 
     L 14 21 2 1 0.5 0 2 0.5 0.5 0.5       0.88 2 
5521 WT 2 week 9.0N control M 7 15 0 0 0 0 0 1 0 0 0.5      0.17 1 
     L 6 13 1 1 0.5 0.5 0.5 0.5 0 0       0.50 1 
    loaded M 9 15 3 4 2 2 1 2 2        2.29 4 
     L 7 15 3 3 2 2 2 1 2 2 0.5      1.94 3 
5523 WT 2 week 9.0N control M 1 10 0.5 0 0 0 0 0.5 0 0 0 0     0.10 0.5 
     L 2 13 0.5 1 1 2 0 1 1 1 0 0 0.5    0.73 2 
    loaded M 14 18 3 2 3 2 2 0.5         2.08 3 
     L 5 10 0.5 1 2 2 2 1         1.42 2 
5563 WT 2 week 9.0N control M 7 15 0.5 0.5 0 0 0 0.5 0.5 0.5 0      0.28 0.5 
     L 7 15 0.5 0.5 0.5 1 0.5 0.5 0.5 0.5 1      0.61 1 
    loaded M 9 16 0.5 1 2 2 0 0.5 0.5 0.5       0.88 2 
     L 10 16 6 5 0.5 0.5 1 0.5 0.5        2.00 6 
5566 WT 2 week 9.0N control M 7 15 2 0.5 0 0 0.5 0.5 0 0.5 0.5      0.50 2 
     L 11 17 0.5 0.5 0.5 0.5 0.5 0.5 0.5        0.50 0.5 
    loaded M 14 19 2 0.5 0.5 2 0 0.5         0.92 2 
     L 13 19 5 2 0 0.5 0.5 2 2        1.71 5 
5549 WT 2 week 9.0N control M 9 17 0 0 0 0 0.5 0 0 0 0      0.06 0.5 
     L 5 11 0 1 0 0.5 0.5 0.5 0        0.36 1 
    loaded M 12 16 2 2 2 0.5 1          1.50 2 
     L 9 14 0.5 2 1 1 0.5 1         1.00 2 
5482 HET 2 week 9.0N control M 5 14 0.5 0 0 0.5 0 0.5 0 0 0.5 1     0.30 1 
     L 3 11 0 0.5 1 0.5 0.5 1 0 0.5 0.5      0.50 1 
    loaded M 5 15 2 2 2 1 0.5 0 1 0.5 1 0.5 0.5    1.00 2 
     L 3 12 3 2 2 2 2 2 2 2 0 0.5 0.5    1.64 3 
5483 HET 2 week 9.0N control M 3 12 0 0 0.5 0 0 0 0 0.5 0.5 0.5     0.20 0.5 
     L 1 9 0.5 1 0.5 1 0.5 0.5 0.5 0.5 1      0.67 1 
    loaded M 4 12 2 0.5 0.5 0.5 1 1 1 1 0.5 0.5 0.5 0.5   0.79 2 
     L 6 14 2 0.5 1 1 2 2 2 1 0.5      1.33 2 
5520 HET 2 week 9.0N control M 1 7 0 0 0 0 0.5 0.5 0.5        0.21 0.5 
     L 1 4 0.5 1 0.5 0.5           0.63 1 
    loaded M 7 16 1 0.5 1 0.5 0 0.5 0 0 0.5 0.5 0.5    0.45 1 
     L 5 15 0.5 1 0.5 2 1 0.5 0.5 0.5 1 1 0.5    0.82 2 
5550 HET 2 week 9.0N control M 7 14 0 2 0.5 0.5 0.5 0.5 0 0       0.50 2 
     L 3 9 0.5 0.5 0.5 1 1 1 2        0.93 2 
    loaded M 8 13 1 1 3 0 0.5 0.5 0.5        0.93 3 
     L 5 10 3 0.5 0.5 0.5 1 3         1.42 3 
5551 HET 2 week 9.0N control M 4 13 0.5 1 0 0 0.5 0.5 1 0 0 0.5     0.40 1 
     L 3 11 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5      0.50 0.5 
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    loaded M 8 14 3 2 0 0 0 1 1 0.5 0.5      0.89 3 
     L 8 16 2 3 0.5 2 0.5 0.5 0.5 0.5 2      1.28 3 
5553 HET 2 week 9.0N control M 8 16 0.5 0 0 0 0 0 2 0.5 0      0.33 2 
     L 3 8 0 0 0.5 0 1 2         0.58 2 
    loaded M 12 16 3 2 2 2 2 2         2.17 3 
     L 8 14 4 3 2 1 0.5 2 2 2       2.06 4 
5509 WT 6 week 9.0N control M 16 20 0.5 0 0 0 0.5          0.20 0.5 
     L 11 16 0.5 0 0.5 1 1 0.5         0.58 1 
    loaded M 19 24 2 1 0.5 1 0 1 2        1.07 2 
     L 17 24 3 3 0.5 0.5 1 0.5 0.5 1 1      1.22 3 
5512 WT 6 week 9.0N control M 7 17 0 0.5 0 0 0 0 0.5 2 0 0 0    0.27 2 
     L 7 15 0.5 0.5 0.5 1 1 0 0 0 0      0.39 1 
    loaded M 22 27 3 4 2 2 0.5 1         2.08 4 
     L 20 27 4 2 2 0.5 2 0.5 0.5 1       1.56 4 
5513 WT 6 week 9.0N control M 2 13 0 0 0 0 0 0 0 0 0 0 0 0.5   0.04 0.5 
     L 4 13 0.5 0.5 0.5 0.5 0 0 0.5 0 0 0.5     0.30 0.5 
    loaded M 15 19 4 3 0.5 0.5 1          1.80 4 
     L 16 19 5 4 1 0.5 0.5          2.20 5 
5514 WT 6 week 9.0N control M 5 15 0.5 0 0 0 0 0 0.5 0.5 0 0 0    0.14 0.5 
     L 8 15 0 0 0 0.5 0.5 0.5 0.5 0       0.25 0.5 
    loaded M 16 21 3 3 2 0.5 0 0.5         1.50 3 
     L 13 18 4 2 3 0.5 0.5 2 2        2.00 4 
5515 WT 6 week 9.0N control M 5 14 0.5 0 0 0 0.5 0 0 0 0 0     0.10 0.5 
     L 7 14 0.5 0 0.5 0.5 0.5 0 0.5 0       0.31 0.5 
    loaded M 11 13 2 3 1 2 0          1.60 3 
     L 13 15 2 2 2            2.00 2 
5517 WT 6 week 9.0N control M 4 14 0 0.5 0 0 0 0.5 1 0 0 0 0    0.18 1 
     L 4 12 0.5 0.5 0.5 0 0 0.5 0 0 0.5      0.28 0.5 
    loaded M 17 20 2 3 3 3 0.5          2.30 3 
     L 13 19 3 3 2 1 0.5 1 1 2       1.69 3 
5510 HET 6 week 9.0N control M 10 18 0.5 0.5 0.5 0.5 0.5 0.5 1 0 0.5      0.50 1 
     L 6 14 0 0 0.5 0 0.5 0.5 1 2 0.5      0.56 2 
    loaded M 20 24 0.5 1 1 0.5 1          0.80 1 
     L 18 24 3 2 1 0.5 0.5 0.5 0.5        1.14 3 
5511 HET 6 week 9.0N control M 3 14 1 0 0 0 0 0.5 0.5 0.5 0 0 0 0.5   0.25 1 
     L 3 13 0.5 0.5 0.5 1 0 0.5 0 0 0.5 0.5 0    0.36 1 
    loaded M 19 24 3 1 2 2 1 3         2.00 3 
     L 18 24 5 3 2 2 2 2 2        2.57 5 
5516 HET 6 week 9.0N control M 8 16 0.5 0.5 0.5 0 0 0 0 0 0      0.17 0.5 
     L 9 16 0.5 0 0 0.5 0 0 0 0.5       0.19 0.5 
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    loaded M 11 18 4 2 1 0 0.5 1 1 2       1.44 4 
     L 13 18 4 3 2 0.5 2 0.5         2.00 4 
5530 HET 6 week 9.0N control M 2 12 0.5 0.5 0 0 0 0 0 0.5 0 0.5     0.20 0.5 
     L 5 13 0 0 0.5 0 0 0.5 1 0.5 0      0.28 1 
    loaded M 16 21 3 2 0.5 1 1 1         1.42 3 
     L 11 18 2 3 3 1 2 2 2 2 2      2.11 3 
5533 HET 6 week 9.0N control M 16 21 0 0 0 0 0 0         0.00 0 
     L 9 16 0.5 0 0 0.5 1 0.5 1 0.5       0.50 1 
    loaded M 11 19 0.5 0.5 0 0 1 1 1 0.5 2      0.72 2 
     L 13 19 4 2 0 1 0.5 0.5 1        1.29 4 
5525 HET 6 week 9.0N control M 4 15 0 0 0 0 0 0 0 0 0 0 0 0.5   0.04 0.5 
     L 5 15 0 0.5 1 1 0.5 0 1 1 2 0 0.5    0.68 2 
    loaded M 12 17 3 3 3 0 0 1         1.67 3 
     L 12 17 4 2 2 2 1 1         2.00 4 
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Histological (OARSI) Score (Scorer #2): OARSI scoring of articular cartilage 
damage measured by Safranin O/Fast Green stain for wildtype (WT) and cho/+ (HET) 
mice. Each column corresponds to a slide separated at a 90 μm interval, with start and 
end slides indicated. Average (Avg) and maximum (Max) scores reported for articular 
cartilage in the medial (M) and lateral (L) tibial plateaus. 
 
ID Genotype Duration Magnitude Limb Plateau Start End 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Avg Max 
5546 WT 1 week 4.5N control M 2 11 0.5 0.5 1 0 0.5 0.5 0.5 0.5 0 1 0.5    0.50 1 
     L 3 10 0.5 2 0.5 2 1 1 0.5 0.5 0.5 1 0.5    0.91 2 
    loaded M 1 11 0.5 1 0 2 0.5 0.5 0 1 0.5 0.5     0.65 2 
     L 1 11 2 2 2 2 1 1 0.5 0.5 0.5 0.5     1.20 2 
5547 WT 1 week 4.5N control M 7 15 0.5 0.5 0.5 0 0 0.5         0.33 0.5 
     L 4 11 1 0.5 1 1 2 0.5 0.5 0.5       0.88 2 
    loaded M 2 12 1 0.5 0.5 0 0 0 1 0.5 0 0.5 1    0.45 1 
     L 2 10 0.5 0.5 1 1 1 2 0.5 0.5 0.5      0.83 2 
5556 WT 1 week 4.5N control M 2 12 0.5 0.5 0.5 0.5 0 0.5 1 1 0.5 0.5 1    0.59 1 
     L 1 10 0.5 1 1 1 1 2 1 0.5 0.5 0.5     0.90 2 
    loaded M 2 12 0.5 0.5 0.5 0.5 2 1 1 0.5 0.5 0.5 0.5    0.73 2 
     L 3 13 2 2 2 3 2 2 2 1 0.5 0.5 0.5    1.59 3 
5567 WT 1 week 4.5N control M 3 13 0.5 0.5 0 0 0 0 0.5 0.5 0 0.5 0.5    0.27 0.5 
     L 3 13 0.5 2 1 1 0.5 2 1 0.5 0.5 0.5 0.5    0.91 2 
    loaded M 2 11 0.5 0.5 0.5 0.5 0.5 0.5 1 1 0.5 0.5     0.60 1 
     L 2 11 4 0.5 0.5 0.5 2 1 0.5 0.5 0.5 0.5     1.05 4 
5554 WT 1 week 4.5N control M 2 12 1 0.5 0.5 0.5 1 1 1 2 2 0.5     1.00 2 
     L 1 9 2 2 2 2 1 1 0.5 0.5       1.38 2 
    loaded M 1 12 0.5 0.5 0.5 0.5 0.5 0.5 2 0.5 0.5 0.5 0.5 0.5   0.63 2 
     L 2 12 0.5 1 2 2 1 0.5 1 2 0.5 0.5     1.10 2 
5557 WT 1 week 4.5N control M 2 11 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5    0.50 0.5 
     L 6 16 2 1 1 1 1 0.5 1 1 0.5 0.5     0.95 2 
    loaded M 1 5 0.5 0.5 0.5 0.5 0.5          0.50 0.5 
     L 3 11 1 1 1 0.5 0.5 1 0.5 0.5       0.75 1 
5545 HET 1 week 4.5N control M 3 12 1 0 0 0.5 0.5 0.5 0.5 0 0.5 0.5     0.40 1 
     L 2 10 0.5 0.5 0.5 0.5 1 0.5 2 2 0.5 0.5     0.85 2 
    loaded M 6 15 2 0.5 0.5 0.5 0.5 2 0.5 0.5 1 2     1.00 2 
     L 4 12 2 0.5 1 0.5 1 1 2 2 2      1.33 2 
5561 HET 1 week 4.5N control M 4 11 0.5 0 0.5 0.5 0.5 2 0.5 0.5 1      0.67 2 
     L 3 11 1 0 2 1 0.5 2 2 0.5 0.5      1.06 2 
    loaded M 8 14 0.5 0.5 0.5 0.5 0.5 0.5 0.5        0.50 0.5 
     L 5 11 0.5 1 1 2 3 3         1.75 3 
5559 HET 1 week 4.5N control M 4 12 2 1 0.5 0.5 0.5 1 0.5 0.5       0.81 2 
     L 2 8 0.5 1 0.5 0.5 0.5 0.5 2 0.5       0.75 2 
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    loaded M 5 12 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5      0.50 0.5 
     L 3 9 0.5 0.5 0.5 0.5 0.5 0.5         0.50 0.5 
5558 HET 1 week 4.5N control M 2 10 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5      0.50 0.5 
     L 5 11 0.5 0.5 2 2 1 0.5 0.5 0.5       0.94 2 
    loaded M 10 15 1 2 0.5 2 1 0.5         1.17 2 
     L 4 8 2 3 0.5 2 2          1.90 3 
5562 HET 1 week 4.5N control M 10 16 0.5 0.5 0.5 0.5 0.5 0.5         0.50 0.5 
     L 3 8 0.5 0.5 2 0.5 0.5          0.80 2 
    loaded M 7 15 1 0.5 0.5 0.5 0.5 1 0.5 0.5       0.63 1 
     L 3 9 3 2 3 1 3 0.5 0.5        1.86 3 
5565 HET 1 week 4.5N control M 7 13 0.5 0.5 0.5 0.5 0.5 0.5 0.5        0.50 0.5 
     L 4 9 0.5 0.5 0.5 1 0.5 0.5         0.58 1 
    loaded M 1 11 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5   0.50 0.5 
     L 2 13 3 3 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5     1.00 3 
5539 WT 2 week 4.5N control M 9 15 0.5 0.5 0.5 0.5 2 2 0.5        0.93 2 
     L 5 12 0.5 2 2 2 2 3 1 1 0.5      1.56 3 
    loaded M 6 14 1 0.5 0.5 1 2 0.5 1        0.93 2 
     L 4 10 3 4 2 2 3 3 2        2.71 4 
5537 WT 2 week 4.5N control M 4 13 0.5 0.5 1 0 0.5 1 1 0.5 0.5 0.5 1    0.64 1 
     L 2 11 2 2 2 1 2 2 2 2 0.5 1     1.65 2 
    loaded M 1 12 0.5 0.5 0.5 0.5 0.5 0.5 1 2 0.5 2 0.5    0.82 2 
     L 3 13 2 0.5 2 3 2 1 1 1 0.5 0.5 0.5    1.27 3 
5538 WT 2 week 4.5N control M 11 15 0.5 0.5 2 2 0.5          1.10 2 
     L 2 7 2 0.5 1 2 3 3         1.92 3 
    loaded M 1 9 3 2 1 0.5 2 2 1 0.5 2      1.56 3 
     L 4 12 4 2 3 3 3 2 2 3 0.5      2.50 4 
5541 WT 2 week 4.5N control M 6 14 0.5 0.5 0.5 1 1 2 0.5 0.5       0.81 2 
     L 2 9  1 2 2 2 2 2 2       1.86 2 
    loaded M 1 11 0.5 0.5 0.5 1 2 2 1 0.5 1 0.5     0.95 2 
     L 3 12 2 2 2 1 2 1 2 3 2 0.5     1.75 3 
5518 WT 2 week 4.5N control M 3 16 0.5 2 0.5 0.5 0.5 0.5 0.5 0 0.5 1 0.5 0.5   0.63 2 
     L 3 14 1 1 2 2 2 1 1 1 1 0.5 0.5    1.18 2 
    loaded M 6 15 1 2 3 0.5 0.5 1 0.5 0.5 0.5 0.5     1.00 3 
     L 3 10 3 1 0.5 2 2 2 2 2       1.81 3 
5522 WT 2 week 4.5N control M 4 14 0.5 0.5 2 0.5 0.5 0.5 0.5 1 0.5 0.5 1    0.73 2 
     L 2 10 0.5 1 1 1 1 2 2 1 1      1.17 2 
    loaded M 3 14 0.5 0.5 0.5 0.5 1 1 1 2 0.5 0.5 0.5    0.77 2 
     L 1 7 1 2 3 2 1 3 0.5        1.79 3 
5472 HET 2 week 4.5N control M 2 10 0.5 0.5 1 0.5 0.5 0.5 1 1 0.5      0.67 1 
     L 1 8 1 2 2 0.5 2 3 2 0.5       1.63 3 
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    loaded M 1 7 0.5 0.5 0.5 0.5 0.5 0.5 0.5 1 0.5      0.56 1 
     L 5 12 1 2 2 1 1 1 1 0.5 0.5      1.11 2 
5474 HET 2 week 4.5N control M 1 6 0.5 0.5 0.5 0.5 0.5 0.5         0.50 0.5 
     L 9 14 2 2 1 0.5 2 2         1.58 2 
    loaded M 1 11 0.5 0.5 1 0.5 1 0.5 0.5 0.5 0.5 0.5     0.60 1 
     L 2 10 3 3 2 1 1 2 0.5 0.5 0.5      1.50 3 
5475 HET 2 week 4.5N control M 2 12 1 1 1 1 0.5 0.5 1  0.5      0.81 1 
     L 2 9 2 2 2 1 2 3 1        1.86 3 
    loaded M 8 14 0.5 0.5 0.5 0.5 1 0.5 0.5 0.5       0.56 1 
     L 2 7 0.5 2 3 4 2 1 0.5        1.86 4 
5490 HET 2 week 4.5N control M 8 15 0.5 0.5 0.5 0.5 0.5 0.5         0.50 0.5 
     L 1 5 0.5 0.5 0.5 1 1          0.70 1 
    loaded M 3 12 0.5 0.5 2 2 0.5 0.5 0.5 0.5 0.5 1     0.85 2 
     L 1 6 1 2 2 3 4 1 0.5        1.93 4 
5491 HET 2 week 4.5N control M 1 9 0.5 1 1 1 2 0.5 1 0.5 1 1     0.95 2 
     L 2 10 1 1 0.5 3 1 3 3 2 1      1.72 3 
    loaded M 2 8 1 1 2 1 0.5 0.5 0.5        0.93 2 
     L 7 13 2 1 0.5 1 2 2 1 0.5       1.25 2 
5493 HET 2 week 4.5N control M 11 15 0.5 0.5 1 1 0.5          0.70 1 
     L 2 5 0.5 0.5 2 2           1.25 2 
    loaded M 3 7 0.5 0.5 0.5 2 2          1.10 2 
     L 11 16 1 0.5 0.5 1 2 1 2        1.14 2 
5535 WT 6 week 4.5N control M 11 17 0.5 1 0.5 0.5 0.5 0 0 0 0.5      0.39 1 
     L 4 11 0.5 0.5 0 1 2 3 3        1.43 3 
    loaded M 8 14 0.5 4 4 0.5 2 2         2.17 4 
     L 15 18 5 3 2 1 1 2 4        2.57 5 
5524 WT 6 week 4.5N control M 4 12 0.5 0.5 0.5 1 0 1 2 2 0.5      0.89 2 
     L 5 13 2 2 2 1 1 1 1 1       1.38 2 
    loaded M 14 19 1 0.5 1 1 3 2 2        1.50 3 
     L 10 16 3 3 3 3 2 3 2 2 3      2.67 3 
5529 WT 6 week 4.5N control M 4 12 0 0 1 0.5 0 1 2 0.5 0.5 0.5     0.60 2 
     L 9 14 3 4 1 0.5 1 2 1        1.79 4 
    loaded M 14 20 1 0.5 0.5 0.5 2 0.5 2        1.00 2 
     L 16 20 2 5 3 2 2 2         2.67 5 
5532 WT 6 week 4.5N control M 10 18 2 0.5 0.5 0.5 0.5 0.5 0.5        0.71 2 
     L 12 18 0.5 1 0.5 2 0.5          0.90 2 
    loaded M 6 13 1 0.5 1 0.5 0.5 0.5 0.5 0.5       0.63 1 
     L 6 14 2 2 1 2 1 1 2 2 0.5      1.50 2 
5534 WT 6 week 4.5N control M 4 16 0.5 1 1 1 0.5 0.5 0.5 2 0.5 0.5 0.5 0.5 2  0.85 2 
     L 4 16 0.5 2 2 3 3 1 0.5 3 3 2 1 0.5 1  1.73 3 
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    loaded M 1 9 0.5 0.5 0.5 0.5 0.5 0.5 1 0.5 0.5 0.5     0.55 1 
     L 5 14 0.5 0.5 2 0.5 2 2 2 2 3      1.61 3 
5528 WT 6 week 4.5N control M 3 14 0.5 0.5 0.5 0.5 0.5 0.5 1 1 0.5 0.5 0.5 0.5   0.58 1 
     L 7 16 1 1 1 1 0.5 0.5 1 0.5 0.5 0.5     0.75 1 
    loaded M 14 20 0.5 0.5 0.5 0.5 1 2 1 0.5       0.81 2 
     L 8 14 3 2 2 2 2 2 0.5        1.93 3 
5531 HET 6 week 4.5N control M 8 17 1 1 0 0 0 0.5 0 1 0.5 2     0.60 2 
     L 8 15 2 2 1 2 1 2 3 2 0.5      1.72 3 
    loaded M 7 18 2 1 0.5 0.5 1 0.5 2 0.5 1 1 0 0.5   0.88 2 
     L 8 15 2 1 2 0.5 1 1 0.5 2 2      1.33 2 
5526 HET 6 week 4.5N control M 3 12 0.5 0.5 0.5 0.5 0.5 2 0.5 0.5 0.5 0.5     0.65 2 
     L 5 13 2 2 1 0.5 1 1 2 2 0.5      1.33 2 
    loaded M 7 16 0.5 1 0.5 0.5 0.5 0.5 1 2 0.5 2 0.5    0.86 2 
     L 5 13 4 2 1 1 2 3 3 3 0.5      2.17 4 
5527 HET 6 week 4.5N control M 2 10 1 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5     0.55 1 
     L 3 11 1 1 2 0.5 0.5 1 2 1 0.5 0.5     1.00 2 
    loaded M 9 18 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5     0.50 0.5 
     L 8 15 2 2 1 0.5 0.5 0.5 0.5 0.5       0.94 2 
5536 HET 6 week 4.5N control M 7 16 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5    0.50 0.5 
     L 4 14 0.5 2 2 0.5 0.5 0.5 2 0.5 0.5 0.5 0.5    0.91 2 
    loaded M 5 12 1 1 0.5 2 2 0.5 1 0.5       1.06 2 
     L 5 12 0.5 2 2 0.5 2 0.5 2 0.5       1.25 2 
5544 HET 6 week 4.5N control M 8 17 0.5 0.5 1 0.5 0.5 0.5 0.5 0.5 0.5 0.5     0.55 1 
     L 8 17 0.5 2 1 1 1 1 1 2 0.5 0.5     1.05 2 
    loaded M 5 15 0.5 0.5 0.5 0.5 0.5 0.5 0.5 1 0.5 0.5     0.55 1 
     L 4 13 4 1 1 0.5 1 1 1 2 2 0.5     1.40 4 
5560 HET 6 week 4.5N control M 8 17 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5     0.50 0.5 
     L 6 14 0.5 1 1 0.5 0.5 0.5 0.5 0.5 0.5      0.61 1 
    loaded M 3 11 1 0.5 1 0.5 0.5 0.5 0.5 0.5 0.5      0.61 1 
     L 8 13 4 4 0.5 0.5 0.5 0.5         1.67 4 
5578 WT 1 week 9.0N control M 4 13 1 0.5 0 1 0 2 1 0.5 1 0     0.70 2 
     L 4 11 2 2 2 2 2 2 1 0.5 1 0.5     1.50 2 
    loaded M 7 15 4 1 1 0.5 0.5 1 0.5 0.5 2      1.22 4 
     L 12 15 5 3 3 2 2          3.00 5 
5576 WT 1 week 9.0N control M 1 10 1 0 0.5 0.5 2 0.5 0.5 0.5 0.5 0.5     0.65 2 
     L 1 10 2 2 2 2 2 2 2 2 1 0.5     1.75 2 
    loaded M 9 14 3 4 3 0.5 2 2         2.42 4 
     L 8 14 2 2 2 2 2 3 4        2.43 4 
5579 WT 1 week 9.0N control M 7 15 0.5 0.5 0.5 0 0.5 2 0.5 0.5 0.5      0.61 2 
     L 4 12 0.5 0.5 2 1 1 2 1 2       1.25 2 
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    loaded M 6 13 0.5 3 2 1 2 1 2 2       1.69 3 
     L 3 9 0.5 0.5 2 3 2 2 2 2       1.75 3 
5571 WT 1 week 9.0N control M 4 12 1 1 1 1 0.5 2 2 1 0.5 0.5     1.05 2 
     L 2 9 2 1 1 0.5 1 2 2 2 1      1.39 2 
    loaded M 7 15 1 0.5 0 0.5 1 1 2 0.5 1      0.83 2 
     L 7 15 3 1 1 2 1 2 2 2 2      1.78 3 
5572 WT 1 week 9.0N control M 8 14 0.5 0.5 0.5 0.5 0 0.5 0.5        0.43 0.5 
     L 8 14 0.5 0.5 2 2 1 1 0.5        1.07 2 
    loaded M 12 15 2 1 0.5 0.5           1.00 2 
     L 13 15 4 3 0.5            2.50 4 
5570 WT 1 week 9.0N control M 7 16 0.5 0.5 0.5 0.5 0 0.5 0.5 0.5 0.5 1     0.50 1 
     L 4 12 0.5 0.5 1 2 1 1 0.5 2 0.5      1.00 2 
    loaded M 7 16 2 0.5 0.5 0.5 0.5 0.5 0.5        0.71 2 
     L 4 12 6 5 3 1 1 2 1        2.71 6 
5564 HET 1 week 9.0N control M 8 16 0.5 0.5 0 0.5 0.5 0.5 0.5 0 0.5      0.39 0.5 
     L 5 13 0.5 1 0.5 0.5 0.5 0.5 0.5 0.5 0.5      0.56 1 
    loaded M 8 16 1 1 1 3 2 1 1 1 0.5 0.5     1.20 3 
     L 5 13 4  0.5 0.5 1 2         1.60 4 
5577 HET 1 week 9.0N control M 13 16 3 2 1 0.5 1 0.5         1.33 3 
     L 10 15 4 5 3 2 2 2         3.00 5 
    loaded M 13 16 3 1 0.5 0.5 0.5          1.10 3 
     L 10 15 5 5 2 3 3 2         3.33 5 
5574 HET 1 week 9.0N control M 7 13 0.5 0.5 1 0 0 0.5 0.5        0.43 1 
     L 4 9 2 2 1 2 3 3         2.17 3 
    loaded M 7 13 2 1 0.5 0.5 1 2         1.17 2 
     L 4 9 1 2 2 2 2 2         1.83 2 
5580 HET 1 week 9.0N control M 10 16 0.5 0.5 0.5 0 0 0.5 0.5        0.36 0.5 
     L 6 12 1 2 2 0.5 2 3 0.5        1.57 3 
    loaded M 10 16 0.5 0.5 0.5 0 0.5 0.5 1 0.5       0.50 1 
     L 6 12 5 2 1 1 0.5 0.5 1 0.5       1.44 5 
5573 HET 1 week 9.0N control M 2 8 0.5 0 0.5 0 0.5 0.5 0.5 0.5       0.38 0.5 
     L 4 10 0.5 2 0.5 0.5 2 1 0.5 0.5       0.94 2 
    loaded M 9 14 0.5 0.5 2 0.5 0.5 0.5         0.75 2 
     L 4 12 3 3 3 2 2 2 3 3 2      2.56 3 
5569 HET 1 week 9.0N control M 3 10 0.5 0.5 1 1 2 0.5 2        1.07 2 
     L 2 7 0.5 1 0.5 2 3 1         1.33 3 
    loaded M 15 20 0.5 1 0.5 0.5 0.5 2         0.83 2 
     L 11 18 5 3 1 4 2 3 3 3       3.00 5 
5519 WT 2 week 9.0N control M 2 8 1 1 0.5 2 0.5 1 0.5        0.93 2 
     L 3 8 1 1 1 1 1 3         1.33 3 
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    loaded M 14 21 0.5 1 0.5 0.5 2 0.5 2        1.00 2 
     L 14 21 2 1 1 2 2 2 1        1.57 2 
5521 WT 2 week 9.0N control M 7 15 1 0.5 0 0.5 1 2 0.5 0.5 0.5      0.72 2 
     L 6 13 2 2 2 3 2 3 1 0.5 0.5      1.78 3 
    loaded M 9 15 2 2 2 1 2 3 0.5        1.79 3 
     L 7 15 5 4 5 4 3 2 1 2 2      3.11 5 
5523 WT 2 week 9.0N control M 1 10 1 1 0.5 0 0.5 2 2 0.5 0.5 0.5     0.85 2 
     L 2 13 1 1 2 2 2 2 2 2 1 0.5     1.55 2 
    loaded M 14 18 2 3 3 2           2.50 3 
     L 5 10 1 2 3 3 3 3         2.50 3 
5563 WT 2 week 9.0N control M 7 15 0.5 1 1 0.5 0.5 1 1 2       0.94 2 
     L 7 15 0.5 0.5 0.5 0.5 0.5 1 0.5 0.5       0.56 1 
    loaded M 9 16 1 1 2 2 1 0.5 1 1       1.19 2 
     L 10 16 6 5 3 2 2 1 0.5        2.79 6 
5566 WT 2 week 9.0N control M 7 15 2 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5      0.67 2 
     L 11 17 3 0.5 0.5 0.5 0.5 1 0.5 0.5       0.88 3 
    loaded M 14 19 5 4 1 1 0.5 0.5         2.00 5 
     L 13 19 5 3 1 1 1 0.5         1.92 5 
5549 WT 2 week 9.0N control M 9 17 0.5 0.5 0.5 1 0.5 0.5 0.5 1 1 0.5 0.5    0.64 1 
     L 5 11 1 1 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5     0.60 1 
    loaded M 12 16 0.5 0.5 0.5 0.5 0.5 2 1 0.5       0.75 2 
     L 9 14 3 2 2 2 2 1 0.5        1.79 3 
5482 HET 2 week 9.0N control M 5 14 3 1 0.5 0.5 0.5 0.5 1 1 1 2     1.10 3 
     L 3 11 1 2 3 1 0.5 2 1 1 0.5 0.5     1.25 3 
    loaded M 5 15 2 1 0.5 1 0.5 0.5 1 2 1 0.5 1    1.00 2 
     L 3 12 2 3 3 2 2 2 2 2 1 1     2.00 3 
5483 HET 2 week 9.0N control M 3 12 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5    0.50 0.5 
     L 1 9 0.5 3 1 2 0.5 2 1 1 0.5      1.28 3 
    loaded M 4 12 3 1 1 1 1 2 3 1 0.5      1.50 3 
     L 6 14 2 3 1 2 1 2 2 2 0.5      1.72 3 
5520 HET 2 week 9.0N control M 1 7 0.5 0.5 0.5 0.5 0.5 1 0.5        0.57 1 
     L 1 4 1 2 0.5 0.5           1.00 2 
    loaded M 7 16 1 1 0.5 0.5 0.5 1 0.5 0.5 0.5 0.5 0.5    0.64 1 
     L 5 15 5 4 3 2 0.5 0.5 0.5 0.5 0.5 0.5 0.5    1.59 5 
5550 HET 2 week 9.0N control M 7 14 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5      0.50 0.5 
     L 3 9 0.5 0.5 0.5 1 1 2 0.5        0.86 2 
    loaded M 8 13 0.5 0.5 0.5 0.5 0.5 2 0.5        0.71 2 
     L 5 10 4 1 1 0.5 0.5 2         1.50 4 
5551 HET 2 week 9.0N control M 4 13 0.5 0.5 0.5 0.5 0 0.5 0.5 2 0.5 0.5 0.5    0.59 2 
     L 3 11 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5      0.50 0.5 
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    loaded M 8 14 3 3 0.5 0.5 0.5 0.5 0.5        1.21 3 
     L 8 16 3 4 1 2 1 0.5 1 2       1.81 4 
5553 HET 2 week 9.0N control M 8 16 0.5 2 0.5 0.5 0.5 0.5 0.5 0 0.5 1 0.5 0.5   0.63 2 
     L 3 8 1 1 2 2 2 1 1 1 1 0.5 0.5    1.18 2 
    loaded M 12 16 1 2 3 0.5 0.5 1 0.5 0.5 0.5 0.5     1.00 3 
     L 8 14 3 1 0.5 2 2 2 2 2       1.81 3 
5509 WT 6 week 9.0N control M 16 20 0.5 2 0.5 0.5 2 0.5         1.00 2 
     L 11 16 2 0.5 2 3 4          2.30 4 
    loaded M 19 24 2 3 5 5 3 3 3        3.43 5 
     L 17 24 1 2 5 4 3 4 3        3.14 5 
5512 WT 6 week 9.0N control M 7 17 0.5 0.5 1 1 1 2 0.5 2 1      1.06 2 
     L 7 15 1 2 0.5 2 1 1 1 2 0.5      1.22 2 
    loaded M 22 27 1 5 5 0.5 3          2.90 5 
     L 20 27 5 5 5 5 5          5.00 5 
5513 WT 6 week 9.0N control M 2 13 0.5 0.5 1 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5    0.55 1 
     L 4 13 1 1 2 2 2 2 1 2 0.5 0.5     1.40 2 
    loaded M 15 19 5 5 5 2 0.5 1         3.08 5 
     L 16 19 6 5 5 2 1          3.80 6 
5514 WT 6 week 9.0N control M 5 15 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 1 0.5     0.55 1 
     L 8 15 0.5 0.5 0.5 0.5 0.5 0.5 1 0.5       0.56 1 
    loaded M 16 21 4 3 2 1 0.5 1         1.92 4 
     L 13 18 6 4 2 1 0.5 1 2 1       2.19 6 
5515 WT 6 week 9.0N control M 5 14 1 1 0.5 0.5 0.5 1 2 0.5 0.5 0.5     0.80 2 
     L 7 14 2 1 2 2 3 2 2 0.5       1.81 3 
    loaded M 11 13 5 3 1 3           3.00 5 
     L 13 15 3 3 3            3.00 3 
5517 WT 6 week 9.0N control M 4 14 0.5 0.5 0.5 0.5 0.5 0.5 1 0.5 0.5      0.56 1 
     L 4 12 2 1 2 1 1 1 0.5 0.5       1.13 2 
    loaded M 17 20 3 3 3 2           2.75 3 
     L 13 19 2 3 2 2 1 2 2        2.00 3 
5510 HET 6 week 9.0N control M 10 18 1 1 0.5 0.5 0.5 2 2 1 0.5      1.00 2 
     L 6 14 1 2 0.5 0.5 2 3 2 4 1      1.78 4 
    loaded M 20 24 4 2 2 1 2          2.20 4 
     L 18 24 6 5 4 4 2 2 1        3.43 6 
5511 HET 6 week 9.0N control M 3 14 1 0.5 0.5 0.5 0 0.5 0.5 0.5   0.5 1   0.55 1 
     L 3 13 1 0.5 0.5 2 0.5 0.5 0.5 1   0.5 0.5   0.75 2 
    loaded M 19 24 2 6 6 4 1 2 2 0.5 0.5      2.67 6 
     L 18 24 3 2 5 5 3 3 2 3 3 2     3.10 5 
5516 HET 6 week 9.0N control M 8 16 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0 0.5 0.5     0.45 0.5 
     L 9 16 0.5 0.5 0.5 0.5 0.5 0.5 1 1 0.5      0.61 1 
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    loaded M 11 18 4 4 2 3 0.5 0.5 2 1 2      2.11 4 
     L 13 18 6 4 3 4 3 1 0.5        3.07 6 
5530 HET 6 week 9.0N control M 2 12 0.5 0.5 0.5 0.5 2 0.5 0.5 0.5 0.5 0.5     0.65 2 
     L 5 13 0.5 0.5 2 2 2 2 2 0.5       1.44 2 
    loaded M 16 21 3 1 0.5 2 1 0.5         1.33 3 
     L 11 18 4 3 4 1 2 2 2 2       2.50 4 
5533 HET 6 week 9.0N control M 16 21 2 2 0.5 0.5 0.5 0.5         1.00 2 
     L 9 16 1 0.5 1 1 2 1 1 2       1.19 2 
    loaded M 11 19 0.5 0.5 1 1 2 2 1 1       1.13 2 
     L 13 19 6 4 2 2 2 2 2        2.86 6 
5525 HET 6 week 9.0N control M 4 15 0.5 2 2 1 0 0.5 0.5 0.5 0.5 1 0.5 0.5   0.79 2 
     L 5 15 1 1 2 2 1 1 1 2 1 0.5 1    1.23 2 
    loaded M 12 17 5 4 3 5 1          3.60 5 
     L 12 17 4 4 5 5 4          4.40 5 
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Histological (OARSI) Score (Average): OARSI scoring of articular cartilage damage 
measured by Safranin O/Fast Green stain for wildtype (WT) and cho/+ (HET) mice. 
Average scores of Scorers #1 and #2 reported for articular cartilage in the medial (M) 
and lateral (L) tibial plateaus. 
 
Magnitude Duration Genotype Limb Medial Lateral 
4.5N 1wk WT Control 0.30 0.61 
  WT Control 0.22 0.69 
  WT Control 0.50 0.73 
  WT Control 0.18 0.70 
  WT Control 0.66 0.99 
  WT Control 0.30 0.66 
 2wk WT Control 0.50 1.00 
  WT Control 0.37 1.18 
  WT Control 0.80 1.21 
  WT Control 0.55 1.43 
  WT Control 0.35 0.76 
  WT Control 0.39 0.83 
 6wk WT Control 0.34 1.34 
  WT Control 0.47 0.94 
  WT Control 0.33 1.10 
  WT Control 0.41 0.66 
  WT Control 0.46 1.15 
  WT Control 0.40 0.63 
9N 1wk WT Control 0.43 1.09 
  WT Control 0.48 1.23 
  WT Control 0.36 0.90 
  WT Control 0.58 1.01 
  WT Control 0.21 0.71 
  WT Control 0.30 0.72 
 2wk WT Control 0.57 0.79 
  WT Control 0.44 1.14 
  WT Control 0.48 1.14 
  WT Control 0.61 0.59 
  WT Control 0.58 0.69 
  WT Control 0.35 0.48 
 6wk WT Control 0.60 1.44 
  WT Control 0.66 0.81 
  WT Control 0.29 0.85 
  WT Control 0.34 0.41 
  WT Control 0.45 1.06 
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  WT Control 0.37 0.70 
4.5N 1wk HET Control 0.43 1.05 
  HET Control 0.36 0.81 
  HET Control 0.60 0.63 
  HET Control 0.33 0.55 
  HET Control 0.36 0.57 
  HET Control 0.36 0.29 
 2wk HET Control 0.36 1.09 
  HET Control 0.38 1.25 
  HET Control 0.45 1.30 
  HET Control 0.41 0.55 
  HET Control 0.53 1.03 
  HET Control 0.45 0.88 
 6wk HET Control 0.33 0.99 
  HET Control 0.50 1.11 
  HET Control 0.50 0.81 
  HET Control 0.35 0.66 
  HET Control 0.38 0.85 
  HET Control 0.38 0.39 
9N 1wk HET Control 0.19 0.33 
  HET Control 0.67 1.79 
  HET Control 0.21 1.58 
  HET Control 0.25 1.07 
  HET Control 0.22 0.72 
  HET Control 0.63 1.04 
 2wk HET Control 0.70 0.88 
  HET Control 0.35 0.97 
  HET Control 0.39 0.81 
  HET Control 0.50 0.89 
  HET Control 0.50 0.50 
  HET Control 0.48 0.88 
 6wk HET Control 0.75 1.17 
  HET Control 0.40 0.56 
  HET Control 0.31 0.40 
  HET Control 0.43 0.86 
  HET Control 0.50 0.84 
  HET Control 0.42 0.95 
4.5N 1wk WT Loaded 0.60 1.01 
  WT Loaded 0.45 0.87 
  WT Loaded 0.50 1.39 
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  WT Loaded 0.63 1.13 
  WT Loaded 0.58 1.03 
  WT Loaded 0.50 0.78 
 2wk WT Loaded 0.77 1.83 
  WT Loaded 0.72 1.18 
  WT Loaded 1.18 2.05 
  WT Loaded 0.75 1.52 
  WT Loaded 0.66 1.23 
  WT Loaded 0.59 1.56 
 6wk WT Loaded 1.58 1.79 
  WT Loaded 1.14 2.15 
  WT Loaded 1.00 1.83 
  WT Loaded 0.51 1.47 
  WT Loaded 0.62 1.28 
  WT Loaded 0.81 1.80 
9N 1wk WT Loaded 1.03 2.38 
  WT Loaded 2.21 1.96 
  WT Loaded 1.31 1.63 
  WT Loaded 1.03 1.61 
  WT Loaded 1.13 2.08 
  WT Loaded 0.48 1.86 
 2wk WT Loaded 1.22 1.22 
  WT Loaded 2.04 2.53 
  WT Loaded 2.29 1.96 
  WT Loaded 1.03 2.39 
  WT Loaded 1.46 1.82 
  WT Loaded 1.13 1.39 
 6wk WT Loaded 2.25 2.18 
  WT Loaded 2.49 3.28 
  WT Loaded 2.44 3.00 
  WT Loaded 1.71 2.09 
  WT Loaded 2.30 2.50 
  WT Loaded 2.53 1.84 
4.5N 1wk HET Loaded 1.80 1.93 
  HET Loaded 0.47 1.48 
  HET Loaded 0.50 0.58 
  HET Loaded 0.79 1.49 
  HET Loaded 0.65 1.48 
  HET Loaded 0.44 0.73 
 2wk HET Loaded 0.53 1.03 
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  HET Loaded 0.53 1.45 
  HET Loaded 0.56 1.57 
  HET Loaded 0.80 1.43 
  HET Loaded 0.71 1.25 
  HET Loaded 1.14 1.20 
 6wk HET Loaded 0.77 1.19 
  HET Loaded 0.73 1.81 
  HET Loaded 0.58 1.07 
  HET Loaded 1.08 1.40 
  HET Loaded 0.46 1.34 
  HET Loaded 0.56 1.29 
9N 1wk HET Loaded 0.90 1.43 
  HET Loaded 1.00 2.54 
  HET Loaded 1.26 1.83 
  HET Loaded 0.41 1.22 
  HET Loaded 0.71 2.22 
  HET Loaded 1.00 2.03 
 2wk HET Loaded 1.00 1.82 
  HET Loaded 1.15 1.53 
  HET Loaded 0.55 1.20 
  HET Loaded 0.82 1.46 
  HET Loaded 1.05 1.55 
  HET Loaded 1.58 1.94 
 6wk HET Loaded 1.50 2.29 
  HET Loaded 2.33 2.84 
  HET Loaded 1.77 2.54 
  HET Loaded 1.38 2.31 
  HET Loaded 0.92 2.07 
  HET Loaded 2.63 3.20 
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Localized Articular Cartilage Thickness: Cartilage thickness (μm) in the posterior 
(Post), middle (Mid), and anterior (ant) regions of the medial and lateral tibial plateaus 
in wildtype (WT) and cho/+ (HET) mice. 
 
     Medial   Lateral   
ID Genotype Duration Magnitude Limb Post Mid Ant Post Mid Ant 
5546 WT 1wk 4.5N control 56.85 74.50 106.85 72.15 86.53 75.28 
5547 WT 1wk 4.5N control 76.65 77.15 127.00 86.18 83.70 33.78 
5556 WT 1wk 4.5N control 73.55 108.53 72.58 87.40 118.58 70.15 
5567 WT 1wk 4.5N control 74.15 89.98 67.75 62.93 107.88 53.28 
5554 WT 1wk 4.5N control 98.78 103.23 55.98 107.08 94.28 29.28 
5557 WT 1wk 4.5N control 74.60 81.53 55.55 70.35 79.40 39.80 
5539 WT 2wk 4.5N control 83.53 86.70 71.95 67.10 98.63 36.53 
5537 WT 2wk 4.5N control 84.50 47.68 63.80 72.63 104.20 75.18 
5538 WT 2wk 4.5N control 63.80 79.48 65.05 61.43 44.28 70.68 
5541 WT 2wk 4.5N control 82.03 83.05 81.73 62.48 71.30 55.83 
5518 WT 2wk 4.5N control 93.50 65.10 83.63 74.08 87.63 53.70 
5522 WT 2wk 4.5N control 75.40 82.85 89.53 53.15 91.08 48.65 
5535 WT 6wk 4.5N control 72.98 99.35 95.28 69.15 113.80 69.90 
5524 WT 6wk 4.5N control 75.83 90.18 92.18 73.40 89.05 63.45 
5529 WT 6wk 4.5N control 72.93 84.90 75.75 75.48 86.08 84.35 
5532 WT 6wk 4.5N control 42.35 73.45 78.70 58.08 64.20 90.75 
5534 WT 6wk 4.5N control 70.48 99.78 106.10 74.58 102.03 66.08 
5528 WT 6wk 4.5N control 72.38 99.53 85.80 96.03 104.58 89.85 
5578 WT 1wk 9N control 126.58 97.98 71.10 75.85 95.73 76.50 
5576 WT 1wk 9N control 70.68 97.68 88.45 93.63 84.55 73.98 
5579 WT 1wk 9N control 102.60 117.73 70.13 65.48 102.98 72.10 
5571 WT 1wk 9N control 53.80 86.98 75.45 58.80 105.85 73.65 
5572 WT 1wk 9N control 50.15 74.55 91.55 80.1 79.925 58.575 
5570 WT 1wk 9N control 89.38 125.10 152.45 71.53 125.13 96.75 
5519 WT 2wk 9N control 78.38 97.50 90.35 96.65 86.90 84.65 
5521 WT 2wk 9N control 119.85 102.68 93.78 108.73 94.10 62.20 
5523 WT 2wk 9N control 86.93 75.70 72.80 60.25 66.65 56.50 
5563 WT 2wk 9N control 48.30 92.80 84.48 80.90 94.55 89.83 
5566 WT 2wk 9N control 68.18 87.70 56.20 87.80 101.90 76.23 
5549 WT 2wk 9N control 91.60 80.70 89.90 101.85 94.58 65.38 
5509 WT 6wk 9N control 65.58 88.80 95.78 54.65 125.73 91.40 
5512 WT 6wk 9N control 72.43 49.23 41.60 52.05 38.35 19.33 
5513 WT 6wk 9N control 86.33 93.03 68.98 70.40 94.85 56.28 
5514 WT 6wk 9N control 91.53 100.35 103.75 91.58 85.55 85.98 
5515 WT 6wk 9N control 55.08 105.38 86.03 94.23 80.70 47.30 
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5517 WT 6wk 9N control 85.83 100.03 85.40 94.18 110.15 51.10 
5545 HET 1wk 4.5N control 80.55 86.55 74.90 82.48 101.28 89.73 
5561 HET 1wk 4.5N control 114.35 116.10 124.35 97.83 96.15 74.85 
5559 HET 1wk 4.5N control 76.70 108.38 98.25 45.55 63.65 24.83 
5558 HET 1wk 4.5N control 48.70 66.05 32.47 97.825 96.15 74.85 
5562 HET 1wk 4.5N control 83.35 100.85 103.68 95.08 99.65 66.15 
5565 HET 1wk 4.5N control 72.55 87.225 92.225 95.075 99.65 66.15 
5472 HET 2wk 4.5N control 90.85 96.775 83.275 83.28 78.15 47.70 
5474 HET 2wk 4.5N control 60.55 97.35 60.525 69.25 67.20 71.00 
5475 HET 2wk 4.5N control 85.60 68.55 73.75 78.25 69.50 69.88 
5490 HET 2wk 4.5N control 65.13 74.85 74.28 76.30 103.40 71.98 
5491 HET 2wk 4.5N control 42.70 107.70 82.00 74.63 86.18 61.38 
5493 HET 2wk 4.5N control 55.98 101.40 74.78 66.83 78.70 51.40 
5531 HET 6wk 4.5N control 83.50 100.15 70.03 86.95 102.40 78.00 
5526 HET 6wk 4.5N control 73.70 94.75 99.48 93.38 86.53 64.08 
5527 HET 6wk 4.5N control 93.70 118.18 91.48 112.98 99.08 55.90 
5536 HET 6wk 4.5N control 86.55 78.48 47.30 81.78 110.15 103.70 
5544 HET 6wk 4.5N control 93.55 99.33 112.10 88.98 87.20 54.05 
5560 HET 6wk 4.5N control 76.53 85.65 90.58 72.58 89.78 45.50 
5564 HET 1wk 9N control 78.58 92.15 125.50 65.65 98.55 69.25 
5577 HET 1wk 9N control 94.65 93.50 90.00 78.65 134.83 89.43 
5574 HET 1wk 9N control 80.73 123.38 105.88 105.23 66.43 77.93 
5580 HET 1wk 9N control 99.10 71.95 110.30 64.33 92.43 67.90 
5573 HET 1wk 9N control 69.80 92.33 85.30 117.83 108.28 85.55 
5569 HET 1wk 9N control 138.85 124.78 104.43 111.10 100.85 79.90 
5482 HET 2wk 9N control 82.13 55.38 45.23 48.03 60.83 19.10 
5483 HET 2wk 9N control 70.40 101.15 105.13 95.68 89.75 63.88 
5520 HET 2wk 9N control 96.25 96.25 91.23 97.95 95.13 53.65 
5550 HET 2wk 9N control 74.93 99.22 119.06 100.24 99.42 82.35 
5551 HET 2wk 9N control 76.87 110.50 71.98 59.18 109.60 73.23 
5553 HET 2wk 9N control 96.15 97.33 108.35 65.15 122.88 74.03 
5510 HET 6wk 9N control 83.35 100.85 103.68 73.60 119.13 71.13 
5511 HET 6wk 9N control 67.03 91.83 105.30 51.98 102.63 54.35 
5516 HET 6wk 9N control 80.98 91.28 95.73 84.90 100.85 71.03 
5530 HET 6wk 9N control 71.83 102.25 84.28 99.55 93.35 84.05 
5533 HET 6wk 9N control 79.80 87.25 142.50 62.55 67.20 97.78 
5525 HET 6wk 9N control 83.93 95.98 96.28 77.68 79.03 56.45 
5546 WT 1wk 4.5N loaded 81.95 87.98 38.25 80.25 72.28 64.13 
5547 WT 1wk 4.5N loaded 102.50 103.15 115.60 78.13 91.25 60.53 
5556 WT 1wk 4.5N loaded 65.65 100.15 81.95 68.95 102.83 54.13 
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5567 WT 1wk 4.5N loaded 57.25 91.53 87.09 64.83 93.30 71.03 
5554 WT 1wk 4.5N loaded 59.43 89.38 91.13 81.90 104.05 32.05 
5557 WT 1wk 4.5N loaded 50.40 83.75 70.78 68.95 78.85 57.88 
5539 WT 2wk 4.5N loaded 64.18 114.63 79.63 74.13 86.58 75.65 
5537 WT 2wk 4.5N loaded 79.45 95.28 94.95 63.03 92.95 66.38 
5538 WT 2wk 4.5N loaded 47.65 78.50 64.13 85.38 70.50 62.05 
5541 WT 2wk 4.5N loaded 69.95 93.83 90.73 97.10 85.78 49.58 
5518 WT 2wk 4.5N loaded 83.65 84.05 64.73 66.75 77.18 61.48 
5522 WT 2wk 4.5N loaded 98.50 65.80 80.48 84.40 82.70 75.10 
5535 WT 6wk 4.5N loaded 56.45 116.03 102.80 89.40 109.25 94.63 
5524 WT 6wk 4.5N loaded 61.00 70.68 93.13 62.88 99.68 110.65 
5529 WT 6wk 4.5N loaded 65.00 73.20 110.35 51.95 77.35 95.23 
5532 WT 6wk 4.5N loaded 49.20 78.08 78.28 53.93 74.93 79.75 
5534 WT 6wk 4.5N loaded 62.10 81.58 85.35 48.70 82.95 48.65 
5528 WT 6wk 4.5N loaded 73.90 94.20 99.50 43.68 90.88 60.43 
5578 WT 1wk 9N loaded 74.43 111.48 128.83 71.00 115.90 123.15 
5576 WT 1wk 9N loaded 68.20 63.60 88.98 64.13 107.73 86.35 
5579 WT 1wk 9N loaded 63.30 80.35 100.95 66.75 81.28 78.88 
5571 WT 1wk 9N loaded 60.08 99.98 69.85 59.35 81.60 73.33 
5572 WT 1wk 9N loaded 60.78 87.15 83.03 86.45 89.05 75.48 
5570 WT 1wk 9N loaded 88.23 111.15 55.20 21.75 80.45 88.93 
5519 WT 2wk 9N loaded 58.40 52.75 103.58 53.38 94.73 91.58 
5521 WT 2wk 9N loaded 65.38 91.78 120.35 36.95 88.98 124.53 
5523 WT 2wk 9N loaded 61.38 96.88 66.55 66.60 95.38 37.85 
5563 WT 2wk 9N loaded 46.63 92.83 91.33 36.23 95.33 83.00 
5566 WT 2wk 9N loaded 41.80 86.63 116.58 29.90 59.58 101.73 
5549 WT 2wk 9N loaded 80.75 76.23 95.28 50.33 104.85 67.73 
5509 WT 6wk 9N loaded 80.75 76.23 95.28 50.33 104.85 67.73 
5512 WT 6wk 9N loaded 50.13 62.15 77.25 71.88 37.15 107.83 
5513 WT 6wk 9N loaded 47.53 100.95 107.18 38.00 67.95 97.55 
5514 WT 6wk 9N loaded 54.83 60.93 102.75 64.80 94.03 100.58 
5515 WT 6wk 9N loaded 47.58 58.73 89.78 N/A N/A N/A 
5517 WT 6wk 9N loaded 66.60 62.83 72.15 49.23 87.63 96.73 
5545 HET 1wk 4.5N loaded 157.13 103.08 102.08 82.03 134.10 45.73 
5561 HET 1wk 4.5N loaded 101.38 131.33 119.95 105.00 121.53 70.80 
5559 HET 1wk 4.5N loaded 83.08 92.20 122.93 100.53 111.88 57.43 
5558 HET 1wk 4.5N loaded 75.90 94.98 117.30 58.20 97.15 95.25 
5562 HET 1wk 4.5N loaded 83.35 100.85 103.68 73.60 119.13 71.13 
5565 HET 1wk 4.5N loaded 82.55 124.00 116.90 74.70 78.88 81.18 
5474 HET 2wk 4.5N loaded 57.38 105.80 45.65 94.53 86.55 39.63 
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5475 HET 2wk 4.5N loaded 86.48 79.68 84.77 37.85 82.43 70.83 
5490 HET 2wk 4.5N loaded 66.10 88.70 63.43 113.03 91.58 58.60 
5491 HET 2wk 4.5N loaded 90.80 96.35 103.10 111.58 80.33 51.50 
5493 HET 2wk 4.5N loaded 59.68 96.70 98.70 65.28 87.75 108.85 
5531 HET 6wk 4.5N loaded 107.80 108.75 82.03 76.30 94.68 43.60 
5526 HET 6wk 4.5N loaded 67.55 93.33 114.58 64.50 75.73 68.53 
5527 HET 6wk 4.5N loaded 93.68 114.78 50.13 82.65 94.98 96.78 
5536 HET 6wk 4.5N loaded 78.10 91.05 83.55 85.18 85.18 67.05 
5544 HET 6wk 4.5N loaded 79.38 96.13 71.03 101.18 92.15 75.28 
5560 HET 6wk 4.5N loaded 66.15 91.40 70.10 62.75 86.43 66.18 
5564 HET 1wk 9N loaded 45.45 94.08 70.70 54.88 94.93 89.08 
5577 HET 1wk 9N loaded 77.85 65.78 102.73 81.38 67.33 88.50 
5574 HET 1wk 9N loaded 67.28 65.80 121.50 72.98 82.53 110.53 
5580 HET 1wk 9N loaded 35.03 53.00 50.60 66.38 79.78 63.83 
5573 HET 1wk 9N loaded 83.83 85.13 38.33 58.75 120.85 70.28 
5569 HET 1wk 9N loaded 91.63 85.03 125.88 33.75 128.98 83.53 
5482 HET 2wk 9N loaded 78.55 100.03 115.73 61.58 95.48 68.35 
5483 HET 2wk 9N loaded 75.95 101.83 106.48 74.25 108.28 74.68 
5520 HET 2wk 9N loaded 74.98 72.10 107.03 52.70 93.25 86.95 
5550 HET 2wk 9N loaded 79.62 80.35 109.78 49.27 97.11 100.94 
5551 HET 2wk 9N loaded 67.53 83.35 114.80 64.70 82.05 115.63 
5553 HET 2wk 9N loaded 71.90 79.93 95.70 45.60 120.13 105.48 
5510 HET 6wk 9N loaded 65.53 76.25 101.28 61.30 76.90 101.38 
5511 HET 6wk 9N loaded 65.08 119.33 87.90 27.50 93.75 110.48 
5516 HET 6wk 9N loaded 56.80 89.58 96.95 39.60 78.83 77.15 
5530 HET 6wk 9N loaded 60.90 88.45 92.93 66.13 36.65 117.43 
5533 HET 6wk 9N loaded 62.83 93.45 89.58 64.23 95.58 100.23 
5525 HET 6wk 9N loaded 64.65 53.95 99.58 62.50 76.83 95.55 
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Osteophyte Measurements: Osteophyte size and maturity (mat) measured by 
Safranin O/Fast Green stain in wildtype (WT) and cho/+ (HET) mice. Size reported as 
absolute width (μm); maturity reported on a scale of 0 to 3. Measurements reported for 
largest osteophytes in the medial (M) tibial plateau. 
 
ID Genotype Duration Magnitude Limb Plateau Size Mat 
5546 WT 1wk 4.5N Loaded M 0 0 
5547 WT 1wk 4.5N Loaded M 0 0 
5556 WT 1wk 4.5N Loaded M 0 0 
5567 WT 1wk 4.5N Loaded M 0 0 
5554 WT 1wk 4.5N Loaded M 0 0 
5557 WT 1wk 4.5N Loaded M 0 0 
5539 WT 2wk 4.5N Loaded M 0 0 
5537 WT 2wk 4.5N Loaded M 0 0 
5538 WT 2wk 4.5N Loaded M 0 0 
5541 WT 2wk 4.5N Loaded M 0 0 
5518 WT 2wk 4.5N Loaded M 0 0 
5522 WT 2wk 4.5N Loaded M 0 0 
5535 WT 6wk 4.5N Loaded M 0 0 
5524 WT 6wk 4.5N Loaded M 0 0 
5529 WT 6wk 4.5N Loaded M 0 0 
5532 WT 6wk 4.5N Loaded M 0 0 
5534 WT 6wk 4.5N Loaded M 0 0 
5528 WT 6wk 4.5N Loaded M 0 0 
5578 WT 1wk 9N Loaded M 66 1 
5576 WT 1wk 9N Loaded M 74 1 
5579 WT 1wk 9N Loaded M 50 1 
5571 WT 1wk 9N Loaded M 52 1 
5572 WT 1wk 9N Loaded M 102 1 
5570 WT 1wk 9N Loaded M 144 1 
5519 WT 2wk 9N Loaded M 290 1 
5521 WT 2wk 9N Loaded M 685 1 
5523 WT 2wk 9N Loaded M 363 1 
5563 WT 2wk 9N Loaded M 136 2 
5566 WT 2wk 9N Loaded M 379 2 
5549 WT 2wk 9N Loaded M 365 1 
5509 WT 6wk 9N Loaded M 1068 3 
5512 WT 6wk 9N Loaded M 856 2 
5513 WT 6wk 9N Loaded M 534 3 
5514 WT 6wk 9N Loaded M 908 3 
5515 WT 6wk 9N Loaded M 311 2 
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5517 WT 6wk 9N Loaded M 1013 3 
5545 HET 1wk 4.5N Loaded M 0 0 
5561 HET 1wk 4.5N Loaded M 0 0 
5559 HET 1wk 4.5N Loaded M 0 0 
5558 HET 1wk 4.5N Loaded M 0 0 
5562 HET 1wk 4.5N Loaded M 0 0 
5565 HET 1wk 4.5N Loaded M 0 0 
5472 HET 2wk 4.5N Loaded M 0 0 
5474 HET 2wk 4.5N Loaded M 0 0 
5475 HET 2wk 4.5N Loaded M 0 0 
5490 HET 2wk 4.5N Loaded M 0 0 
5491 HET 2wk 4.5N Loaded M 0 0 
5493 HET 2wk 4.5N Loaded M 0 0 
5531 HET 6wk 4.5N Loaded M 0 0 
5526 HET 6wk 4.5N Loaded M 0 0 
5527 HET 6wk 4.5N Loaded M 0 0 
5536 HET 6wk 4.5N Loaded M 0 0 
5544 HET 6wk 4.5N Loaded M 0 0 
5560 HET 6wk 4.5N Loaded M 0 0 
5564 HET 1wk 9N Loaded M 97 2 
5577 HET 1wk 9N Loaded M 164 1 
5574 HET 1wk 9N Loaded M 57 1 
5580 HET 1wk 9N Loaded M 125 1 
5573 HET 1wk 9N Loaded M 65 1 
5569 HET 1wk 9N Loaded M 76 1 
5482 HET 2wk 9N Loaded M 172 2 
5483 HET 2wk 9N Loaded M 402 1 
5520 HET 2wk 9N Loaded M 94 2 
5550 HET 2wk 9N Loaded M 447 2 
5551 HET 2wk 9N Loaded M 303 2 
5553 HET 2wk 9N Loaded M 318 2 
5510 HET 6wk 9N Loaded M 772 3 
5511 HET 6wk 9N Loaded M 1080 2 
5516 HET 6wk 9N Loaded M 321 3 
5530 HET 6wk 9N Loaded M 538 2 
5533 HET 6wk 9N Loaded M 315 2 
5525 HET 6wk 9N Loaded M 389 3 
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Subchondral Bone Plate MicroCT Data: Subchondral bone plate thickness (Th) and 
tissue mineral density (TMD) in the medial (Med) and lateral (Lat) aspects of the tibial 
plateau in wildtype (WT) and cho/+ (HET) mice. 
 
     Med  Lat  
ID Genotype Duration Magnitude Limb 
Th 
(mm) 
TMD 
(mg HA/ccm) 
Th 
(mm) 
TMD 
(mg HA/ccm) 
5546 WT 1 Week 4.5N Control 0.096 912.4 0.082 892.2 
5547 WT 1 Week 4.5N Control 0.091 895.6 0.085 892.5 
5554 WT 1 Week 4.5N Control 0.103 951.8 0.09 915.1 
5556 WT 1 Week 4.5N Control 0.096 918.7 0.083 886 
5557 WT 1 Week 4.5N Control 0.099 925.5 0.082 899.3 
5567 WT 1 Week 4.5N Control 0.088 898.9 0.089 891.2 
5546 WT 1 Week 4.5N Loaded 0.09 923.1 0.08 897.4 
5547 WT 1 Week 4.5N Loaded 0.089 893.7 0.082 895 
5554 WT 1 Week 4.5N Loaded 0.113 966.4 0.084 928.4 
5556 WT 1 Week 4.5N Loaded 0.093 901.3 0.075 861.9 
5557 WT 1 Week 4.5N Loaded 0.099 933.9 0.085 903.1 
5567 WT 1 Week 4.5N Loaded 0.093 891 0.091 889.1 
5561 HET 1 Week 4.5N Control 0.092 917.1 0.09 913.3 
5545 HET 1 Week 4.5N Control 0.092 922.4 0.086 904.9 
5559 HET 1 Week 4.5N Control 0.091 903.8 0.082 897.4 
5558 HET 1 Week 4.5N Control 0.092 899.1 0.084 898.9 
5565 HET 1 Week 4.5N Control 0.098 904.7 0.092 907.5 
5562 HET 1 Week 4.5N Control 0.087 898.9 0.081 887.5 
5561 HET 1 Week 4.5N Loaded 0.104 929.5 0.084 898.4 
5545 HET 1 Week 4.5N Loaded 0.104 935.5 0.082 902.1 
5559 HET 1 Week 4.5N Loaded 0.096 913.8 0.081 881.3 
5558 HET 1 Week 4.5N Loaded 0.087 868.9 0.084 883.6 
5565 HET 1 Week 4.5N Loaded 0.099 895.5 0.09 898.1 
5562 HET 1 Week 4.5N Loaded 0.09 901.5 0.081 899.3 
5537 WT 2 week 4.5N Control 0.107 962.5 0.088 904.9 
5538 WT 2 week 4.5N Control 0.12 963.8 0.092 908.2 
5539 WT 2 week 4.5N Control 0.094 924.1 0.089 898 
5541 WT 2 week 4.5N Control 0.113 945.9 0.102 937.7 
5518 WT 2 week 4.5N Control 0.086 883.7 0.082 877 
5522 WT 2 week 4.5N Control 0.088 880.7 0.082 894.7 
5537 WT 2 week 4.5N Loaded 0.1 957.1 0.088 933.1 
5538 WT 2 week 4.5N Loaded 0.11 982.1 0.083 915.6 
5539 WT 2 week 4.5N Loaded 0.087 904.3 0.083 901.4 
5541 WT 2 week 4.5N Loaded 0.119 966.6 0.098 937 
5518 WT 2 week 4.5N Loaded 0.088 875.4 0.08 857.7 
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5522 WT 2 Week 4.5N Loaded 0.084 887.5 0.081 879.8 
5472 HET 2 week 4.5N Control 0.091 931.2 0.078 898.7 
5474 HET 2 week 4.5N Control 0.092 903.8 0.08 884 
5490 HET 2 week 4.5N Control 0.107 964.1 0.086 935.1 
5491 HET 2 week 4.5N Control 0.097 926.3 0.086 905.4 
5493 HET 2 week 4.5N Control 0.097 923.4 0.083 907 
5475 HET 2 week 4.5N Control 0.102 925 0.087 901.3 
5472 HET 2 week 4.5N Loaded 0.093 901.7 0.082 883.8 
5474 HET 2 week 4.5N Loaded 0.084 903.2 0.073 888.3 
5490 HET 2 week 4.5N Loaded 0.109 949.7 0.083 924.7 
5491 HET 2 week 4.5N Loaded 0.089 906.6 0.087 910.8 
5493 HET 2 week 4.5N Loaded 0.096 903.4 0.091 905.9 
5475 HET 2 week 4.5N Loaded 0.107 934.6 0.084 913.5 
5532 WT 6 Week 4.5N Control 0.09 871.5 0.085 856.4 
5534 WT 6 Week 4.5N Control 0.095 961.8 0.085 923.2 
5524 WT 6 Week 4.5N Control 0.1 936.1 0.086 921.1 
5535 WT 6 Week 4.5N Control 0.105 963.3 0.089 937.2 
5528 WT 6 Week 4.5N Control 0.083 889.9 0.083 886.1 
5529 WT 6 Week 4.5N Control 0.087 891.4 0.078 879.2 
5532 WT 6 Week 4.5N Loaded 0.085 878.6 0.084 881.9 
5534 WT 6 Week 4.5N Loaded 0.098 926.9 0.088 906.9 
5524 WT 6 Week 4.5N Loaded 0.104 950.8 0.091 908.6 
5535 WT 6 Week 4.5N Loaded 0.102 928.4 0.087 895.4 
5528 WT 6 Week 4.5N Loaded 0.087 891 0.083 895.9 
5529 WT 6 Week 4.5N Loaded 0.084 884.4 0.08 864 
5526 HET 6 Week 4.5N Control 0.098 957.1 0.086 919.1 
5527 HET 6 Week 4.5N Control 0.106 933.8 0.092 911.6 
5536 HET 6 Week 4.5N Control 0.084 886.5 0.082 892.4 
5544 HET 6 Week 4.5N Control 0.099 911.7 0.086 893.7 
5560 HET 6 Week 4.5N Control 0.094 901.7 0.084 900.8 
5531 HET 6 Week 4.5N Control 0.089 881.9 0.081 888.7 
5526 HET 6 Week 4.5N Loaded 0.101 948.2 0.087 909.7 
5527 HET 6 Week 4.5N Loaded 0.102 914.1 0.077 896.6 
5536 HET 6 Week 4.5N Loaded 0.08 867 0.084 906.5 
5544 HET 6 Week 4.5N Loaded 0.092 915.5 0.082 899 
5560 HET 6 Week 4.5N Loaded 0.099 918.8 0.09 904.6 
5531 HET 6 Week 4.5N Loaded 0.09 879.7 0.083 901.2 
5570 WT 1 Week 9N Control 0.106 918.1 0.086 906.6 
5571 WT 1 Week 9N Control 0.112 948.3 0.095 905.2 
5578 WT 1 Week 9N Control 0.122 970.2 0.098 916.9 
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5576 WT 1 Week 9N Control 0.116 969.4 0.103 924.5 
5579 WT 1 Week 9N Control 0.108 972.6 0.103 930.6 
5572 WT 1 Week 9N Control 0.104 958.5 0.087 921.4 
5570 WT 1 Week 9N Loaded 0.107 906.3 0.082 868.8 
5571 WT 1 Week 9N Loaded 0.116 955.5 0.1 917.8 
5578 WT 1 Week 9N Loaded 0.108 928.2 0.087 913.8 
5576 WT 1 Week 9N Loaded 0.117 955.2 0.099 916 
5579 WT 1 Week 9N Loaded 0.11 953 0.093 914.4 
5572 WT 1 Week 9N Loaded 0.108 912.9 0.086 862.1 
5577 HET 1 Week 9N Control 0.109 940.3 0.082 900.1 
5580 HET 1 Week 9N Control 0.086 931.9 0.091 915 
5574 HET 1 Week 9N Control 0.108 931.1 0.1 912.8 
5573 HET 1 Week 9N Control 0.103 952.5 0.087 902.1 
5569 HET 1 Week 9N Control 0.097 904.4 0.087 901.7 
5564 HET 1 Week 9N Control 0.09 883.8 0.087 917.5 
5577 HET 1 Week 9N Loaded 0.104 952.8 0.085 916.2 
5580 HET 1 Week 9N Loaded 0.102 939.1 0.095 922.6 
5574 HET 1 Week 9N Loaded 0.107 919 0.086 899.8 
5573 HET 1 Week 9N Loaded 0.108 922.7 0.09 901.3 
5569 HET 1 Week 9N Loaded 0.111 918.6 0.088 892 
5564 HET 1 Week 9N Loaded 0.097 921.53 0.087 913.6 
5521 WT 2 Week 9N Control 0.092 953.4 0.094 933.5 
5519 WT 2 Week 9N Control 0.084 877.6 0.081 874 
5563 WT 2 Week 9N Control 0.092 885.8 0.082 876.4 
5566 WT 2 Week 9N Control 0.083 869.4 0.077 873.9 
5549 WT 2 Week 9N Control 0.09 900.8 0.082 856.2 
5523 WT 2 Week 9N Control 0.104 971.5 0.096 945 
5521 WT 2 Week 9N Loaded 0.089 909.7 0.083 876.6 
5519 WT 2 Week 9N Loaded 0.074 851.9 0.069 845.7 
5563 WT 2 Week 9N Loaded 0.091 885.8 0.082 881.7 
5566 WT 2 Week 9N Loaded 0.087 858 0.081 865.6 
5549 WT 2 Week 9N Loaded 0.085 871.7 0.074 872.8 
5523 WT 2 Week 9N Loaded 0.094 906.7 0.075 876.8 
5550 HET 2 Week 9N Control 0.116 936 0.096 901.8 
5551 HET 2 week 9N Control 0.088 913.2 0.085 893.5 
5553 HET 2 Week 9N Control 0.097 897.6 0.083 880.4 
5483 HET 2 Week 9N Control 0.092 887.7 0.085 889.8 
5482 HET 2 Week 9N Control 0.099 938.2 0.091 910.8 
5520 HET 2 Week 9N Control 0.083 858.2 0.077 867.2 
5550 HET 2 Week 9N Loaded 0.081 854.9 0.075 853.6 
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5551 HET 2 Week 9N Loaded 0.099 891.6 0.079 864.6 
5553 HET 2 Week 9N Loaded 0.082 855.2 0.077 863.3 
5483 HET 2 Week 9N Loaded 0.093 870.6 0.082 864.4 
5482 HET 2 Week 9N Loaded 0.103 914.5 0.087 903.9 
5520 HET 2 Week 9N Loaded 0.086 855.2 0.075 849.9 
5509 WT 6 Week 9N Control 0.088 877.1 0.075 879.1 
5512 WT 6 Week 9N Control 0.091 927.3 0.087 912.9 
5513 WT 6 Week 9N Control 0.093 897.6 0.089 893.9 
5517 WT 6 Week 9N Control 0.084 882.3 0.083 879.6 
5514 WT 6 Week 9N Control 0.09 926.2 0.086 902.5 
5509 WT 6 Week 9N Loaded 0.07 842.4 0.066 804.8 
5512 WT 6 Week 9N Loaded 0.087 871.7 0.078 874.4 
5513 WT 6 Week 9N Loaded 0.081 888.2 0.073 860.3 
5517 WT 6 Week 9N Loaded 0.083 889.2 0.072 828.4 
5514 WT 6 Week 9N Loaded 0.094 900.8 0.095 911.8 
5510 HET 6 Week 9N Control 0.093 910 0.081 879.3 
5511 HET 6 Week 9N Control 0.08 884 0.08 888.9 
5516 HET 6 Week 9N Control 0.085 880.2 0.082 900.4 
5525 HET 6 Week 9N Control 0.1 964.2 0.086 906.8 
5533 HET 6 Week 9N Control 0.093 888.6 0.088 894.8 
5530 HET 6 Week 9N Control 0.088 902 0.079 875.8 
5510 HET 6 Week 9N Loaded 0.071 816.4 0.07 860.4 
5511 HET 6 Week 9N Loaded 0.066 822.1 0.059 802.6 
5516 HET 6 Week 9N Loaded 0.078 846.1 0.082 858.5 
5525 HET 6 Week 9N Loaded 0.08 874.8 0.084 876.7 
5533 HET 6 Week 9N Loaded 0.075 839 0.07 814.8 
5530 HET 6 Week 9N Loaded 0.083 853.8 0.083 873.4 
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Epiphyseal Cancellous Bone MicroCT Data: Indices of cancellous bone architecture 
proximal to the growth plate in wildtype (WT) and cho/+ (HET) mice. Outcome 
measures: bone volume fraction (BV/TV), trabecular thickness (Tb.Th), trabecular 
separation (Tb.Sp), and tissue mineral density (TMD). 
 
ID Genotype Duration Magnitude Limb BV/TV 
Tb.Th 
(mm) 
Tb.Sp 
(mm) 
TMD 
(mg HA/ccm) 
5546 WT 1 Week 4.5N Control 0.2643 0.0586 0.2137 935.59 
5547 WT 1 Week 4.5N Control 0.266 0.0548 0.1985 932.99 
5554 WT 1 Week 4.5N Control 0.2884 0.0551 0.1769 928.43 
5556 WT 1 Week 4.5N Control 0.2807 0.0608 0.2307 932.08 
5557 WT 1 Week 4.5N Control 0.2637 0.0533 0.1837 928.89 
5567 WT 1 Week 4.5N Control 0.3059 0.0529 0.1765 917.82 
5546 WT 1 Week 4.5N Loaded 0.2767 0.0575 0.2079 954.8 
5547 WT 1 Week 4.5N Loaded 0.2601 0.0541 0.199 945.42 
5554 WT 1 Week 4.5N Loaded 0.2984 0.0547 0.1819 946.14 
5556 WT 1 Week 4.5N Loaded 0.2567 0.0582 0.226 934.29 
5557 WT 1 Week 4.5N Loaded 0.2693 0.0525 0.1861 931.42 
5567 WT 1 Week 4.5N Loaded 0.3135 0.0532 0.176 935.46 
5561 HET 1 Week 4.5N Control 0.3318 0.0583 0.1883 933.12 
5545 HET 1 Week 4.5N Control 0.288 0.0583 0.1983 950.5 
5559 HET 1 Week 4.5N Control 0.2968 0.0556 0.1844 933.96 
5558 HET 1 Week 4.5N Control 0.2918 0.0571 0.1842 945.1 
5565 HET 1 Week 4.5N Control 0.3056 0.0574 0.1926 946.99 
5562 HET 1 Week 4.5N Control 0.2702 0.0531 0.1794 919.7 
5561 HET 1 Week 4.5N Loaded 0.3275 0.0585 0.1789 935.66 
5545 HET 1 Week 4.5N Loaded 0.2685 0.0575 0.2124 956.75 
5559 HET 1 Week 4.5N Loaded 0.2455 0.0515 0.203 931.75 
5558 HET 1 Week 4.5N Loaded 0.2759 0.0558 0.1935 932.34 
5565 HET 1 Week 4.5N Loaded 0.2824 0.0575 0.208 937.09 
5562 HET 1 Week 4.5N Loaded 0.2576 0.054 0.1904 938.72 
5537 WT 2 week 4.5N Control 0.3175 0.0581 0.1692 933.38 
5538 WT 2 week 4.5N Control 0.2511 0.0544 0.2078 932.01 
5539 WT 2 week 4.5N Control 0.3033 0.0522 0.1995 949.07 
5541 WT 2 week 4.5N Control 0.3753 0.0548 0.1693 949.92 
5518 WT 2 week 4.5N Control 0.2641 0.046 0.1924 910.98 
5522 WT 2 week 4.5N Control 0.2818 0.0486 0.1977 900.236 
5537 WT 2 week 4.5N Loaded 0.3353 0.0599 0.1646 942.04 
5538 WT 2 week 4.5N Loaded 0.2558 0.057 0.2165 940.54 
5539 WT 2 week 4.5N Loaded 0.27 0.0514 0.2081 943.47 
5541 WT 2 week 4.5N Loaded 0.3827 0.0546 0.1879 964.18 
5518 WT 2 week 4.5N Loaded 0.2324 0.0474 0.1965 900.562 
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5522 WT 2 week 4.5N Loaded 0.2529 0.0458 0.197 924.588 
5472 HET 2 week 4.5N Control 0.2406 0.0504 0.1966 968.54 
5474 HET 2 week 4.5N Control 0.2507 0.0502 0.1953 946.33 
5490 HET 2 week 4.5N Control 0.2892 0.0462 0.2006 959.096 
5491 HET 2 week 4.5N Control 0.2844 0.0475 0.21 958.315 
5493 HET 2 week 4.5N Control 0.3247 0.0533 0.1807 954.278 
5475 HET 2 week 4.5N Control 0.2424 0.0438 0.2034 952.064 
5472 HET 2 week 4.5N Loaded 0.229 0.0495 0.2022 950.18 
5474 HET 2 week 4.5N Loaded 0.2365 0.047 0.1948 951.28 
5490 HET 2 week 4.5N Loaded 0.2437 0.047 0.2211 955.775 
5491 HET 2 week 4.5N Loaded 0.2743 0.0498 0.2056 964.891 
5493 HET 2 week 4.5N Loaded 0.3212 0.0523 0.1942 960.593 
5475 HET 2 week 4.5N Loaded 0.2426 0.0465 0.2024 943.925 
5532 WT 6 Week 4.5N Control 0.2405 0.051 0.1899 915.54 
5534 WT 6 Week 4.5N Control 0.3247 0.0624 0.1928 960.14 
5524 WT 6 Week 4.5N Control 0.2384 0.0555 0.2128 933.12 
5535 WT 6 Week 4.5N Control 0.2391 0.0542 0.2058 957.47 
5528 WT 6 Week 4.5N Control 0.2238 0.0539 0.2147 936.7 
5529 WT 6 Week 4.5N Control 0.2287 0.0498 0.2242 946.33 
5532 WT 6 Week 4.5N Loaded 0.2256 0.0507 0.1967 923.61 
5534 WT 6 Week 4.5N Loaded 0.2662 0.0537 0.2037 952.78 
5524 WT 6 Week 4.5N Loaded 0.2163 0.0511 0.2064 937.48 
5535 WT 6 Week 4.5N Loaded 0.2156 0.0515 0.1991 935.07 
5528 WT 6 Week 4.5N Loaded 0.2057 0.0503 0.2053 927.39 
5529 WT 6 Week 4.5N Loaded 0.2411 0.049 0.2159 931.23 
5526 HET 6 Week 4.5N Control 0.3108 0.0592 0.1968 946.53 
5527 HET 6 Week 4.5N Control 0.2523 0.0534 0.209 935.98 
5536 HET 6 Week 4.5N Control 0.2359 0.0523 0.1897 935.46 
5544 HET 6 Week 4.5N Control 0.1974 0.0504 0.2218 916.06 
5560 HET 6 Week 4.5N Control 0.2042 0.0548 0.2337 922.9 
5531 HET 6 Week 4.5N Control 0.2102 0.0529 0.2316 916.91 
5526 HET 6 Week 4.5N Loaded 0.2814 0.0592 0.2157 958.77 
5527 HET 6 Week 4.5N Loaded 0.2214 0.052 0.2128 930.71 
5536 HET 6 Week 4.5N Loaded 0.2075 0.0496 0.1914 933.64 
5544 HET 6 Week 4.5N Loaded 0.2038 0.0527 0.2286 939.89 
5560 HET 6 Week 4.5N Loaded 0.2443 0.0564 0.2049 950.11 
5531 HET 6 Week 4.5N Loaded 0.2112 0.0502 0.2032 922.57 
5570 WT 1 Week 9N Control 0.2691 0.0561 0.1934 925.24 
5571 WT 1 Week 9N Control 0.2609 0.0565 0.2081 915.08 
5578 WT 1 Week 9N Control 0.3169 0.061 0.1809 937.81 
  173 
5576 WT 1 Week 9N Control 0.2913 0.0571 0.1785 937.55 
5579 WT 1 Week 9N Control 0.3031 0.0557 0.2008 946.14 
5572 WT 1 Week 9N Control 0.2741 0.0542 0.1828 931.55 
5570 WT 1 Week 9N Loaded 0.2971 0.0571 0.1852 913.91 
5571 WT 1 Week 9N Loaded 0.2462 0.0568 0.2148 919.05 
5578 WT 1 Week 9N Loaded 0.2838 0.0571 0.1913 933.18 
5576 WT 1 Week 9N Loaded 0.2633 0.052 0.1915 917.95 
5579 WT 1 Week 9N Loaded 0.2752 0.0556 0.1878 928.3 
5572 WT 1 Week 9N Loaded 0.2833 0.0561 0.1872 912.15 
5577 HET 1 Week 9N Control 0.2644 0.0533 0.1871 926.02 
5580 HET 1 Week 9N Control 0.2982 0.0575 0.1825 939.3 
5574 HET 1 Week 9N Control 0.2953 0.0569 0.1838 935.96 
5573 HET 1 Week 9N Control 0.2744 0.0524 0.1788 913.58 
5569 HET 1 Week 9N Control 0.2528 0.0536 0.1959 926.02 
5564 HET 1 Week 9N Control 0.2839 0.0508 0.1904 930.12 
5577 HET 1 Week 9N Loaded 0.3036 0.0558 0.1873 936.44 
5580 HET 1 Week 9N Loaded 0.3281 0.0585 0.1856 930.71 
5574 HET 1 Week 9N Loaded 0.2592 0.0526 0.2048 890.93 
5573 HET 1 Week 9N Loaded 0.2642 0.0527 0.1868 936.7 
5569 HET 1 Week 9N Loaded 0.253 0.0521 0.1884 914.04 
5564 HET 1 Week 9N Loaded 0.3147 0.0553 0.1857 942.36 
5521 WT 2 week 9N Control 0.2714 0.056 0.2011 959.1 
5519 WT 2 week 9N Control 0.2299 0.0484 0.1836 914.04 
5563 WT 2 week 9N Control 0.3085 0.0532 0.1911 921.33 
5566 WT 2 week 9N Control 0.2445 0.048 0.2144 910.39 
5549 WT 2 week 9N Control 0.2346 0.0472 0.202 924 
5523 WT 2 week 9N Control 0.3323 0.0605 0.1984 973.3555 
5521 WT 2 week 9N Loaded 0.2257 0.0529 0.2044 895.22 
5519 WT 2 week 9N Loaded 0.165 0.0448 0.2015 885.26 
5563 WT 2 week 9N Loaded 0.2778 0.0508 0.1925 919.57 
5566 WT 2 week 9N Loaded 0.2384 0.0472 0.1997 890.73 
5549 WT 2 week 9N Loaded 0.2524 0.0489 0.197 908.9 
5523 WT 2 week 9N Loaded 0.2917 0.0526 0.1982 925.76 
5550 HET 2 week 9N Control 0.2664 0.0528 0.188 922.5 
5551 HET 2 week 9N Control 0.2157 0.0491 0.2015 919.77 
5553 HET 2 week 9N Control 0.2994 0.0504 0.1761 910.39 
5483 HET 2 week 9N Control 0.2606 0.0512 0.2068 941.256 
5482 HET 2 week 9N Control 0.304 0.0518 0.1987 978.043 
5520 HET 2 week 9N Control 0.2573 0.0473 0.1873 900.041 
5550 HET 2 week 9N Loaded 0.196 0.048 0.2032 891.19 
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5551 HET 2 week 9N Loaded 0.2317 0.0514 0.1963 916.38 
5553 HET 2 week 9N Loaded 0.2337 0.0409 0.1789 867.94 
5483 HET 2 week 9N Loaded 0.2704 0.0479 0.2005 948.418 
5482 HET 2 week 9N Loaded 0.3111 0.0529 0.2106 959.877 
5520 HET 2 week 9N Loaded 0.2008 0.0472 0.2093 887.41 
5509 WT 6 Week 9N Control 0.2433 0.0537 0.2079 931.49 
5512 WT 6 Week 9N Control 0.2597 0.0575 0.2095 969.51 
5513 WT 6 Week 9N Control 0.238 0.0563 0.221 927.71 
5515 WT 6 Week 9N Control 0.2346 0.0514 0.2006 954.02 
5517 WT 6 Week 9N Control 0.2343 0.0528 0.2076 930.25 
5514 WT 6 Week 9N Control 0.2672 0.0523 0.2065 960.07 
5509 WT 6 Week 9N Loaded 0.1372 0.0514 0.2348 907.27 
5512 WT 6 Week 9N Loaded 0.1503 0.05 0.2378 894.38 
5513 WT 6 Week 9N Loaded 0.2396 0.0636 0.2027 916.77 
5515 WT 6 Week 9N Loaded 0.1491 0.0465 0.2317 892.16 
5517 WT 6 Week 9N Loaded 0.2047 0.0506 0.2098 920.29 
5514 WT 6 Week 9N Loaded 0.3418 0.0718 0.153 950.57 
5510 HET 6 Week 9N Control 0.2585 0.0555 0.199 918.79 
5511 HET 6 Week 9N Control 0.2147 0.0523 0.2141 937.35 
5516 HET 6 Week 9N Control 0.2407 0.0558 0.2226 923.87 
5525 HET 6 Week 9N Control 0.2583 0.0543 0.2037 944.06 
5533 HET 6 Week 9N Control 0.2558 0.0558 0.1968 931.36 
5530 HET 6 Week 9N Control 0.2548 0.0537 0.1951 940.28 
5510 HET 6 Week 9N Loaded 0.1651 0.048 0.2233 880.7 
5511 HET 6 Week 9N Loaded 0.1235 0.0482 0.239 863.32 
5516 HET 6 Week 9N Loaded 0.2492 0.0574 0.2099 894.57 
5525 HET 6 Week 9N Loaded 0.1785 0.05 0.2104 908.25 
5533 HET 6 Week 9N Loaded 0.1606 0.0487 0.2115 887.08 
5530 HET 6 Week 9N Loaded 0.2252 0.0572 0.2009 898.74 
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Metaphyseal Cancellous Bone MicroCT Data: Indices of cancellous bone 
architecture distal to the growth plate in wildtype (WT) and cho/+ (HET) mice. 
Outcome measures: bone volume fraction (BV/TV), trabecular thickness (Tb.Th), 
trabecular separation (Tb.Sp), and tissue mineral density (TMD). 
 
ID Genotype Duration Magnitude Limb BV/TV 
Tb.Th 
(mm) 
Tb.Sp 
(mm) 
TMD 
(mg HA/ccm) 
5546 WT 1 Week 4.5N Control 0.0744 0.046 0.288 808.561 
5547 WT 1 Week 4.5N Control 0.0826 0.0467 0.2748 786.749 
5554 WT 1 Week 4.5N Control 0.1564 0.0624 0.273 851.3392 
5556 WT 1 Week 4.5N Control 0.153 0.0625 0.2403 850.2323 
5557 WT 1 Week 4.5N Control 0.1309 0.0523 0.2501 844.307 
5567 WT 1 Week 4.5N Control 0.0969 0.0488 0.2438 760.575 
5546 WT 1 Week 4.5N Loaded 0.0859 0.0494 0.2603 852.315 
5547 WT 1 Week 4.5N Loaded 0.0801 0.0458 0.2759 822.56 
5554 WT 1 Week 4.5N Loaded 0.1685 0.0628 0.2558 853.0972 
5556 WT 1 Week 4.5N Loaded 0.1352 0.0585 0.2468 833.564 
5557 WT 1 Week 4.5N Loaded 0.1379 0.0531 0.2467 845.414 
5567 WT 1 Week 4.5N Loaded 0.0911 0.0441 0.2537 823.472 
5561 HET 1 Week 4.5N Control 0.0953 0.0501 0.2723 836.754 
5545 HET 1 Week 4.5N Control 0.1105 0.06 0.2823 850.7532 
5559 HET 1 Week 4.5N Control 0.1101 0.0483 0.2624 801.725 
5558 HET 1 Week 4.5N Control 0.1237 0.055 0.264 823.407 
5565 HET 1 Week 4.5N Control 0.1348 0.0495 0.2318 826.402 
5562 HET 1 Week 4.5N Control 0.0951 0.0477 0.2574 809.733 
5561 HET 1 Week 4.5N Loaded 0.1197 0.0514 0.2462 828.29 
5545 HET 1 Week 4.5N Loaded 0.1053 0.0569 0.272 868.658 
5559 HET 1 Week 4.5N Loaded 0.1155 0.0533 0.2568 835.777 
5558 HET 1 Week 4.5N Loaded 0.1239 0.052 0.2412 823.537 
5565 HET 1 Week 4.5N Loaded 0.111 0.0489 0.2622 807.389 
5562 HET 1 Week 4.5N Loaded 0.1051 0.0481 0.2523 823.146 
5537 WT 2 week 4.5N Control 0.1811 0.056 0.2396 837.21 
5538 WT 2 week 4.5N Control 0.1301 0.0608 0.3268 834.9315 
5539 WT 2 week 4.5N Control 0.0937 0.0485 0.2888 840.335 
5541 WT 2 week 4.5N Control 0.1967 0.0609 0.284 832.1317 
5518 WT 2 week 4.5N Control 0.0741 0.0416 0.2513 792.349 
5522 WT 2 week 4.5N Control 0.0746 0.0455 0.269 801.139 
5537 WT 2 week 4.5N Loaded 0.1702 0.0566 0.2701 833.564 
5538 WT 2 week 4.5N Loaded 0.107 0.0531 0.3059 852.641 
5539 WT 2 week 4.5N Loaded 0.1104 0.0572 0.2968 828.29 
5541 WT 2 week 4.5N Loaded 0.1953 0.0623 0.2485 861.0406 
5518 WT 2 week 4.5N Loaded 0.0845 0.0481 0.2483 775.225 
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5522 WT 2 week 4.5N Loaded 0.0833 0.0445 0.2633 822.886 
5472 HET 2 week 4.5N Control 0.0665 0.0438 0.2505 891.707 
5474 HET 2 week 4.5N Control 0.0765 0.04 0.2434 855.701 
5490 HET 2 week 4.5N Control 0.1181 0.0507 0.256 897.697 
5491 HET 2 week 4.5N Control 0.1 0.0433 0.2377 831.285 
5493 HET 2 week 4.5N Control 0.1556 0.0518 0.2304 837.601 
5475 HET 2 week 4.5N Control 0.084 0.0454 0.2615 866.054 
5472 HET 2 week 4.5N Loaded 0.077 0.0466 0.2429 892.488 
5474 HET 2 week 4.5N Loaded 0.0888 0.0469 0.2445 892.098 
5490 HET 2 week 4.5N Loaded 0.1021 0.0469 0.2599 876.211 
5491 HET 2 week 4.5N Loaded 0.1096 0.0466 0.2453 860.584 
5493 HET 2 week 4.5N Loaded 0.1404 0.0514 0.2343 842.614 
5475 HET 2 week 4.5N Loaded 0.0818 0.0452 0.2626 866.249 
5532 WT 6 Week 4.5N Control 0.0465 0.0451 0.3071 812.728 
5534 WT 6 Week 4.5N Control 0.1494 0.059 0.2738 833.499 
5524 WT 6 Week 4.5N Control 0.127 0.0547 0.2723 801.334 
5535 WT 6 Week 4.5N Control 0.1006 0.0502 0.2984 844.567 
5528 WT 6 Week 4.5N Control 0.0489 0.0451 0.323 824.318 
5529 WT 6 Week 4.5N Control 0.0574 0.045 0.306 831.09 
5532 WT 6 Week 4.5N Loaded 0.0575 0.0456 0.2948 812.403 
5534 WT 6 Week 4.5N Loaded 0.1142 0.0525 0.2985 831.61 
5524 WT 6 Week 4.5N Loaded 0.1523 0.0577 0.2526 838.317 
5535 WT 6 Week 4.5N Loaded 0.1131 0.0519 0.2831 846 
5528 WT 6 Week 4.5N Loaded 0.0584 0.0467 0.3556 814.617 
5529 WT 6 Week 4.5N Loaded 0.0577 0.0478 0.3018 810.775 
5526 HET 6 Week 4.5N Control 0.1346 0.0562 0.2638 841.898 
5527 HET 6 Week 4.5N Control 0.0817 0.046 0.293 808.757 
5536 HET 6 Week 4.5N Control 0.0874 0.048 0.2527 821.714 
5544 HET 6 Week 4.5N Control 0.0692 0.044 0.3089 776.137 
5560 HET 6 Week 4.5N Control 0.103 0.0486 0.2619 836.624 
5531 HET 6 Week 4.5N Control 0.0485 0.0469 0.3218 802.376 
5526 HET 6 Week 4.5N Loaded 0.1333 0.0575 0.2576 866.965 
5527 HET 6 Week 4.5N Loaded 0.0857 0.0463 0.2812 830.569 
5536 HET 6 Week 4.5N Loaded 0.084 0.0471 0.2619 847.497 
5544 HET 6 Week 4.5N Loaded 0.0701 0.049 0.2947 835.452 
5560 HET 6 Week 4.5N Loaded 0.0969 0.0492 0.255 851.664 
5531 HET 6 Week 4.5N Loaded 0.0401 0.0499 0.328 852.25 
5570 WT 1 Week 9N Control 0.1277 0.0502 0.2837 789.614 
5571 WT 1 Week 9N Control 0.1376 0.0613 0.3061 818.0679 
5578 WT 1 Week 9N Control 0.1983 0.0627 0.2911 853.618 
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5576 WT 1 Week 9N Control 0.1619 0.0578 0.2768 827.834 
5579 WT 1 Week 9N Control 0.1835 0.0649 0.3304 839.4891 
5572 WT 1 Week 9N Control 0.1251 0.0596 0.2774 853.943 
5570 WT 1 Week 9N Loaded 0.1244 0.0493 0.2703 800.488 
5571 WT 1 Week 9N Loaded 0.1326 0.0591 0.3 829.006 
5578 WT 1 Week 9N Loaded 0.1412 0.05 0.286 804.069 
5576 WT 1 Week 9N Loaded 0.1512 0.0551 0.3025 800.683 
5579 WT 1 Week 9N Loaded 0.199 0.0627 0.2634 846.2606 
5572 WT 1 Week 9N Loaded 0.1144 0.0518 0.2829 806.869 
5577 HET 1 Week 9N Control 0.1306 0.0592 0.3164 815.137 
5580 HET 1 Week 9N Control 0.1384 0.0534 0.2981 814.682 
5574 HET 1 Week 9N Control 0.1655 0.0606 0.2661 809.9291 
5573 HET 1 Week 9N Control 0.1194 0.0599 0.2793 851.209 
5569 HET 1 Week 9N Control 0.1145 0.0523 0.323 796.256 
5564 HET 1 Week 9N Control 0.0849 0.0462 0.2664 823.146 
5577 HET 1 Week 9N Loaded 0.1332 0.0574 0.3 821.714 
5580 HET 1 Week 9N Loaded 0.1416 0.052 0.2706 821.649 
5574 HET 1 Week 9N Loaded 0.15 0.0575 0.2929 806.283 
5573 HET 1 Week 9N Loaded 0.1091 0.0615 0.2813 864.8821 
5569 HET 1 Week 9N Loaded 0.0955 0.0497 0.3424 814.031 
5564 HET 1 Week 9N Loaded 0.0996 0.0515 0.2723 840.921 
5521 WT 2 week 9N Control 0.1338 0.0612 0.3197 870.2211 
5519 WT 2 week 9N Control 0.0533 0.038 0.2715 836.168 
5563 WT 2 week 9N Control 0.1077 0.049 0.2467 819.891 
5566 WT 2 week 9N Control 0.0707 0.0423 0.2988 774.769 
5549 WT 2 week 9N Control 0.0605 0.0429 0.2827 818.393 
5523 WT 2 week 9N Control 0.1591 0.0625 0.2692 849.0604 
5521 WT 2 week 9N Loaded 0.1075 0.0511 0.3053 812.077 
5519 WT 2 week 9N Loaded 0.0739 0.0587 0.2895 836.363 
5563 WT 2 week 9N Loaded 0.1395 0.0617 0.2503 857.134 
5566 WT 2 week 9N Loaded 0.0804 0.0504 0.2885 815.658 
5549 WT 2 week 9N Loaded 0.0775 0.0549 0.2821 852.901 
5523 WT 2 week 9N Loaded 0.1347 0.0571 0.2727 820.932 
5550 HET 2 week 9N Control 0.1139 0.0506 0.2442 810.319 
5551 HET 2 week 9N Control 0.0752 0.0412 0.2596 777.799 
5553 HET 2 week 9N Control 0.1146 0.0479 0.239 770.928 
5483 HET 2 week 9N Control 0.0743 0.0437 0.2843 840.596 
5482 HET 2 week 9N Control 0.107 0.043 0.2396 858.892 
5520 HET 2 week 9N Control 0.0788 0.0453 0.259 784.926 
5550 HET 2 week 9N Loaded 0.0916 0.0534 0.2636 832.652 
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5551 HET 2 week 9N Loaded 0.0921 0.0501 0.2677 817.416 
5553 HET 2 week 9N Loaded 0.1077 0.0479 0.2463 800.162 
5483 HET 2 week 9N Loaded 0.1073 0.0545 0.2663 874.583 
5482 HET 2 week 9N Loaded 0.1366 0.0566 0.2558 874.127 
5520 HET 2 week 9N Loaded 0.0943 0.0553 0.2633 816.44 
5509 WT 6 Week 9N Control 0.0645 0.0446 0.3148 801.009 
5512 WT 6 Week 9N Control 0.0579 0.0416 0.3679 826.532 
5513 WT 6 Week 9N Control 0.0816 0.0488 0.2884 785.578 
5515 WT 6 Week 9N Control 0.0703 0.0451 0.2918 871.783 
5517 WT 6 Week 9N Control 0.061 0.0424 0.3047 792.219 
5514 WT 6 Week 9N Control 0.0752 0.05 0.3121 850.492 
5509 WT 6 Week 9N Loaded 0.1003 0.06787 0.3131 867.0959 
5512 WT 6 Week 9N Loaded 0.1056 0.0762 0.2934 872.9557 
5513 WT 6 Week 9N Loaded 0.0932 0.0646 0.2951 850.3625 
5515 WT 6 Week 9N Loaded 0.0351 0.0615 0.3574 837.601 
5517 WT 6 Week 9N Loaded 0.0841 0.0625 0.3023 847.5628 
5514 WT 6 Week 9N Loaded 0.0814 0.064 0.3448 798.6651 
5510 HET 6 Week 9N Control 0.096 0.0434 0.2526 794.433 
5511 HET 6 Week 9N Control 0.0546 0.038 0.2757 827.964 
5516 HET 6 Week 9N Control 0.0758 0.0475 0.3016 786.033 
5525 HET 6 Week 9N Control 0.1133 0.0527 0.2818 833.043 
5533 HET 6 Week 9N Control 0.07 0.0482 0.3026 813.705 
5530 HET 6 Week 9N Control 0.0766 0.0451 0.2749 838.382 
5510 HET 6 Week 9N Loaded 0.1074 0.0555 0.2621 795.018 
5511 HET 6 Week 9N Loaded 0.0765 0.0589 0.2948 819.565 
5516 HET 6 Week 9N Loaded 0.1017 0.0599 0.2671 801.92 
5525 HET 6 Week 9N Loaded 0.1276 0.0629 0.292 829.918 
5533 HET 6 Week 9N Loaded 0.0782 0.0609 0.2925 822.4954 
5530 HET 6 Week 9N Loaded 0.1155 0.0592 0.2556 822.69 
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Metaphyseal Cortical Shell MicroCT Data: Metaphyseal cortical shell tissue 
mineral density (TMD) and thickness (Ct.Th) of the tibia in wildtype (WT) and cho/+ 
(HET) mice. 
 
ID Genotype Duration Magnitude Limb 
TMD 
(mg HA/ccm) 
Ct.Th 
(mm) 
5546 WT 1 Week 4.5N Control 1024.076 0.165 
5547 WT 1 Week 4.5N Control 1019.063 0.154 
5554 WT 1 Week 4.5N Control 1019.128 0.172 
5556 WT 1 Week 4.5N Control 1014.961 0.173 
5557 WT 1 Week 4.5N Control 1004.999 0.155 
5567 WT 1 Week 4.5N Control 993.0187 0.16 
5546 WT 1 Week 4.5N Loaded 1011.054 0.156 
5547 WT 1 Week 4.5N Loaded 1021.667 0.155 
5554 WT 1 Week 4.5N Loaded 1023.165 0.17 
5556 WT 1 Week 4.5N Loaded 996.5347 0.169 
5557 WT 1 Week 4.5N Loaded 1006.106 0.153 
5567 WT 1 Week 4.5N Loaded 1012.877 0.155 
5561 HET 1 Week 4.5N Control 1002.981 0.168 
5545 HET 1 Week 4.5N Control 1009.036 0.166 
5559 HET 1 Week 4.5N Control 999.2693 0.154 
5558 HET 1 Week 4.5N Control 986.3775 0.146 
5565 HET 1 Week 4.5N Control 991.0655 0.168 
5562 HET 1 Week 4.5N Control 982.7964 0.152 
5561 HET 1 Week 4.5N Loaded 999.3996 0.164 
5545 HET 1 Week 4.5N Loaded 1013.008 0.164 
5559 HET 1 Week 4.5N Loaded 998.6834 0.154 
5558 HET 1 Week 4.5N Loaded 984.0987 0.149 
5565 HET 1 Week 4.5N Loaded 1008.189 0.151 
5562 HET 1 Week 4.5N Loaded 996.9905 0.145 
5537 WT 2 week 4.5N Control 1006.171 0.166 
5538 WT 2 week 4.5N Control 986.3775 0.151 
5539 WT 2 week 4.5N Control 993.4095 0.141 
5541 WT 2 week 4.5N Control 1009.882 0.16 
5518 WT 2 week 4.5N Control 963.3286 0.132 
5522 WT 2 week 4.5N Control 973.5508 0.141 
5537 WT 2 week 4.5N Loaded 1003.697 0.161 
5538 WT 2 week 4.5N Loaded 1011.119 0.157 
5539 WT 2 week 4.5N Loaded 1003.111 0.147 
5541 WT 2 week 4.5N Loaded 1028.634 0.175 
5518 WT 2 week 4.5N Loaded 952.1948 0.138 
5522 WT 2 week 4.5N Loaded 984.9451 0.139 
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5472 HET 2 week 4.5N Control 992.1723 0.134 
5474 HET 2 week 4.5N Control 971.9882 0.126 
5490 HET 2 week 4.5N Control 999.8554 0.143 
5491 HET 2 week 4.5N Control 977.0668 0.137 
5493 HET 2 week 4.5N Control 1005.064 0.156 
5475 HET 2 week 4.5N Control 993.4745 0.139 
5472 HET 2 week 4.5N Loaded 970.5558 0.124 
5474 HET 2 week 4.5N Loaded 997.3161 0.131 
5490 HET 2 week 4.5N Loaded 975.8948 0.142 
5491 HET 2 week 4.5N Loaded 985.466 0.139 
5493 HET 2 week 4.5N Loaded 988.5262 0.149 
5475 HET 2 week 4.5N Loaded 982.0803 0.135 
5532 WT 6 Week 4.5N Control 977.0016 0.137 
5534 WT 6 Week 4.5N Control 999.5298 0.156 
5524 WT 6 Week 4.5N Control 985.6613 0.147 
5535 WT 6 Week 4.5N Control 1005.911 0.145 
5528 WT 6 Week 4.5N Control 985.1404 0.136 
5529 WT 6 Week 4.5N Control 971.0115 0.127 
5532 WT 6 Week 4.5N Loaded 970.8814 0.137 
5534 WT 6 Week 4.5N Loaded 980.3223 0.142 
5524 WT 6 Week 4.5N Loaded 982.5361 0.142 
5535 WT 6 Week 4.5N Loaded 1003.827 0.147 
5528 WT 6 Week 4.5N Loaded 997.6417 0.138 
5529 WT 6 Week 4.5N Loaded 975.9599 0.132 
5526 HET 6 Week 4.5N Control 1000.246 0.165 
5527 HET 6 Week 4.5N Control 986.3775 0.142 
5536 HET 6 Week 4.5N Control 963.0682 0.132 
5544 HET 6 Week 4.5N Control 963.5239 0.137 
5560 HET 6 Week 4.5N Control 995.4279 0.146 
5531 HET 6 Week 4.5N Control 965.2819 0.132 
5526 HET 6 Week 4.5N Loaded 1007.473 0.161 
5527 HET 6 Week 4.5N Loaded 990.6749 0.145 
5536 HET 6 Week 4.5N Loaded 986.8333 0.128 
5544 HET 6 Week 4.5N Loaded 974.5275 0.139 
5560 HET 6 Week 4.5N Loaded 993.6699 0.146 
5531 HET 6 Week 4.5N Loaded 955.7758 0.125 
5570 WT 1 Week 9N Control 991.1957 0.156 
5571 WT 1 Week 9N Control 988.982 0.156 
5578 WT 1 Week 9N Control 1006.757 0.163 
5576 WT 1 Week 9N Control 998.6182 0.165 
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5579 WT 1 Week 9N Control 1016.133 0.16 
5572 WT 1 Week 9N Control 1010.078 0.161 
5570 WT 1 Week 9N Loaded 985.466 0.151 
5571 WT 1 Week 9N Loaded 990.805 0.171 
5578 WT 1 Week 9N Loaded 994.1907 0.157 
5576 WT 1 Week 9N Loaded 994.2559 0.169 
5579 WT 1 Week 9N Loaded 1010.989 0.169 
5572 WT 1 Week 9N Loaded 985.2707 0.163 
5577 HET 1 Week 9N Control 974.267 0.142 
5580 HET 1 Week 9N Control 997.5114 0.151 
5574 HET 1 Week 9N Control 990.805 0.153 
5573 HET 1 Week 9N Control 982.6663 0.152 
5569 HET 1 Week 9N Control 983.9034 0.154 
5564 HET 1 Week 9N Control 992.1723 0.148 
5577 HET 1 Week 9N Loaded 988.4611 0.16 
5580 HET 1 Week 9N Loaded 987.4844 0.158 
5574 HET 1 Week 9N Loaded 985.9218 0.176 
5573 HET 1 Week 9N Loaded 991.3911 0.158 
5569 HET 1 Week 9N Loaded 979.4759 0.158 
5564 HET 1 Week 9N Loaded 1009.752 0.167 
5521 WT 2 week 9N Control 1014.505 0.163 
5519 WT 2 week 9N Control 969.3839 0.126 
5563 WT 2 week 9N Control 998.8787 0.161 
5566 WT 2 week 9N Control 964.3703 0.135 
5549 WT 2 week 9N Control 976.611 0.131 
5523 WT 2 week 9N Control 980.4526 0.154 
5521 WT 2 week 9N Loaded 973.2905 0.168 
5519 WT 2 week 9N Loaded 953.1714 0.161 
5563 WT 2 week 9N Loaded 1011.64 0.181 
5566 WT 2 week 9N Loaded 967.5607 0.162 
5549 WT 2 week 9N Loaded 968.2119 0.15 
5523 WT 2 week 9N Loaded 1019.974 0.156 
5550 HET 2 week 9N Control 970.4256 0.134 
5551 HET 2 week 9N Control 949.5252 0.129 
5553 HET 2 week 9N Control 890.7308 0.113 
5483 HET 2 week 9N Control 984.5545 0.141 
5482 HET 2 week 9N Control 1000.116 0.144 
5520 HET 2 week 9N Control 926.8669 0.123 
5550 HET 2 week 9N Loaded 961.4404 0.151 
5551 HET 2 week 9N Loaded 947.572 0.143 
  182 
5553 HET 2 week 9N Loaded 968.5374 0.153 
5483 HET 2 week 9N Loaded 971.5976 0.151 
5482 HET 2 week 9N Loaded 985.9218 0.155 
5520 HET 2 week 9N Loaded 935.6916 0.138 
5509 WT 6 Week 9N Control 974.9182 0.148 
5512 WT 6 Week 9N Control 1004.608 0.139 
5513 WT 6 Week 9N Control 981.1037 0.154 
5515 WT 6 Week 9N Control 1011.185 0.132 
5517 WT 6 Week 9N Control 983.7081 0.135 
5514 WT 6 Week 9N Control 1015.482 0.143 
5509 WT 6 Week 9N Loaded 981.0385 0.153 
5512 WT 6 Week 9N Loaded 1002.981 0.166 
5513 WT 6 Week 9N Loaded 997.1859 0.187 
5515 WT 6 Week 9N Loaded 1017.565 0.132 
5517 WT 6 Week 9N Loaded 1014.505 0.188 
5514 WT 6 Week 9N Loaded 1000.441 0.167 
5510 HET 6 Week 9N Control 953.6271 0.129 
5511 HET 6 Week 9N Control 976.2204 0.122 
5516 HET 6 Week 9N Control 970.8814 0.137 
5525 HET 6 Week 9N Control 979.9317 0.142 
5533 HET 6 Week 9N Control 981.6246 0.138 
5530 HET 6 Week 9N Control 987.9402 0.138 
5510 HET 6 Week 9N Loaded 960.5939 0.159 
5511 HET 6 Week 9N Loaded 975.1135 0.158 
5516 HET 6 Week 9N Loaded 986.2474 0.173 
5525 HET 6 Week 9N Loaded 982.5361 0.166 
5533 HET 6 Week 9N Loaded 948.4835 0.147 
5530 HET 6 Week 9N Loaded 975.5693 0.161 
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Matrix metalloproteinase (MMP)-13 Immunostaining: MMP-13 levels in articular 
cartilage of the medial tibial plateau determined by immunohistochemistry with anti-
MMP13 antibodies. MMP-13 levels reported as percentage of positive 
immunostaining per cartilage area. 
 
ID Genotype Duration Magnitude Limb 
Percent MMP13 
per Cartilage Area 
5579 WT 1wk 9.0N Control 0.051044 
5572 WT 1wk 9.0N Control 1.944739 
5579 WT 1wk 9.0N Loaded 0.19419 
5571 WT 1wk 9.0N Loaded 0.268459 
5572 WT 1wk 9.0N Loaded 1.141847 
5570 WT 1wk 9.0N Loaded 1.656129 
5574 HET 1wk 9.0N Control 1.89645 
5573 HET 1wk 9.0N Control 1.595822 
5564 HET 1wk 9.0N Loaded 0.305861 
5574 HET 1wk 9.0N Loaded 0.011749 
5580 HET 1wk 9.0N Loaded 0.685305 
5573 HET 1wk 9.0N Loaded 3.1385 
5523 WT 2wk 9.0N Control 0.501446 
5566 WT 2wk 9.0N Control 0.528736 
5523 WT 2wk 9.0N Loaded 1.262565 
5563 WT 2wk 9.0N Loaded 0.47223 
5566 WT 2wk 9.0N Loaded 6.531734 
5549 WT 2wk 9.0N Loaded 1.722938 
5520 HET 2wk 9.0N Control 1.692745 
5551 HET 2wk 9.0N Control 2.388889 
5520 HET 2wk 9.0N Loaded 0.236063 
5550 HET 2wk 9.0N Loaded 1.602997 
5551 HET 2wk 9.0N Loaded 3.855533 
5553 HET 2wk 9.0N Loaded 0.423343 
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Discoidin Domain Receptor (DDR)-2 Immunostaining: DDR-2 levels in articular 
cartilage of the medial tibial plateau determined by immunohistochemistry with anti-
DDR2 antibodies. DDR-2 levels reported as percentage of positive immunostaining 
per cartilage area. 
 
ID Genotype Duration Magnitude Limb 
Percent DDR2 
per Cartilage Area 
5578 WT 1wk 9.0N Control 0.094971 
5572 WT 1wk 9.0N Control 2.596529 
5570 WT 1wk 9.0N Control 0.23227 
5578 WT 1wk 9.0N Loaded 3.90657 
5572 WT 1wk 9.0N Loaded 0.371918 
5570 WT 1wk 9.0N Loaded 1.138243 
5564 HET 1wk 9.0N Control 0.470486 
5573 HET 1wk 9.0N Control 0.081419 
5569 HET 1wk 9.0N Control 3.710968 
5564 HET 1wk 9.0N Loaded 1.320071 
5573 HET 1wk 9.0N Loaded 2.181808 
5569 HET 1wk 9.0N Loaded 0.208747 
5519 WT 2wk 9.0N Control 1.994681 
5566 WT 2wk 9.0N Control 0.206309 
5549 WT 2wk 9.0N Control 0.047784 
5519 WT 2wk 9.0N Loaded 0.098778 
5566 WT 2wk 9.0N Loaded 1.582475 
5549 WT 2wk 9.0N Loaded 1.626953 
5482 HET 2wk 9.0N Control 7.455687 
5551 HET 2wk 9.0N Control 2.272 
5553 HET 2wk 9.0N Control 1.095361 
5482 HET 2wk 9.0N Loaded 0.087044 
5551 HET 2wk 9.0N Loaded 0.749114 
5553 HET 2wk 9.0N Loaded 0.010569 
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Chondrocyte apoptosis: Chondrocyte apoptosis determined by TUNEL assay in 
articular cartilage in the medial tibial plateau. Chondrocyte apoptosis reported as 
percent positive TUNEL staining per DAPI area. 
 
ID Genotype Duration Magnitude Limb 
Percent TUNEL 
per DAPI Area 
5578 WT 1wk 9.0N control 0.091463 
5579 WT 1wk 9.0N control 0.85443 
5572 WT 1wk 9.0N control 0.626374 
5578 WT 1wk 9.0N loaded 0.367647 
5576 WT 1wk 9.0N loaded 1.13913 
5579 WT 1wk 9.0N loaded 2.449275 
5571 WT 1wk 9.0N loaded 1.679245 
5572 WT 1wk 9.0N loaded 1.736364 
5570 WT 1wk 9.0N loaded 0.066116 
5574 HET 1wk 9.0N control 1.506944 
5573 HET 1wk 9.0N control 0.023077 
5569 HET 1wk 9.0N control 0 
5564 HET 1wk 9.0N loaded 0.666667 
5577 HET 1wk 9.0N loaded 0.431034 
5574 HET 1wk 9.0N loaded 2.945455 
5580 HET 1wk 9.0N loaded 1 
5573 HET 1wk 9.0N loaded 1.344262 
5569 HET 1wk 9.0N loaded 0.28169 
5519 WT 2wk 9.0N control 0.18239 
5523 WT 2wk 9.0N control 1.53211 
5566 WT 2wk 9.0N control 0.384058 
5519 WT 2wk 9.0N loaded 0.478632 
5521 WT 2wk 9.0N loaded 0.620253 
5523 WT 2wk 9.0N loaded 2.917647 
5563 WT 2wk 9.0N loaded 0.181818 
5566 WT 2wk 9.0N loaded 0.495413 
5549 WT 2wk 9.0N loaded 0.394737 
5482 HET 2wk 9.0N control 1.623288 
5520 HET 2wk 9.0N control 0.056818 
5551 HET 2wk 9.0N control 0.261538 
5482 HET 2wk 9.0N loaded 0.963768 
5483 HET 2wk 9.0N loaded 4.140496 
5520 HET 2wk 9.0N loaded 0.719512 
5550 HET 2wk 9.0N loaded 0.175926 
5551 HET 2wk 9.0N loaded 1.378378 
5553 HET 2wk 9.0N loaded 3.207547 
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Modified Mankin Score: Mankin scoring of articular cartilage measured by Safranin 
O/Fast Green stain for wildtype (WT) and cho/+ (HET) mice. Individual and average 
scores reported for articular cartilage in the medial and lateral tibial plateaus. 
 
ID Genotype Duration Magnitude Limb Medial Lateral Average 
5578 WT 1wk 9N control 4 4.222222 4.111111 
5576 WT 1wk 9N control 4.2 4.2 4.2 
5579 WT 1wk 9N control 3.111111 3.555556 3.333333 
5571 WT 1wk 9N control 2.333333 2.375 2.354167 
5572 WT 1wk 9N control 3 3.571429 3.285714 
5570 WT 1wk 9N control 2.6 3.2 2.9 
5519 WT 2wk 9N control 2.75 4.142857 3.446429 
5521 WT 2wk 9N control 3.375 4.222222 3.798611 
5523 WT 2wk 9N control 2.636364 3.454545 3.045455 
5563 WT 2wk 9N control 3.111111 4.222222 3.666667 
5566 WT 2wk 9N control 2.777778 3.25 3.013889 
5549 WT 2wk 9N control 2.888889 3.333333 3.111111 
5509 WT 6wk 9N control 4 4.625 4.3125 
5512 WT 6wk 9N control 3.545455 4.1 3.822727 
5513 WT 6wk 9N control 3.076923 3 3.038462 
5514 WT 6wk 9N control 2.363636 3.5 2.931818 
5515 WT 6wk 9N control 3.4 4.375 3.8875 
5517 WT 6wk 9N control 3.454545 4 3.727273 
5564 HET 1wk 9N control 3.888889 4.2 4.044444 
5577 HET 1wk 9N control 5.666667 5.142857 5.404762 
5574 HET 1wk 9N control 3.428571 4.166667 3.797619 
5580 HET 1wk 9N control 3.714286 3 3.357143 
5573 HET 1wk 9N control 4 3.75 3.875 
5569 HET 1wk 9N control 4.125 3.5 3.8125 
5482 HET 2wk 9N control 3.727273 4.5 4.113636 
5483 HET 2wk 9N control 4.090909 4.8 4.445455 
5520 HET 2wk 9N control 3.666667 3.75 3.708333 
5550 HET 2wk 9N control 3.444444 4.125 3.784722 
5551 HET 2wk 9N control 3.5 3.5 3.5 
5553 HET 2wk 9N control 4.666667 4.666667 4.666667 
5510 HET 6wk 9N control 4.333333 4.6 4.466667 
5511 HET 6wk 9N control 2.75 3.555556 3.152778 
5516 HET 6wk 9N control 3.818182 4 3.909091 
5530 HET 6wk 9N control 4.307692 4.2 4.253846 
5533 HET 6wk 9N control 2.714286 3.333333 3.02381 
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5525 HET 6wk 9N control 3.461538 3.75 3.605769 
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APPENDIX B: CHAPTER 3 DATA 
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Histological (OARSI) Score: OARSI scoring of articular cartilage damage measured 
by Safranin O/Fast Green stain. Each column corresponds to a slide separated at a 90 
μm interval. Scores reported for articular cartilage in the medial (M) and lateral (L) 
tibial plateaus. 
 
ID Group Plateau 1 7 13 19 25 31 37 43 49 55 61 67 73 79 85 91 Average Max 
B1L control M  0 0 0 0 1 0.5 1 0 0 0 0.5     0.272727 1 
  L 0.5 0.5 0.5 1 0 0 0 0.5         0.375 1 
B2L control M  0 0 0 0 0 0 0.5 1 0.5 0 0.5     0.227273 1 
  L 0 0.5 1 1 0.5 1 1 0 0 0.5       0.55 1 
B3L control M  0 0 0 0 0 0 1 0 1 0 0     0.181818 1 
  L 0 0.5 0.5 0.5 0 0 0 0 0        0.166667 0.5 
F1R control M  0 0.5 0 0 0 1 1 2 0 0 0.5 0    0.416667 2 
  L 0 1 2 1 1 1 1  0 0 0.5      0.75 2 
F2R control M 0.5 0 0 0 0 0.5 1 0.5 1 0 0 0.5     0.333333 1 
  L 0 2 2 2 2 0.5 0.5 1 0 0 0.5      0.954545 2 
B1R saline M    0.5 0.5 0 0 0 0 0 0.5 0 0.5 0   0.181818 0.5 
  L   3 0.5 0 1 0.5 0 0.5 0 0.5 0     0.6 3 
B2R saline M  0.5 0 0 0 0 0 0 0.5 0.5 0 0.5     0.181818 0.5 
  L   0.5 3 1 0.5 0.5 2 0.5 0 0 0     0.8 3 
B3R saline M    5 5 4 4 1 0 0 0 0 0 0.5   1.772727 5 
  L    3 1 0 1 0.5 0.5 0 0 0.5     0.722222 3 
F1L saline M    6 5 5 5 6 5 3 0 2 0 0 0  3.083333 6 
  L    6 5 4 2 1 0.5 0.5 1 0.5 0 0   1.863636 6 
F2L saline M      5 5 5 5 4 3 2 0 0.5   3.277778 5 
  L    5 4 2 2 1 0.5 0.5 0.5 0     1.722222 5 
D1R bolus M    4 4 4 3 3 0 0 0.5 0 0.5    1.9 4 
  L     4 1 2 0.5 0 0 0.5 0 0    0.888889 4 
D2R bolus M        5 5 4 4 3 3 2 1 0 3 5 
  L     3 4 3 3 2 1 1 1 0    2 4 
D3R bolus M   6 6 2 0 0 0 0 0 0 0 0.5    1.318182 6 
  L  0 0 0.5 1 0.5 0.5 0 0 0 0      0.25 1 
H1L bolus M      4 4 3 0.5 0 0 0 0 0 0.5 0 1.090909 4 
  L    3 2 0.5 0.5 0 0.5 0 0 0.5     0.777778 3 
H2L bolus M     5 5 5 4 2 1 2 0 0.5 0   2.45 5 
  L  6 4 2 1 1 2 2 0.5 0.5       2.111111 6 
C1R NPs M      5 5 4 4 3 2 2     3.571429 5 
  L   0.5 4 3 2 1 0.5 0.5 0.5 0.5 0     1.25 4 
C2R NPs M   5 5 2 0 0 0 0 0 0.5 0 0.5    1.181818 5 
  L      6 2 2 0 0 0.5 1 0.5    1.5 6 
C3R NPs M  5 4 4 4 3 3 0 0.5 0.5 0 0.5     2.227273 5 
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  L 4 3 1 2 1 1 1 0 0        1.444444 4 
G1L NPs M    5 5 4 3 3 0 0 0 0 0 0 0.5  1.708333 5 
  L   2 2 2 2 0 1 1 1 0 0     1.1 2 
G2L NPs M      5 5 5 4 3 3 2 0 0.5 0.5  2.8 5 
  L   3 3 2 2 0.5 0.5 0.5 0.5       1.5 3 
A1R gel+NPs M  2 3 0 0 0 0 0 0.5 0.5 0.5 0.5 0    0.583333 3 
  L   0 0 0.5 0.5 0.5 0.5 1 0.5 0.5 0.5     0.45 1 
A2R gel+NPs M       6 6 5 2 0 0 0.5 0 0.5  2.222222 6 
  L        6 4 1 2 1 0 0.5 0.5  1.875 6 
A3R gel+NPs M   0.5 0 0 0 0 0 0 0 0 0.5 0 0   0.083333 0.5 
  L 0.5 0 0 0.5 0.5 0.5 1 0 0.5 0       0.35 1 
E1L gel+NPs M     4 4 3 3 2 0 0 0.5 0.5 0.5   1.75 4 
  L 3 2 0.5 1 0 0.5 0.5 0         0.9375 3 
E2L gel+NPs M  4 3 0 0 0.5 0 0 0.5 0.5       0.944444 4 
  L      2 2 0.5 1 0 0 1 1    0.9375 2 
I1R gel only M    6 5 4 0.5 0 0 0.5 0 0 0.5    1.65 6 
  L   4 2 2 2 0.5 0.5 1 0 0.5 0     1.25 4 
I2R gel only M      0.5 0 0 0 0 0 1 5 6   1.388889 6 
  L  0 0 0.5 0 1 0 0.5 2 0 4      0.8 4 
I3R gel only M 3 0 0 0.5 0 0 0 0.5 0 0.5 0.5 0     0.416667 3 
  L  3 0.5 1 1 0.5 0.5 1 0.5 0.5 0 0     0.772727 3 
G4L gel only M       0 0 0 0 0 0 0.5 0.5 0.5  0.166667 0.5 
  L   3 2 1 1 0.5 0.5 0 0.5 0.5      1 3 
H4L gel only M     3 0 0 0 0.5 1 0 0.5 0.5    0.611111 3 
  L   3 2 2 2 0.5 1 1 2 0.5 0.5     1.45 3 
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Osteophyte Measurements: Osteophyte size and maturity (mat) measured by 
Safranin O/Fast Green stain. Size reported as absolute width (μm); maturity reported 
on a scale of 0 to 3. Measurements reported for osteophytes in the posterior (post), 
middle (mid), and anterior (ant) regions of the medial (M) tibial plateau, and average 
(avg) of all three regions. 
 
      post  mid  ant  avg  
ID Group Plateau post mid ant Size Mat Size Mat Size Mat Size Mat 
B1L control M 13 37 61 0 0 0 0 0 0 0 0 
B2L control M 13 37 61 0 0 0 0 0 0 0 0 
B3L control M 13 37 61 0 0 0 0 0 0 0 0 
F1R control M 13 37 67 0 0 0 0 0 0 0 0 
F2R control M 7 31 61 0 0 0 0 0 0 0 0 
B1R saline M 25 49 73 248.3 1 225.4 1 210.7 2 228.1333 1.333333 
B2R saline M 13 37 61 43.9 1 81.4 1 62.9 1 62.73333 1 
B3R saline M 25 49 73 454.2 1 286 1 160.8 2 300.3333 1.333333 
F1L saline M 25 49 79 498.7 1 413.3 1 309.9 2 407.3 1.333333 
F2L saline M 37 55 73 386 1 344.3 1 335.9 2 355.4 1.333333 
D1R bolus M 25 43 67 221.2 1 175.3 1 96.1 1 164.2 1 
D2R bolus M 49 67 85 391.8 1 367.3 1 358.9 1 372.6667 1 
D3R bolus M 19 43 67 277.5 1 288.2 1 219.1 1 261.6 1 
H1L bolus M 37 61 85 296.4 1 232.2 2 208.7 1 245.7667 1.333333 
H2L bolus M 31 49 73 248.3 1 237.9 1 180.4 1 222.2 1 
C1R NPs M 37 49 61 309.8 1 248.3 1 240.1 1 266.0667 1 
C2R NPs M 19 43 67 196.2 1 171.2 2 0 0 122.4667 1 
C3R NPs M 13 37 61 286 1 306.7 1 240 1 277.5667 1 
G1L NPs M 25 49 79 233.7 1 156.5 1 31.3 1 140.5 1 
G2L NPs M 37 55 79 415.6 1 277.2 1 429.9 2 374.2333 1.333333 
A1R gel+NPs M 13 43 67 194.5 1 81.5 1 0 0 92 0.666667 
A2R gel+NPs M 43 61 79 202.6 1 175.3 2 200.3 2 192.7333 1.666667 
A3R gel+NPs M 19 49 73 110.6 1 52.2 1 0 0 54.26667 0.666667 
E1L gel+NPs M 31 49 73 211 1 150.4 1 225.4 2 195.6 1.333333 
E2L gel+NPs M 13 31 49 81.5 1 233.8 2 35.5 1 116.9333 1.333333 
I1R gel only M 25 43 67 356.8 1 273.5 1 211 1 280.4333 1 
I2R gel only M 73 55 37 400.7 1 210.9 2 113.2 2 241.6 1.666667 
I3R gel only M 7 31 61 136.3 1 59.9 2 62.6 1 86.26667 1.333333 
G4L gel only M 43 61 79 121.3 1 185.7 1 200.3 2 169.1 1.333333 
H4L gel only M 31 49 67 41.7 1 102.2 1 194.1 2 112.6667 1.333333 
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Synovitis Scoring: Synovitis scores reflecting thickness and cell density of the 
synovium measured by Safranin O/Fast Green stain. Measurements reported for 
synovium in the posterior (post), middle (mid), and anterior (ant) regions of the medial 
(M) tibial plateau, and average (avg) of all three regions. 
 
ID Group Plateau post mid ant post mid ant avg 
B1L control M 13 37 61 1 0 2 1 
B2L control M 13 37 61 1 1 0 0.666667 
B3L control M 13 37 61 0 0 0 0 
F1R control M 13 37 67 1 1 0 0.666667 
F2R control M 7 31 61 0 0 0 0 
B1R saline M 25 49 73 2 3 5 3.333333 
B2R saline M 13 37 61  2 5 3.5 
B3R saline M 25 49 73 4 4 3 3.666667 
F1L saline M 25 49 79 4 3 4 3.666667 
F2L saline M 37 55 73 5 5  5 
D1R bolus M 25 43 67 4 2 1 2.333333 
D2R bolus M 49 67 85 3 5 4 4 
D3R bolus M 19 43 67  3 5 4 
H1L bolus M 37 61 85  3 4 3.5 
H2L bolus M 31 49 73 5 4 3 4 
C1R NPs M 37 49 61 2 5 3 3.333333 
C2R NPs M 19 43 67 5 5 3 4.333333 
C3R NPs M 13 37 61 5 5 5 5 
G1L NPs M 25 49 79 3 5 5 4.333333 
G2L NPs M 37 55 79 5 4 4 4.333333 
A1R gel+NPs M 13 43 67 5 4 5 4.666667 
A2R gel+NPs M 43 61 79 3 4 4 3.666667 
A3R gel+NPs M 19 49 73 3 2  2.5 
E1L gel+NPs M 31 49 73 5 5 4 4.666667 
E2L gel+NPs M 13 31 49 4 3 4 3.666667 
I1R gel only M 25 43 67 4 3 3 3.333333 
I2R gel only M 73 55 37     
I3R gel only M 7 31 61 3 3  3 
G4L gel only M 43 61 79 2 3 4 3 
H4L gel only M 31 49 67 3 4 4 3.666667 
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Particle Release and Mechanical Properties of Hydrogels following In Vitro 
Dynamic Cyclic Compression: Particle release measured by flow cytometry. Storage 
and loss modulus (Pa) measured by rheometry. 
 
Gel ID PEG-MAL wt% Loading Condition % Particle Release Storage Modulus Loss Modulus 
1 2.50% Control 31 109.5685 7.10443 
2 2.50% Control 1 234.09575 10.521875 
3 2.50% Control 5 205.06125 19.411 
4 2.50% Control 0 219.99925 8.0105225 
5 2.50% Control 0 151.633 6.1430225 
6 2.50% Control 9 107.9185 3.2986025 
7 5% Control 0 1793.5225 56.125275 
8 5% Control 0 780.268 37.3024 
9 5% Control 0 1066.3 52.4038 
10 5% Control 0 651.68375 47.6812 
11 5% Control 0 439.9895 22.84645 
12 5% Control 0 443.216 27.06755 
13 10% Control 0 1934.3025 62.281725 
14 10% Control 0 1944.8275 77.077275 
15 10% Control 0 1531.13 61.057725 
16 10% Control 3 1054.2125 121.31625 
17 10% Control 0 782.673 49.832575 
18 10% Control 22 1191.08 73.99235 
19 20% Control 1 860.909 501.694 
20 20% Control 0 1390.175 499.60025 
21 20% Control 0 1125.11 494.10725 
22 20% Control 0 1296.735 400.52125 
23 20% Control 0 2422.695 1228.165 
24 20% Control 0 765.08075 312.866 
25 2.50% 20% Strain 16 361.5945 25.670525 
26 2.50% 20% Strain 15 262.497 13.038625 
27 2.50% 20% Strain 21 264.475 10.848475 
28 2.50% 20% Strain 29 184.1305 9.1982275 
29 2.50% 20% Strain 39 176.25875 9.2238275 
30 2.50% 20% Strain 36 148.66275 6.9662575 
31 5% 20% Strain 3 766.79325 36.0171 
32 5% 20% Strain 8 647.32275 24.33475 
33 5% 20% Strain 2 845.3625 31.95695 
34 5% 20% Strain 5 306.24075 9.4040775 
35 5% 20% Strain 15 568.49 27.00565 
36 5% 20% Strain 14 482.4935 22.748025 
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37 10% 20% Strain 9 1205.14 128.42025 
38 10% 20% Strain 0 1378.545 75.829375 
39 10% 20% Strain 4 1818.915 71.967125 
40 10% 20% Strain 11 1980.9825 77.669725 
41 10% 20% Strain 13 1232.0825 52.697625 
42 10% 20% Strain 9 1048.82 63.419125 
43 20% 20% Strain 0 684.71525 433.7 
44 20% 20% Strain 0 1897.7425 551.4145 
45 20% 20% Strain 0 3632.6475 683.171 
46 20% 20% Strain 0 2496.5 224.682 
47 20% 20% Strain 1 2020.0825 1040.1 
48 20% 20% Strain 0 3386.8775 302.87775 
49 2.50% 40% Strain 26 150.731 6.4832325 
50 2.50% 40% Strain 12 239.00925 11.47355 
51 2.50% 40% Strain 18 194.2005 11.6767 
52 2.50% 40% Strain 12 184.763 10.12335 
53 2.50% 40% Strain 36 173.298 7.896695 
54 2.50% 40% Strain 26 129.11175 7.69943 
55 5% 40% Strain 0 1941.3925 144.70975 
56 5% 40% Strain 27 1219.0275 33.491775 
57 5% 40% Strain 20 410.33075 19.937575 
58 5% 40% Strain 27 427.542 30.25605 
59 5% 40% Strain 0 1062.085 42.14945 
60 5% 40% Strain 0 620.186 28.726525 
61 10% 40% Strain 0 2256.8325 414.394 
62 10% 40% Strain 0 1478.07 145.9215 
63 10% 40% Strain 23 1609.4175 106.78125 
64 10% 40% Strain 0 1744.3775 147.10525 
65 10% 40% Strain 27 1416.145 235.47025 
66 10% 40% Strain 23 1630.5775 129.11025 
67 20% 40% Strain 34 1937.65 886.56075 
68 20% 40% Strain 21 1762.9675 712.3045 
69 20% 40% Strain 35 1135.3375 424.41925 
70 20% 40% Strain 12 3108.75 414.6015 
71 20% 40% Strain 1 2391.4575 1005.51825 
72 20% 40% Strain 0 1928.5125 664.98175 
73 2.50% 80% Strain 56 137.8735 10.3264375 
74 2.50% 80% Strain 87 119.11625 4.5019475 
75 2.50% 80% Strain 73 57.488 2.4981525 
76 2.50% 80% Strain 59 135.575 4.4262775 
  195 
77 2.50% 80% Strain 58 179.5685 6.3305125 
78 2.50% 80% Strain 44 93.6641 4.6108425 
79 5% 80% Strain 45 615.432 42.38195 
80 5% 80% Strain 59 532.34575 26.991475 
81 5% 80% Strain 68 625.95375 18.56935 
82 5% 80% Strain 69 555.031 21.80035 
83 5% 80% Strain 55 513.10125 28.9666 
84 5% 80% Strain 37 529.93025 24.592425 
85 10% 80% Strain 45 1309.305 184.36275 
86 10% 80% Strain 34 996.1095 58.632775 
87 10% 80% Strain 43 1138.96 189.702 
88 10% 80% Strain 15 1047.7125 61.315175 
89 10% 80% Strain 44 1543.6125 81.6793 
90 10% 80% Strain 28 774.38925 55.97795 
91 20% 80% Strain 40 2588.6925 205.7315 
92 20% 80% Strain 39 1809.9475 207.71225 
93 20% 80% Strain 46 1119.655 325.2665 
94 20% 80% Strain 78 1934.78 346.9705 
95 20% 80% Strain 58 2231.435 121.0615 
96 20% 80% Strain 67 2332.8425 234.938 
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Hydrogel Mass Changes and Swelling Ratio: Daily changes in hydrogel mass (g) in 
excess PBS and corresponding swelling ratios compared to initial mass. 
 
Sample 
# 
PEG-MAL 
wt% 
Outcome 
Day 
0 
Day 
1 
Day 
2 
Day 
3 
Day 
4 
Day 
5 
Day 
6 
Day 
7 
Day 
8 
Day 
9 
Day 
10 
Day 
16 
1 2.50% Mass 38.5 46.7 46.7 47.2 47 48.8 46.6 46.7 44.7 44 41.9 38.5 
2 2.50% Mass 32 44.8 42.9 43.6 42.9 43.4 44.1 45.4 44.8 26.9 23.2 21.9 
3 2.50% Mass 36.4 47 44.5 43.5 44 43.9 43 46.9 46.8 42 36.4 29.5 
4 2.50% Mass 40.7 49 52.2 53.6 51.4 50.2 51.5 50.1 54.1 39 37.9 35.3 
5 2.50% Mass 31.2 36.8 39.5 34.1 34.6 31.2 35.7 34.8 32.9 34.7 30.7 30.8 
6 2.50% Mass 37.6 31.7 33 32.7 32.8 32.6 32.6 32.8 25.8 25.1 23.5 24.5 
1 5% Mass 39.6 63.7 69.2 69.5 73.1 76.4 69.1 69.1 77.7 70.6 78.9 72.2 
2 5% Mass 40.6 80.6 80.3 75.1 82.3 79.8 83.6 80.7 86.7 85.4 83.2 82.7 
3 5% Mass 42.6 72.9 77.7 83.5 88.2 83.9 84.4 85.8 81.9 84.2 78.8 76.5 
4 5% Mass 40.9 68.1 68.5 70.8 73.4 74.6 74.9 76.1 74.5 73 72.4 62.6 
5 5% Mass 42.7 77.4 78 78.9 82.1 78.6 90.5 85.5 81.4 83.1 85.1 76.4 
6 5% Mass 39.5 70.2 72.5 72.2 69.6 70.5 71.3 72.3 72.1 70.4 70.4 65.6 
1 10% Mass 37.1 99.3 
107.
4 
112.
6 
115.
3 
108 
118.
8 
127.
6 
109.
1 
120.
5 
124.5 116.9 
2 10% Mass 39.9 99.5 
105.
8 
103.
4 
117 
109.
4 
111.
8 
113.
8 
115.
4 
118.
1 
126 117.4 
3 10% Mass 39.2 
111.
6 
115.
1 
124.
8 
121.
1 
122.
1 
131.
6 
128.
7 
122.
2 
126.
6 
123.7 121.2 
4 10% Mass 43.7 88.1 
103.
2 
101.
9 
102.
6 
103.
8 
105.
5 
115 
114.
8 
112.
9 
106.6 105.6 
5 10% Mass 42.9 98.3 
102.
4 
104.
7 
101.
8 
106.
1 
108.
8 
106.
2 
106.
6 
110.
1 
100.6 104.4 
6 10% Mass 41.4 94.8 
107.
8 
99.7 
106.
7 
105.
7 
105.
3 
105.
7 
105.
1 
107.
8 
93.4 95.8 
1 20% Mass 39.1 
128.
7 
144.
7 
151.
3 
154.
5 
154.
9 
151.
1 
150.
3 
147.
4 
152.
5 
149.6 174.4 
2 20% Mass 40 
123.
2 
154.
7 
134.
8 
139.
1 
148 155 
155.
1 
139 
148.
1 
161.9 149.5 
3 20% Mass 41.5 
141.
1 
159.
4 
152.
7 
158.
3 
149.
2 
159.
1 
166.
1 
165.
7 
170.
8 
170.9 169.2 
4 20% Mass 38.8 
136.
4 
153.
5 
151.
1 
138.
5 
152.
5 
146.
1 
146.
5 
147.
5 
145.
9 
152.7 166.8 
5 20% Mass 40.6 
151.
5 
168.
1 
154.
6 
154.
4 
166.
8 
153.
2 
159.
3 
166.
4 
148.
3 
168.4 153.2 
6 20% Mass 42.1 
131.
5 
166.
8 
174.
2 
170.
5 
170.
4 
167.
1 
166.
1 
169.
1 
181.
9 
183.8 178 
1 2.50% 
Swelling 
Ratio 
100.
0 
121.
3 
121.
3 
122.
6 
122.
1 
126.
8 
121.
0 
121.
3 
116.
1 
114.
3 
108.8 100.0 
2 2.50% 
Swelling 
Ratio 
100.
0 
140.
0 
134.
1 
136.
3 
134.
1 
135.
6 
137.
8 
141.
9 
140.
0 
84.1 72.5 68.4 
3 2.50% 
Swelling 
Ratio 
100.
0 
129.
1 
122.
3 
119.
5 
120.
9 
120.
6 
118.
1 
128.
8 
128.
6 
115.
4 
100.0 81.0 
4 2.50% 
Swelling 
Ratio 
100.
0 
120.
4 
128.
3 
131.
7 
126.
3 
123.
3 
126.
5 
123.
1 
132.
9 
95.8 93.1 86.7 
5 2.50% 
Swelling 
Ratio 
100.
0 
117.
9 
126.
6 
109.
3 
110.
9 
100.
0 
114.
4 
111.
5 
105.
4 
111.
2 
98.4 98.7 
6 2.50% 
Swelling 
Ratio 
100.
0 
84.3 87.8 87.0 87.2 86.7 86.7 87.2 68.6 66.8 62.5 65.2 
1 5% 
Swelling 
Ratio 
100.
0 
160.
9 
174.
7 
175.
5 
184.
6 
192.
9 
174.
5 
174.
5 
196.
2 
178.
3 
199.2 182.3 
2 5% 
Swelling 
Ratio 
100.
0 
198.
5 
197.
8 
185.
0 
202.
7 
196.
6 
205.
9 
198.
8 
213.
5 
210.
3 
204.9 203.7 
  197 
3 5% 
Swelling 
Ratio 
100.
0 
171.
1 
182.
4 
196.
0 
207.
0 
196.
9 
198.
1 
201.
4 
192.
3 
197.
7 
185.0 179.6 
4 5% 
Swelling 
Ratio 
100.
0 
166.
5 
167.
5 
173.
1 
179.
5 
182.
4 
183.
1 
186.
1 
182.
2 
178.
5 
177.0 153.1 
5 5% 
Swelling 
Ratio 
100.
0 
181.
3 
182.
7 
184.
8 
192.
3 
184.
1 
211.
9 
200.
2 
190.
6 
194.
6 
199.3 178.9 
6 5% 
Swelling 
Ratio 
100.
0 
177.
7 
183.
5 
182.
8 
176.
2 
178.
5 
180.
5 
183.
0 
182.
5 
178.
2 
178.2 166.1 
1 10% 
Swelling 
Ratio 
100.
0 
267.
7 
289.
5 
303.
5 
310.
8 
291.
1 
320.
2 
343.
9 
294.
1 
324.
8 
335.6 315.1 
2 10% 
Swelling 
Ratio 
100.
0 
249.
4 
265.
2 
259.
1 
293.
2 
274.
2 
280.
2 
285.
2 
289.
2 
296.
0 
315.8 294.2 
3 10% 
Swelling 
Ratio 
100.
0 
284.
7 
293.
6 
318.
4 
308.
9 
311.
5 
335.
7 
328.
3 
311.
7 
323.
0 
315.6 309.2 
4 10% 
Swelling 
Ratio 
100.
0 
201.
6 
236.
2 
233.
2 
234.
8 
237.
5 
241.
4 
263.
2 
262.
7 
258.
4 
243.9 241.6 
5 10% 
Swelling 
Ratio 
100.
0 
229.
1 
238.
7 
244.
1 
237.
3 
247.
3 
253.
6 
247.
6 
248.
5 
256.
6 
234.5 243.4 
6 10% 
Swelling 
Ratio 
100.
0 
229.
0 
260.
4 
240.
8 
257.
7 
255.
3 
254.
3 
255.
3 
253.
9 
260.
4 
225.6 231.4 
1 20% 
Swelling 
Ratio 
100.
0 
329.
2 
370.
1 
387.
0 
395.
1 
396.
2 
386.
4 
384.
4 
377.
0 
390.
0 
382.6 446.0 
2 20% 
Swelling 
Ratio 
100.
0 
308.
0 
386.
8 
337.
0 
347.
8 
370.
0 
387.
5 
387.
8 
347.
5 
370.
3 
404.8 373.8 
3 20% 
Swelling 
Ratio 
100.
0 
340.
0 
384.
1 
368.
0 
381.
4 
359.
5 
383.
4 
400.
2 
399.
3 
411.
6 
411.8 407.7 
4 20% 
Swelling 
Ratio 
100.
0 
351.
5 
395.
6 
389.
4 
357.
0 
393.
0 
376.
5 
377.
6 
380.
2 
376.
0 
393.6 429.9 
5 20% 
Swelling 
Ratio 
100.
0 
373.
2 
414.
0 
380.
8 
380.
3 
410.
8 
377.
3 
392.
4 
409.
9 
365.
3 
414.8 377.3 
6 20% 
Swelling 
Ratio 
100.
0 
312.
4 
396.
2 
413.
8 
405.
0 
404.
8 
396.
9 
394.
5 
401.
7 
432.
1 
436.6 422.8 
 
  
  198 
APPENDIX C: CHAPTER 4 DATA   
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Histological (OARSI) Score: OARSI scoring of articular cartilage damage measured 
by Safranin O/Fast Green stain. Each column corresponds to a slide separated at a 90 
μm interval. Scores reported for articular cartilage in the medial (M) and lateral (L) 
tibial plateaus. 
 
Mouse ID Group Duration Plateau 1 7 13 19 25 31 37 43 49 55 61 67 73 79 85 91 97 103 109 Avg Max 
K1L control +0-weeks M    0 0 0 0 0 1 0 0 0        0.111 1 
   L  0 0 0.5 0.5 0 0.5 0            0.214 0.5 
K2L control +0-weeks M 0 0 0 0 0.5 0 0 0 0           0.056 0.5 
   L  0 0 1 0.5 0 0 0 0 0 0         0.150 1 
K3L control +0-weeks M 0 0 0 0 0 0 0.5 0 0 0 0.5         0.091 0.5 
   L 0 0 0.5 0.5 0.5 1 0.5 0 0 0          0.300 1 
N1L control +0-weeks M     0 0 0 0 0 0 0 0 0 0 0.5     0.045 0.5 
   L  0 0.5 0.5 0.5 0.5 0 0.5 0           0.313 0.5 
N2L control +0-weeks M   0 0 0 0 0 0 0.5 0 0 0 0.5       0.091 0.5 
   L  0 0 0 0.5 0 0 0.5 0 0          0.111 0.5 
N3L control +0-weeks M  0 0 0 0 0 0.5 0 0 0 0.5         0.100 0.5 
   L  0 0 0.5 1 1 0.5 0 0 0          0.333 1 
O1L control +0-weeks M   0 0 0 0 0 0.5 0 0 0 0 0.5       0.091 0.5 
   L 0.5 0.5 0 0.5 0 0 0 0 0           0.167 0.5 
K1R DMM-only +0-weeks M    0 0 0 0 0 0 0 0 0 0       0.000 0 
   L 0 0 0 0 0 0 0             0.000 0 
K2R DMM-only +0-weeks M   0 0 0 0 0.5 0.5 0 2 2 0        0.500 2 
   L 1 0.5 0.5 0 0 0 0             0.286 1 
K3R DMM-only +0-weeks M  0 0 0 0 0 0 0.5 1 0.5 1 0.5        0.318 1 
   L 0 0 1 0 0 0 0 0.5 0 0.5          0.200 1 
N1R DMM-only +0-weeks M 0 0 0 0 0 0 0 0 0 0 0.5         0.045 0.5 
   L  0 0 0.5 0.5 0.5 0 0 0 0.5          0.222 0.5 
N2R DMM-only +0-weeks M   0 0 0 0 0 0.5 0 0 0.5 0.5        0.150 0.5 
   L 0 0 0 0 0.5 1 0 0 0           0.167 1 
N3R DMM-only +0-weeks M  0 0 0 0 0 0.5 0.5 0 0 0 0        0.091 0.5 
   L   0 0.5 0.5 0 0.5 0 0 0 0         0.167 0.5 
O1R DMM-only +0-weeks M   0 0 0 0 0 0 0 0.5 0 2 2       0.409 2 
   L   2 2 0.5 0.5 0 0 0 0          0.625 2 
J1L control +2-weeks M   0 0 0 0 0 0.5 1 0.5 0 0.5 0.5       0.273 1 
   L 0 0 1 0.5 0.5 0 0 0 0           0.222 1 
J2L control +2-weeks M    0 0 0 0 0.5 0.5 0.5 0.5 0 0.5 0.5      0.273 0.5 
   L 0 0 2 1 1 0.5 0.5 0.5 2 0.5          0.800 2 
J3L control +2-weeks M  0 0 0 0 0 0.5 2 1 0.5 0 0        0.364 2 
  200 
   L 1 1 1 1 1 0 0             0.714 1 
P1L control +2-weeks M   0 0 0 0 0 0.5 0.5 0.5 0 0        0.150 0.5 
   L   0.5 1 0.5 0 0 0 0 0          0.250 1 
P2L control +2-weeks M  0 0 0 0 0 0.5 0.5 0 0 0         0.100 0.5 
   L  0.5 0.5 0.5 0.5 0 0 0 0           0.250 0.5 
P3L control +2-weeks M 0 0 0 0.5 0.5 0.5 0 0 0           0.167 0.5 
   L  0 0.5 0.5 0.5 0 0 0 0           0.188 0.5 
O3L control +2-weeks M  0 0 0 0 0 2 0.5 0 0 0         0.250 2 
   L  0.5 1 0 0 0.5 0.5 0 0 0          0.278 1 
J1R DMM-only +2-weeks M       0 0 0 1 0 0.5 0.5 2 0     0.444 2 
   L   0 1 0.5 2 0 0 0           0.500 2 
J2R DMM-only +2-weeks M   0 0 0 0 1 0.5 0.5 0.5 0.5 2        0.500 2 
   L 0 0 1 1 1 0 2 0            0.625 2 
J3R DMM-only +2-weeks M     0 1 2 2 2 0.5 0 0.5        1.000 2 
   L  0 1 2 1 1 1 0            0.857 2 
P1R DMM-only +2-weeks M      0 0 0 1 0 0.5 0.5 0.5 0      0.278 1 
   L   0 0 1 0.5 0 1 0 0.5          0.375 1 
P2R DMM-only +2-weeks M     0 0 0 0 0 0 0.5 0.5 0.5       0.167 0.5 
   L  0 0 0.5 0.5 0 0.5 0 0           0.188 0.5 
P3R DMM-only +2-weeks M    0 0 0 0 0.5 0.5 0.5 1 0.5 1       0.400 1 
   L 0 0 0 0 1 1 0             0.286 1 
O3R DMM+1.0N +2-weeks M   0 0 2 1 1 1 2 2 2         1.222 2 
   L  0 1 1 0 0 0.5 0 0.5           0.375 1 
L1R DMM+1.0N +2-weeks M       0 0 0 0 0 0.5 0.5 0.5 0     0.167 0.5 
   L   0 0 0.5 0 1 0.5 0           0.286 1 
L2R DMM+1.0N +2-weeks M    0 0 0 0 0 0.5 0.5 0.5 0 0.5       0.200 0.5 
   L  0 0 0 0 0 0.5 0 0 0          0.056 0.5 
L3R DMM+1.0N +2-weeks M      0 0 0 0 0 0.5 0.5 0.5       0.188 0.5 
   L 0 0 0 0.5 1 0.5 0             0.286 1 
M1R DMM+1.0N +2-weeks M    0 0 0 0 0 0 0 0.5 0.5        0.111 0.5 
   L  0 0 1 0.5 1 0 1 0.5           0.500 1 
M2R DMM+1.0N +2-weeks M     0 0 0 0.5 0.5 0.5 0 0.5 1 0.5      0.350 1 
   L  0 0 0.5 0.5 0 0 0            0.143 0.5 
M3R DMM+1.0N +2-weeks M     0 0 0 0 0 0 1 0 0.5 0      0.150 1 
   L  0 0 0.5 0 0.5 0 0            0.143 0.5 
O2R DMM+1.0N +2-weeks M  0 0 0 0 1 2 1 2 0.5 0 2        0.773 2 
   L  0 1 1 0.5 0.5 0 0 0           0.375 1 
A1L control +6-weeks M  0 0 0 0 0.5 1 0.5 0 0 0 0.5        0.227 1 
  201 
   L   0.5 0.5 0.5 1 1 1 0 0          0.563 1 
A2L control +6-weeks M           0 0.5 0 0 0 0 0.5 1 0 0.222 1 
   L      0 0.5 1 0.5 0 0.5 0.5        0.429 1 
A3L control +6-weeks M  0 0 0 1 0.5 2 1 0 0 0 0        0.409 2 
   L  0 0 1 1 1 2 0 1 0          0.667 2 
I1L control +6-weeks M  0 0.5 0 2 1 0.5 1 0.5 0 0 0        0.500 2 
   L  0 0.5 0.5 0.5 0.5 2 2 0 0          0.667 2 
I2L control +6-weeks M  0 0.5 0 0.5 1 0.5 0 0.5 0 0 0 0       0.250 1 
   L  0 0 0.5 1 0.5 2 2 2 0 0         0.800 2 
I4L control +6-weeks M   0.5 0 1 0.5 0.5 0 0 0 0         0.278 1 
   L     0.5 0.5 0.5 1 0.5 0.5 0 0        0.438 1 
I5L control +6-weeks M 0 0 0 0 0.5 0.5 0.5 0 0           0.167 0.5 
   L  0.5 0.5 0.5 0.5 0.5 0 0 0           0.313 0.5 
A1R DMM-only +6-weeks M       0 0 0 0 1 2 1 3 2 2    1.100 3 
   L 0 0 1 1 1 1 2             0.857 2 
A2R DMM-only +6-weeks M 0 0 0 1 1 2 2 2 1 0.5 2 2        1.125 2 
   L 0 0 0 0.5 1 0.5 0.5 0 0 0          0.250 1 
A3R DMM-only +6-weeks M        0 0 0 2 2 1 3 3 2 2 0  1.364 3 
   L 0 2 2 0.5 2 2 0.5             1.286 2 
I1R DMM-only +6-weeks M  0 0 0 1 2 2 2 0.5 0.5 0.5 2        0.955 2 
   L  1 2 2 1 1 1 1 0           1.125 2 
I2R DMM-only +6-weeks M      0 0 1 1 2 3 3 2 1      1.444 3 
   L 0 1 0.5 0 2 2              0.917 2 
I4R DMM-only +6-weeks M    0 0 0 0.5 0.5 0.5 0.5 0.5 2        0.500 2 
   L   1 0.5 0.5 1 1 0            0.667 1 
I5R DMM-only +6-weeks M   0.5 0.5 0.5 0.5 0.5 2 1 1          0.813 2 
   L   0.5 1 1 2 0.5 1 0           0.857 2 
C1R DMM+1.0N +6-weeks M 0 0 0 0 0.5 0.5 0.5 0.5 0.5 1 0.5 0        0.333 1 
   L 0 0 1 0.5 0.5 0.5 0 0 0 0.5          0.300 1 
C2R DMM+1.0N +6-weeks M   0 0 0 0 0.5 0.5 2 2 2 1 0       0.727 2 
   L 2 0.5 0.5 0.5 0 0 0             0.500 2 
C3R DMM+1.0N +6-weeks M        0 0 0 0 0 0.5 0.5 0.5 0.5 0.5   0.250 0.5 
   L 0 0.5 2 2 1 1 2 0            1.063 2 
D1R DMM+1.0N +6-weeks M   0 0 0 0 0 0.5 0.5 2 0.5 0 0.5 0      0.333 2 
   L 0 0.5 0.5 0.5 0.5 1 0.5 0 0           0.389 1 
D2R DMM+1.0N +6-weeks M  0.5 0.5 0 0.5 0.5 0.5 0.5 0.5 1 2 2 1       0.792 2 
   L    0 0.5 1 1 1 1 0 0 0 0       0.450 1 
D3R DMM+1.0N +6-weeks M      0 0 0 1 0.5 0.5 0.5 0.5 0.5 0 0    0.318 1 
  202 
   L   0 1 2 0.5 0 1 0 0          0.563 2 
G1R DMM+1.0N +6-weeks M      0 0 0 0 0 0 0 0 0      0.000 0 
   L 0 1 1 2 0               0.800 2 
E1R DMM+2.0N +6-weeks M     0 1 0 0.5 0 2 0.5 0.5 0.5 0      0.500 2 
   L 0 1 0.5 1 0 0 0             0.357 1 
E2R DMM+2.0N +6-weeks M     0 0 0 0 1 2 0 0 0 0      0.300 2 
   L 2 0 0.5 1 0 0 0.5             0.571 2 
E3R DMM+2.0N +6-weeks M  0 0 0.5 1 1 2 2 2 2 2 2        1.318 2 
   L   0.5 1 0.5 0.5 0.5 2 2 0          0.875 2 
F1R DMM+2.0N +6-weeks M    0 0 0 0 1 0.5 0 0 0 0       0.150 1 
   L 0.5 0 0 1 1 2 0 0 0           0.500 2 
F2R DMM+2.0N +6-weeks M 0 0 0.5 1 2 0 0.5 0.5 0           0.500 2 
   L   0.5 0 2 2 0 0 0 0 0         0.500 2 
F3R DMM+2.0N +6-weeks M      0 0 0 0 0 0.5 1 0.5 0.5 2 0.5    0.455 2 
   L 0.5 0 0.5 1 0.5 0              0.417 1 
G2R DMM+2.0N +6-weeks M     0.5 0 0 0 0 0.5 0.5 0.5 0 0      0.200 0.5 
   L 0 0 0.5 0.5 0.5 0.5 0 0            0.250 0.5 
B1R DMM+4.5N +6-weeks M        0.5 0 0 0.5 0.5 0.5 1      0.429 1 
   L 1 0 0.5 0.5 0.5 0 0.5             0.429 1 
B2R DMM+4.5N +6-weeks M         0 0.5 0 0 0.5 2 0.5 2 2   0.833 2 
   L  2 3 0.5 1 0 0.5             1.167 3 
B3R DMM+4.5N +6-weeks M    0 0 0 1 1 1 2 2 2 1 0.5      0.955 2 
   L 2 2 2 1 2 1 0 0.5 0.5           1.222 2 
H1R DMM+4.5N +6-weeks M   0 0 0.5 0.5 0.5 0.5 1 0.5          0.438 1 
   L   0.5 0.5 0 0.5 0.5 0.5 0 0          0.313 0.5 
H2R DMM+4.5N +6-weeks M       0 0 0 0.5 0 2 2 1 2 2 0   0.864 2 
   L 3 2 2 1 1 0.5              1.583 3 
H3R DMM+4.5N +6-weeks M  0 0 0 0.5 0.5 0.5 2 2 2 1 1        0.864 2 
   L 0.5 0.5 1 1 2 0.5 2 0            0.938 2 
H4R DMM+4.5N +6-weeks M  0 1 0 0.5 0 0.5 1 1 2 2         0.800 2 
   L  0.5 1 0.5 2 2 2 0.5            1.214 2 
H5R DMM+4.5N +6-weeks M    0 0 0 0.5 1 0.5 1 0.5 2 0.5 0      0.545 2 
   L  3 0 2 0.5 1 1 0.5 0.5 0          0.944 3 
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Osteophyte Measurements: Osteophyte size and maturity (mat) measured by 
Safranin O/Fast Green stain. Size reported as absolute width (μm); maturity reported 
on a scale of 0 to 3. Measurements reported for osteophytes in the posterior, middle, 
and anterior regions of the medial tibial plateau, and average of all three regions. 
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Subchondral Bone Plate MicroCT Data: Subchondral bone plate thickness (Th) and 
tissue mineral density (TMD) in the medial (Med) and lateral (Lat) aspects of the tibial 
plateau. 
 
    Med  Lat  
Mouse ID Group Duration Limb 
Th 
(mm) 
TMD 
(mg HA/ccm) 
Th 
(mm) 
TMD 
(mg HA/ccm) 
K1 DMM-only +0-weeks control 0.107 868.5 0.098 873.4 
K2 DMM-only +0-weeks control 0.116 883.5 0.1 841.6 
K3 DMM-only +0-weeks control 0.111 889.8 0.097 876.6 
N1 DMM-only +0-weeks control 0.107 861.4 0.101 868.9 
N2 DMM-only +0-weeks control 0.108 895 0.098 856 
N3 DMM-only +0-weeks control 0.094 841.7 0.094 834.4 
O1 DMM-only +0-weeks control 0.114 891.6 0.098 852.5 
J1 DMM-only +2-weeks control 0.114 890 0.102 863.6 
J2 DMM-only +2-weeks control 0.118 903.9 0.1 891.5 
J3 DMM-only +2-weeks control 0.112 898.6 0.099 892.2 
P1 DMM-only +2-weeks control 0.108 900.9 0.096 872.6 
P2 DMM-only +2-weeks control 0.093 844.4 0.091 856.2 
P3 DMM-only +2-weeks control 0.099 886.9 0.094 864.8 
O3 DMM+1.0N +2-weeks control 0.117 898.4 0.101 884.1 
L1 DMM+1.0N +2-weeks control 0.108 879.4 0.097 849.2 
L2 DMM+1.0N +2-weeks control 0.103 869.7 0.088 861.4 
L3 DMM+1.0N +2-weeks control 0.099 857 0.09 868.1 
M1 DMM+1.0N +2-weeks control 0.096 858.5 0.086 843.6 
M2 DMM+1.0N +2-weeks control 0.1 852 0.091 849 
M3 DMM+1.0N +2-weeks control 0.088 836.6 0.102 869 
O2 DMM+1.0N +2-weeks control 0.107 899.6 0.095 874.1 
A1 DMM-only +6-weeks control 0.121 910.8 0.093 878.5 
A2 DMM-only +6-weeks control 0.122 912.3 0.103 879.5 
A3 DMM-only +6-weeks control 0.124 914.4 0.097 887.8 
I1 DMM-only +6-weeks control 0.111 893.4 0.101 892.7 
I2 DMM-only +6-weeks control 0.123 932.6 0.097 880.5 
I3 DMM-only +6-weeks control 0.101 885.9 0.087 868.2 
I4 DMM-only +6-weeks control 0.109 875.4 0.093 870.5 
I5 DMM-only +6-weeks control 0.098 848.2 0.09 863 
C1 DMM+1.0N +6-weeks control 0.107 868.4 0.088 862.3 
C2 DMM+1.0N +6-weeks control 0.106 895.1 0.088 873.9 
C3 DMM+1.0N +6-weeks control 0.099 872.8 0.082 859.4 
D1 DMM+1.0N +6-weeks control 0.097 860.5 0.089 879.9 
D2 DMM+1.0N +6-weeks control 0.106 892.2 0.095 899.2 
D3 DMM+1.0N +6-weeks control 0.106 870.7 0.088 862.7 
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G1 DMM+1.0N +6-weeks control 0.103 888.4 0.09 854.1 
E1 DMM+2.0N +6-weeks control 0.124 909 0.099 880.9 
E2 DMM+2.0N +6-weeks control 0.112 914.3 0.096 865 
E3 DMM+2.0N +6-weeks control 0.116 899.9 0.094 865.3 
F1 DMM+2.0N +6-weeks control 0.109 897.5 0.092 850.2 
F2 DMM+2.0N +6-weeks control 0.102 884.7 0.095 867.8 
F3 DMM+2.0N +6-weeks control 0.085 856.9 0.087 856.6 
G2 DMM+2.0N +6-weeks control 0.113 899.1 0.095 873.1 
B1 DMM+4.5N +6-weeks control 0.1 894.5 0.09 870.7 
B2 DMM+4.5N +6-weeks control 0.102 873.2 0.088 870.9 
B3 DMM+4.5N +6-weeks control 0.102 892.8 0.091 872.8 
H1 DMM+4.5N +6-weeks control 0.1 868.4 0.098 863.6 
H2 DMM+4.5N +6-weeks control 0.116 897.2 0.104 900.6 
H3 DMM+4.5N +6-weeks control 0.106 905.1 0.094 876.4 
H4 DMM+4.5N +6-weeks control 0.108 880.8 0.09 854.3 
H5 DMM+4.5N +6-weeks control 0.102 881.2 0.085 880.6 
K1 DMM-only +0-weeks DMM-treated 0.111 886.1 0.101 854.1 
K2 DMM-only +0-weeks DMM-treated 0.107 869.6 0.094 863.1 
K3 DMM-only +0-weeks DMM-treated 0.109 873.6 0.099 860.2 
N1 DMM-only +0-weeks DMM-treated 0.11 873.2 0.093 854 
N2 DMM-only +0-weeks DMM-treated 0.116 892.5 0.099 865 
N3 DMM-only +0-weeks DMM-treated 0.098 854.9 0.089 849.7 
O1 DMM-only +0-weeks DMM-treated 0.114 890.4 0.096 879.4 
J1 DMM-only +2-weeks DMM-treated 0.114 894.3 0.092 869.6 
J2 DMM-only +2-weeks DMM-treated 0.104 869.6 0.098 863.4 
J3 DMM-only +2-weeks DMM-treated 0.115 902.2 0.095 876.2 
P1 DMM-only +2-weeks DMM-treated 0.109 883 0.094 844.6 
P2 DMM-only +2-weeks DMM-treated 0.103 878 0.095 864.2 
P3 DMM-only +2-weeks DMM-treated 0.111 912.1 0.094 864.8 
O3 DMM+1.0N +2-weeks DMM-treated 0.125 926.5 0.099 884.2 
L1 DMM+1.0N +2-weeks DMM-treated 0.107 884.4 0.096 859.5 
L2 DMM+1.0N +2-weeks DMM-treated 0.107 881.1 0.088 851.3 
L3 DMM+1.0N +2-weeks DMM-treated 0.103 871.5 0.092 865.4 
M1 DMM+1.0N +2-weeks DMM-treated 0.109 894 0.087 865.4 
M2 DMM+1.0N +2-weeks DMM-treated 0.106 891.4 0.09 862.3 
M3 DMM+1.0N +2-weeks DMM-treated 0.098 864 0.085 843.2 
O2 DMM+1.0N +2-weeks DMM-treated 0.109 906.7 0.091 866.2 
A1 DMM-only +6-weeks DMM-treated 0.123 934.3 0.096 890 
A2 DMM-only +6-weeks DMM-treated 0.127 926.8 0.097 874.6 
A3 DMM-only +6-weeks DMM-treated 0.135 941.4 0.119 912.3 
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I1 DMM-only +6-weeks DMM-treated 0.133 931.2 0.099 887.9 
I2 DMM-only +6-weeks DMM-treated 0.123 940.3 0.111 904.9 
I3 DMM-only +6-weeks DMM-treated 0.117 924.2 0.093 875.9 
I4 DMM-only +6-weeks DMM-treated 0.119 898.8 0.098 866.5 
I5 DMM-only +6-weeks DMM-treated 0.11 903.9 0.098 882.7 
C1 DMM+1.0N +6-weeks DMM-treated 0.117 891.2 0.094 850 
C2 DMM+1.0N +6-weeks DMM-treated 0.111 913.7 0.103 881.2 
C3 DMM+1.0N +6-weeks DMM-treated 0.103 878.2 0.09 878 
D1 DMM+1.0N +6-weeks DMM-treated 0.103 861.9 0.088 858.5 
D2 DMM+1.0N +6-weeks DMM-treated 0.117 910.3 0.092 864.4 
D3 DMM+1.0N +6-weeks DMM-treated 0.116 897.6 0.092 859.4 
G1 DMM+1.0N +6-weeks DMM-treated 0.127 929 0.089 860.9 
E1 DMM+2.0N +6-weeks DMM-treated 0.122 891.3 0.096 879.8 
E2 DMM+2.0N +6-weeks DMM-treated 0.117 932.6 0.092 863.4 
E3 DMM+2.0N +6-weeks DMM-treated 0.142 934.6 0.121 905.9 
F1 DMM+2.0N +6-weeks DMM-treated 0.106 909.9 0.092 865.7 
F2 DMM+2.0N +6-weeks DMM-treated 0.113 895.1 0.1 906.7 
F3 DMM+2.0N +6-weeks DMM-treated 0.099 879.7 0.09 876.5 
G2 DMM+2.0N +6-weeks DMM-treated 0.107 882.4 0.109 889.1 
B1 DMM+4.5N +6-weeks DMM-treated 0.103 866.7 0.085 856.5 
B2 DMM+4.5N +6-weeks DMM-treated 0.114 879.4 0.087 848.1 
B3 DMM+4.5N +6-weeks DMM-treated 0.11 892.2 0.097 870.5 
H1 DMM+4.5N +6-weeks DMM-treated 0.097 862.7 0.095 833.2 
H2 DMM+4.5N +6-weeks DMM-treated 0.111 898.2 0.104 898.3 
H3 DMM+4.5N +6-weeks DMM-treated 0.106 912.5 0.1 883.6 
H4 DMM+4.5N +6-weeks DMM-treated 0.114 913.7 0.092 877.1 
H5 DMM+4.5N +6-weeks DMM-treated 0.108 893.4 0.084 844.3 
 
  
  209 
Epiphyseal Cancellous Bone MicroCT Data: Indices of cancellous bone architecture 
proximal to the growth plate. Outcome measures: bone volume fraction (BV/TV), 
trabecular number (Tb.N), trabecular thickness (Tb.Th), trabecular separation (Tb.Sp), 
and tissue mineral density (TMD). 
 
 
Mouse ID Group Duration Limb BV/TV Tb.N 
Tb.Th 
(mm) 
Tb.Sp 
(mm) 
TMD 
(mg HA/ccm) 
A1 DMM-only +6-weeks control 0.2766 6.0152 0.0475 0.1651 943.485 
A2 DMM-only +6-weeks control 0.3112 6.5956 0.0498 0.1546 954.859 
A3 DMM-only +6-weeks control 0.3596 6.2192 0.0513 0.1631 951.447 
I1 DMM-only +6-weeks control 0.3214 6.6313 0.0507 0.1573 970.402 
I2 DMM-only +6-weeks control 0.3535 6.4142 0.0536 0.1561 968.064 
I3 DMM-only +6-weeks control 0.2949 5.9289 0.0498 0.1718 956.312 
I4 DMM-only +6-weeks control 0.2632 6.0283 0.0456 0.1692 939.694 
I5 DMM-only +6-weeks control 0.2705 6.5197 0.0456 0.1572 955.806 
C1 DMM+1.0N +6-weeks control 0.2604 5.8743 0.0451 0.1728 934.892 
C2 DMM+1.0N +6-weeks control 0.2863 6.5181 0.0447 0.155 945.381 
C3 DMM+1.0N +6-weeks control 0.2809 6.0151 0.0483 0.1671 925.225 
D1 DMM+1.0N +6-weeks control 0.2886 6.3085 0.0488 0.1597 937.546 
D2 DMM+1.0N +6-weeks control 0.3464 6.2554 0.0555 0.1633 950.183 
D3 DMM+1.0N +6-weeks control 0.3129 6.239 0.0516 0.1618 929.648 
G1 DMM+1.0N +6-weeks control 0.2694 5.9706 0.0464 0.1671 929.648 
E1 DMM+2.0N +6-weeks control 0.3285 6.3625 0.0488 0.1597 945.128 
E2 DMM+2.0N +6-weeks control 0.3496 7.0135 0.0482 0.1442 951.952 
E3 DMM+2.0N +6-weeks control 0.3423 6.0714 0.0518 0.166 936.535 
F1 DMM+2.0N +6-weeks control 0.3098 6.1335 0.0503 0.1617 936.282 
F2 DMM+2.0N +6-weeks control 0.3026 5.8837 0.0505 0.1714 938.051 
F3 DMM+2.0N +6-weeks control 0.2716 6.2087 0.0471 0.1605 923.835 
G2 DMM+2.0N +6-weeks control 0.3137 6.1186 0.0517 0.1622 939.694 
B1 DMM+4.5N +6-weeks control 0.322 6.1038 0.0503 0.164 944.623 
B2 DMM+4.5N +6-weeks control 0.2797 6.0106 0.0504 0.1673 937.104 
B3 DMM+4.5N +6-weeks control 0.3171 6.4492 0.0479 0.1558 936.914 
H1 DMM+4.5N +6-weeks control 0.3114 6.6713 0.0489 0.1495 937.04 
H2 DMM+4.5N +6-weeks control 0.372 7.1083 0.0553 0.146 970.844 
H3 DMM+4.5N +6-weeks control 0.3652 6.1303 0.0552 0.1606 947.782 
H4 DMM+4.5N +6-weeks control 0.3362 6.7845 0.0507 0.1465 934.197 
H5 DMM+4.5N +6-weeks control 0.2942 5.9455 0.0506 0.1707 947.592 
A1 DMM-only +6-weeks DMM-treated 0.2599 6.0856 0.0447 0.166 960.924 
A2 DMM-only +6-weeks DMM-treated 0.2869 6.0735 0.0491 0.1671 954.859 
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A3 DMM-only +6-weeks DMM-treated 0.3209 6.0625 0.0499 0.1653 958.144 
I1 DMM-only +6-weeks DMM-treated 0.3431 6.5636 0.0525 0.1519 952.394 
I2 DMM-only +6-weeks DMM-treated 0.3111 6.0579 0.0515 0.1655 960.861 
I3 DMM-only +6-weeks DMM-treated 0.2664 5.7122 0.0485 0.1778 953.721 
I4 DMM-only +6-weeks DMM-treated 0.2741 5.7599 0.0515 0.1764 946.013 
I5 DMM-only +6-weeks DMM-treated 0.2913 5.96 0.0475 0.1698 957.702 
C1 DMM+1.0N +6-weeks DMM-treated 0.2694 5.7972 0.0474 0.175 944.433 
C2 DMM+1.0N +6-weeks DMM-treated 0.2825 5.8259 0.0494 0.1724 954.669 
C3 DMM+1.0N +6-weeks DMM-treated 0.2553 5.7053 0.0498 0.1786 941.59 
D1 DMM+1.0N +6-weeks DMM-treated 0.2849 5.9009 0.0496 0.1697 943.738 
D2 DMM+1.0N +6-weeks DMM-treated 0.2969 6.2845 0.0487 0.1609 938.873 
D3 DMM+1.0N +6-weeks DMM-treated 0.2861 6.1093 0.0497 0.17 933.881 
G1 DMM+1.0N +6-weeks DMM-treated 0.2435 5.7032 0.0461 0.1737 927.499 
E1 DMM+2.0N +6-weeks DMM-treated 0.3116 6.1153 0.0487 0.1675 945.76 
E2 DMM+2.0N +6-weeks DMM-treated 0.3036 6.4458 0.0454 0.1554 950.309 
E3 DMM+2.0N +6-weeks DMM-treated 0.3296 6.0585 0.054 0.1645 952.078 
F1 DMM+2.0N +6-weeks DMM-treated 0.337 6.1375 0.0524 0.1646 951.32 
F2 DMM+2.0N +6-weeks DMM-treated 0.2586 5.3876 0.0499 0.1865 934.26 
F3 DMM+2.0N +6-weeks DMM-treated 0.3013 5.8645 0.0515 0.1709 958.144 
G2 DMM+2.0N +6-weeks DMM-treated 0.2977 5.6878 0.0565 0.1722 960.545 
B1 DMM+4.5N +6-weeks DMM-treated 0.2957 6.1472 0.0508 0.16 942.537 
B2 DMM+4.5N +6-weeks DMM-treated 0.2566 5.7034 0.0489 0.1768 937.988 
B3 DMM+4.5N +6-weeks DMM-treated 0.314 6.3082 0.0515 0.1603 942.601 
H1 DMM+4.5N +6-weeks DMM-treated 0.2404 6.4562 0.043 0.1563 943.548 
H2 DMM+4.5N +6-weeks DMM-treated 0.3991 6.8792 0.0561 0.1468 951.331 
H3 DMM+4.5N +6-weeks DMM-treated 0.3384 6.3229 0.0531 0.1594 944.18 
H4 DMM+4.5N +6-weeks DMM-treated 0.3336 6.3333 0.0557 0.1571 954.353 
H5 DMM+4.5N +6-weeks DMM-treated 0.2584 6.053 0.0467 0.1702 953.279 
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Metaphyseal Cancellous Bone MicroCT Data: Indices of cancellous bone 
architecture distal to the growth plate. Outcome measures: bone volume fraction 
(BV/TV), trabecular number (Tb.N), trabecular thickness (Tb.Th), trabecular 
separation (Tb.Sp), and tissue mineral density (TMD). 
 
Mouse ID Group Duration Limb BV/TV Tb.N 
Tb.Th 
(mm) 
Tb.Sp 
(mm) 
TMD 
(mg HA/ccm) 
A1 DMM-only +6-weeks control 0.2327 5.3686 0.0544 0.1797 888.135 
A2 DMM-only +6-weeks control 0.2323 4.747 0.0577 0.2128 881.88 
A3 DMM-only +6-weeks control 0.2487 4.6271 0.0591 0.2166 900.709 
I1 DMM-only +6-weeks control 0.2559 5.2364 0.0609 0.1902 891.1682 
I2 DMM-only +6-weeks control 0.2734 5.1422 0.0659 0.1896 905.4481 
I3 DMM-only +6-weeks control 0.2059 5.424 0.0556 0.1808 904.058 
I4 DMM-only +6-weeks control 0.1811 5.0476 0.0558 0.1968 885.607 
I5 DMM-only +6-weeks control 0.2042 5.1699 0.055 0.1917 888.767 
C1 DMM+1.0N +6-weeks control 0.1748 5.3586 0.0504 0.1848 880.047 
C2 DMM+1.0N +6-weeks control 0.1714 5.0782 0.0495 0.1947 890.852 
C3 DMM+1.0N +6-weeks control 0.1531 4.9121 0.0485 0.201 881.121 
D1 DMM+1.0N +6-weeks control 0.1531 4.7109 0.0484 0.2128 882.385 
D2 DMM+1.0N +6-weeks control 0.1882 5.1761 0.0509 0.1892 896.223 
D3 DMM+1.0N +6-weeks control 0.1662 5.0496 0.0494 0.1957 888.198 
G1 DMM+1.0N +6-weeks control 0.1727 5.306 0.0495 0.184 891.484 
E1 DMM+2.0N +6-weeks control 0.2303 5.5237 0.0551 0.1756 878.088 
E2 DMM+2.0N +6-weeks control 0.2178 5.671 0.0519 0.1708 879.036 
E3 DMM+2.0N +6-weeks control 0.236 5.3052 0.0552 0.1827 885.987 
F1 DMM+2.0N +6-weeks control 0.2004 5.1174 0.0544 0.1908 889.083 
F2 DMM+2.0N +6-weeks control 0.1868 5.0076 0.0523 0.1956 891.484 
F3 DMM+2.0N +6-weeks control 0.154 5.0251 0.0474 0.1972 881.827 
G2 DMM+2.0N +6-weeks control 0.1894 5.0081 0.0543 0.1961 892.432 
B1 DMM+4.5N +6-weeks control 0.1497 4.6205 0.0485 0.2145 878.152 
B2 DMM+4.5N +6-weeks control 0.1594 4.6746 0.0509 0.2141 886.176 
B3 DMM+4.5N +6-weeks control 0.1811 5.2599 0.0513 0.1866 898.813 
H1 DMM+4.5N +6-weeks control 0.1813 5.3128 0.0497 0.1843 856.289 
H2 DMM+4.5N +6-weeks control 0.2551 5.6587 0.0562 0.1752 872.275 
H3 DMM+4.5N +6-weeks control 0.2684 4.8715 0.0654 0.2003 911.8931 
H4 DMM+4.5N +6-weeks control 0.2673 5.5275 0.0619 0.1745 909.7448 
H5 DMM+4.5N +6-weeks control 0.224 4.8479 0.0627 0.202 881.0586 
A1 DMM-only +6-weeks DMM-treated 0.2135 5.2157 0.0538 0.188 876.446 
A2 DMM-only +6-weeks DMM-treated 0.2155 4.5658 0.0552 0.219 880.805 
A3 DMM-only +6-weeks DMM-treated 0.2345 4.5142 0.0594 0.2207 892.305 
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I1 DMM-only +6-weeks DMM-treated 0.2612 4.9343 0.0652 0.1988 893.7588 
I2 DMM-only +6-weeks DMM-treated 0.2493 4.8321 0.0641 0.2057 904.4371 
I3 DMM-only +6-weeks DMM-treated 0.1785 5.1822 0.0533 0.1907 883.143 
I4 DMM-only +6-weeks DMM-treated 0.1696 4.9807 0.0519 0.1986 874.234 
I5 DMM-only +6-weeks DMM-treated 0.1876 5.5148 0.0506 0.1775 894.137 
C1 DMM+1.0N +6-weeks DMM-treated 0.1649 5.0366 0.05 0.1978 873.792 
C2 DMM+1.0N +6-weeks DMM-treated 0.1646 4.9857 0.049 0.1978 895.78 
C3 DMM+1.0N +6-weeks DMM-treated 0.1341 4.5654 0.0469 0.2192 874.045 
D1 DMM+1.0N +6-weeks DMM-treated 0.1437 4.8565 0.0466 0.2039 880.679 
D2 DMM+1.0N +6-weeks DMM-treated 0.1758 5.0415 0.0517 0.1966 897.36 
D3 DMM+1.0N +6-weeks DMM-treated 0.1553 5.0567 0.0483 0.1946 877.772 
G1 DMM+1.0N +6-weeks DMM-treated 0.1749 5.0409 0.0511 0.1959 876.193 
E1 DMM+2.0N +6-weeks DMM-treated 0.2172 5.2173 0.0552 0.1896 866.526 
E2 DMM+2.0N +6-weeks DMM-treated 0.206 5.5214 0.0517 0.1739 887.187 
E3 DMM+2.0N +6-weeks DMM-treated 0.2218 5.3333 0.0555 0.1816 867.979 
F1 DMM+2.0N +6-weeks DMM-treated 0.192 5.1828 0.0528 0.1888 895.78 
F2 DMM+2.0N +6-weeks DMM-treated 0.1752 4.7635 0.0524 0.2083 877.141 
F3 DMM+2.0N +6-weeks DMM-treated 0.1529 4.9037 0.049 0.2017 896.981 
G2 DMM+2.0N +6-weeks DMM-treated 0.1812 4.9364 0.055 0.2003 900.393 
B1 DMM+4.5N +6-weeks DMM-treated 0.1492 4.6889 0.0492 0.2115 876.193 
B2 DMM+4.5N +6-weeks DMM-treated 0.1568 4.5193 0.0528 0.2217 883.775 
B3 DMM+4.5N +6-weeks DMM-treated 0.1721 4.8515 0.0534 0.2054 882.764 
H1 DMM+4.5N +6-weeks DMM-treated 0.1511 4.9328 0.0485 0.2018 853.32 
H2 DMM+4.5N +6-weeks DMM-treated 0.2515 5.6391 0.056 0.1721 886.239 
H3 DMM+4.5N +6-weeks DMM-treated 0.2638 5.107 0.0641 0.1885 895.844 
H4 DMM+4.5N +6-weeks DMM-treated 0.2522 5.5394 0.058 0.1741 896.918 
H5 DMM+4.5N +6-weeks DMM-treated 0.2094 4.5142 0.0611 0.2223 887.314 
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Meniscal Ossicle MicroCT Data: Volume (BV) and tissue mineral density (TMD) of 
medial meniscal ossicle. 
 
Mouse ID Group Duration Limb BV 
TMD 
(mg HA/ccm) 
A1 DMM-only +6-weeks control 0.0873 698.8 
A2 DMM-only +6-weeks control 0.0863 689.7 
A3 DMM-only +6-weeks control 0.0925 752.8 
I1 DMM-only +6-weeks control 0.0938 771.9 
I2 DMM-only +6-weeks control 0.0975 813.3 
I3 DMM-only +6-weeks control 0.0866 690.5 
I4 DMM-only +6-weeks control 0.0902 775.2 
I5 DMM-only +6-weeks control 0.0988 793.2 
C1 DMM+1.0N +6-weeks control 0.0835 771 
C2 DMM+1.0N +6-weeks control 0.0885 795.1 
C3 DMM+1.0N +6-weeks control 0.0892 774.6 
D1 DMM+1.0N +6-weeks control 0.0904 768.2 
D2 DMM+1.0N +6-weeks control 0.0848 708.9 
D3 DMM+1.0N +6-weeks control 0.0893 679.7 
G1 DMM+1.0N +6-weeks control 0.0861 709.6 
E1 DMM+2.0N +6-weeks control 0.0919 681 
E2 DMM+2.0N +6-weeks control 0.0784 731.2 
E3 DMM+2.0N +6-weeks control 0.088 686.5 
F1 DMM+2.0N +6-weeks control 0.091 715 
F2 DMM+2.0N +6-weeks control 0.0926 783 
F3 DMM+2.0N +6-weeks control 0.0746 687 
G2 DMM+2.0N +6-weeks control 0.0968 712.5 
B1 DMM+4.5N +6-weeks control 0.0871 693.8 
B2 DMM+4.5N +6-weeks control 0.0975 706.2 
B3 DMM+4.5N +6-weeks control 0.0865 705.8 
H1 DMM+4.5N +6-weeks control 0.0888 792.2 
H2 DMM+4.5N +6-weeks control 0.094 788.9 
H3 DMM+4.5N +6-weeks control 0.0936 710.3 
H4 DMM+4.5N +6-weeks control 0.0939 779.2 
H5 DMM+4.5N +6-weeks control 0.0854 771.4 
A1 DMM-only +6-weeks DMM-treated 0.1609 756.3 
A2 DMM-only +6-weeks DMM-treated 0.2098 710.1 
A3 DMM-only +6-weeks DMM-treated 0.2152 716.5 
I1 DMM-only +6-weeks DMM-treated 0.1454 681.2 
I2 DMM-only +6-weeks DMM-treated 0.1276 676.3 
I3 DMM-only +6-weeks DMM-treated 0.1191 741.4 
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I4 DMM-only +6-weeks DMM-treated 0.1144 678.7 
I5 DMM-only +6-weeks DMM-treated 0.135 734.8 
C1 DMM+1.0N +6-weeks DMM-treated 0.1513 709.1 
C2 DMM+1.0N +6-weeks DMM-treated 0.143 762.4 
C3 DMM+1.0N +6-weeks DMM-treated 0.1453 703.6 
D1 DMM+1.0N +6-weeks DMM-treated 0.1278 682 
D2 DMM+1.0N +6-weeks DMM-treated 0.1342 685.5 
D3 DMM+1.0N +6-weeks DMM-treated 0.1677 716.2 
G1 DMM+1.0N +6-weeks DMM-treated 0.1202 737.9 
E1 DMM+2.0N +6-weeks DMM-treated 0.1572 674 
E2 DMM+2.0N +6-weeks DMM-treated 0.1101 712.9 
E3 DMM+2.0N +6-weeks DMM-treated 0.1517 671.7 
F1 DMM+2.0N +6-weeks DMM-treated 0.1056 767.6 
F2 DMM+2.0N +6-weeks DMM-treated 0.1448 691.8 
F3 DMM+2.0N +6-weeks DMM-treated 0.1418 754.2 
G2 DMM+2.0N +6-weeks DMM-treated 0.1307 727.6 
B1 DMM+4.5N +6-weeks DMM-treated 0.0964 686.9 
B2 DMM+4.5N +6-weeks DMM-treated 0.1313 651.4 
B3 DMM+4.5N +6-weeks DMM-treated 0.1414 693 
H1 DMM+4.5N +6-weeks DMM-treated 0.144 673.4 
H2 DMM+4.5N +6-weeks DMM-treated 0.1689 734 
H3 DMM+4.5N +6-weeks DMM-treated 0.1395 729.1 
H4 DMM+4.5N +6-weeks DMM-treated 0.1362 728.3 
H5 DMM+4.5N +6-weeks DMM-treated 0.1581 672.9 
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Chondrocyte number and apoptosis: Chondrocyte number and apoptosis 
determined by DAPI staining and TUNEL assay in articular cartilage in the medial 
(M) tibial plateau. Chondrocyte number reported as percent positive DAPI staining per 
cartilage area. Chondrocyte apoptosis reported as percent positive TUNEL staining per 
DAPI area. 
 
Mouse ID Group Duration Plateau 
Percent DAPI 
per Cartilage Area 
Percent TUNEL 
per DAPI Area 
K1L control +0-weeks M 12.863 1.267 
K2L control +0-weeks M 12.754 1.151 
K3L control +0-weeks M 6.047 1.305 
N2L control +0-weeks M 14.085 2.986 
N3L control +0-weeks M 7.347 3.543 
K1R DMM-only +0-weeks M 10.986 4.089 
K2R DMM-only +0-weeks M 6.352 5.896 
K3R DMM-only +0-weeks M 8.075 5.351 
N1R DMM-only +0-weeks M 8.907 4.858 
N2R DMM-only +0-weeks M 8.274 3.289 
N3R DMM-only +0-weeks M 12.418 0.400 
J1R DMM-only +2-weeks M 9.234 8.382 
J2R DMM-only +2-weeks M 10.361 19.080 
J3R DMM-only +2-weeks M 5.362 17.553 
P1R DMM-only +2-weeks M 6.049 8.810 
P2R DMM-only +2-weeks M 11.612 1.878 
P3R DMM-only +2-weeks M 7.143 8.275 
L1R DMM+1.0N +2-weeks M 7.741 2.627 
L2R DMM+1.0N +2-weeks M 7.685 10.080 
M1R DMM+1.0N +2-weeks M 8.578 1.224 
M2R DMM+1.0N +2-weeks M 9.528 4.708 
M3R DMM+1.0N +2-weeks M 9.946 1.079 
A1R DMM-only +6-weeks M 5.298 7.938 
A2R DMM-only +6-weeks M 6.487 20.693 
A3R DMM-only +6-weeks M 3.754 31.501 
I1R DMM-only +6-weeks M 5.673 6.094 
I2R DMM-only +6-weeks M 3.317 54.564 
I4R DMM-only +6-weeks M 4.584 13.025 
C1R DMM+1.0N +6-weeks M 8.766 5.829 
C2R DMM+1.0N +6-weeks M 4.887 23.803 
C3R DMM+1.0N +6-weeks M 5.751 18.213 
D1R DMM+1.0N +6-weeks M 5.292 8.338 
D2R DMM+1.0N +6-weeks M 2.874 54.522 
D3R DMM+1.0N +6-weeks M 5.469 15.101 
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E1R DMM+2.0N +6-weeks M 3.311 8.204 
E2R DMM+2.0N +6-weeks M 5.985 14.238 
E3R DMM+2.0N +6-weeks M 5.082 19.252 
F1R DMM+2.0N +6-weeks M 2.815 21.741 
F2R DMM+2.0N +6-weeks M 4.467 38.646 
F3R DMM+2.0N +6-weeks M 2.247 34.253 
B1R DMM+4.5N +6-weeks M 11.105 2.155 
B2R DMM+4.5N +6-weeks M 3.349 33.799 
B3R DMM+4.5N +6-weeks M 5.297 0.984 
H1R DMM+4.5N +6-weeks M 5.207 6.701 
H2R DMM+4.5N +6-weeks M 2.320 76.321 
H3R DMM+4.5N +6-weeks M 6.084 11.206 
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Picrosirius Red Staining: Aligned collagen content in cartilage surface of medial (M) 
tibial plateau determined by picrosirius red staining. Surface collagen content reported 
as percentage of positive picrosirius red staining on the cartilage surface. 
 
Mouse ID Group Duration Plateau 
Picrosirius staining 
(% Cartilage Surface) 
K1L control +0-weeks M 33.5 
K2L control +0-weeks M 50.6 
K3L control +0-weeks M 70.2 
N1L control +0-weeks M 57.4 
N2L control +0-weeks M 43.6 
N3L control +0-weeks M 67.8 
K1R DMM-only +0-weeks M 51.5 
K2R DMM-only +0-weeks M 33.7 
K3R DMM-only +0-weeks M 73.3 
N1R DMM-only +0-weeks M 55.8 
N2R DMM-only +0-weeks M 73.7 
N3R DMM-only +0-weeks M 71.3 
J1L control +2-weeks M 63.3 
J2L control +2-weeks M 71.8 
J3L control +2-weeks M 51.1 
P1L control +2-weeks M 67.2 
P2L control +2-weeks M 55.9 
P3L control +2-weeks M 56.6 
J1R DMM-only +2-weeks M 49.1 
J2R DMM-only +2-weeks M 59.4 
J3R DMM-only +2-weeks M 34.4 
P1R DMM-only +2-weeks M 63.2 
P2R DMM-only +2-weeks M 47.6 
P3R DMM-only +2-weeks M 60.3 
L1R DMM+1.0N +2-weeks M 44.2 
L2R DMM+1.0N +2-weeks M 68.7 
L3R DMM+1.0N +2-weeks M 76.5 
M1R DMM+1.0N +2-weeks M 52.8 
M2R DMM+1.0N +2-weeks M 76.6 
M3R DMM+1.0N +2-weeks M 69.9 
A1L control +6-weeks M 42.7 
A2L control +6-weeks M 38.5 
A3L control +6-weeks M 42.6 
I1L control +6-weeks M 46 
I2L control +6-weeks M 47.3 
I4L control +6-weeks M 54.5 
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A2R DMM-only +6-weeks M 58 
A3R DMM-only +6-weeks M 8.3 
I1R DMM-only +6-weeks M 37.5 
I2R DMM-only +6-weeks M 10.2 
I4R DMM-only +6-weeks M 53.8 
C1R DMM+1.0N +6-weeks M 33.2 
C2R DMM+1.0N +6-weeks M 21.4 
C3R DMM+1.0N +6-weeks M 48.9 
D1R DMM+1.0N +6-weeks M 37 
D2R DMM+1.0N +6-weeks M 25 
D3R DMM+1.0N +6-weeks M 36.2 
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Cleaved Aggrecan Immunostaining: Cleaved aggrecan levels in articular cartilage of 
the medial tibial plateau determined by immunohistochemistry with anti-NITEGE 
antibodies. Cleaved aggrecan levels reported as percentage of positive 
immunostaining per cartilage area. 
 
Mouse ID Group Duration Plateau 
NITEGE Positive Signal 
(% Cartilage Area) 
J1L control +2-weeks M 0.441331 
J2L control +2-weeks M 0.132415 
J3L control +2-weeks M 0.356629 
O3L control +2-weeks M 0.83271 
J1R DMM-only +2-weeks M 0.241816 
J2R DMM-only +2-weeks M 1.055916 
J3R DMM-only +2-weeks M 1.221493 
O3R DMM-only +2-weeks M 1.541642 
L1R DMM+1.0N +2-weeks M 0.245954 
L2R DMM+1.0N +2-weeks M 0.36317 
L3R DMM+1.0N +2-weeks M 0.517325 
M1R DMM+1.0N +2-weeks M 1.620706 
A1L control +6-weeks M 0.325998 
A2L control +6-weeks M 0.157626 
A3L control +6-weeks M 0.114579 
I2L control +6-weeks M 0.193819 
A1R DMM-only +6-weeks M 0.18561 
A2R DMM-only +6-weeks M 0.374999 
A3R DMM-only +6-weeks M 0.651711 
I2R DMM-only +6-weeks M 0.288624 
C1R DMM+1.0N +6-weeks M 0.218258 
C3R DMM+1.0N +6-weeks M 0.48381 
D1R DMM+1.0N +6-weeks M 0.153103 
D3R DMM+1.0N +6-weeks M 0.299251 
 
 
  
 
 
